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Abstract
Sugar Conjugates of 3-Hydroxy-4-pyridinones:
Synthesis and Investigations into their Potential
for Drug Delivery to the Brain.
by Ferdinand C. Fuchs
Parkinson’s disease is the second most common neurodegenerative disease after Alzhei-
mer’s disease, with an incidence of 8-18 cases per 100,000 per year and currently about
125,000 cases in the UK. While lifestyle and genetic risk factors for Parkinson’s disease have
been identiﬁed, the aetiology remains unclear. The current treatment options are limited
to the management of symptoms. Iron is misdistributed and accumulates in the aﬀected
brain regions (particularly the substantia nigra) as the disease progresses. Iron chelation
has been identiﬁed as a treatment that slows down disease progression, demonstrating
promising results in two clinical trials. Currently available iron chelators only enter the
brain to a very limited extent, which restricts their use for the treatment of Parkinson’s
disease due to low eﬀective doses achieved in the brain and potential systemic side eﬀects.
This thesis focused on the development of novel iron chelators that have been conjugated
to sugars. In principle, this strategy could lead to the targeting of molecules to the brain
and increase their penetration by facilitated transport across the blood-brain barrier by
the glucose transporter GLUT1. The molecules are based on the 3-hydroxypyridin-4-one
scaﬀold, which is the basis of the clinically used iron chelator deferiprone.
Hydroxypyridinone iron chelators could be linked to the sugars via ether, amide and
triazole linkers, but the deprotection of the resulting conjugates could only be achieved for
some molecules, while others could not be successfully deprotected without degradation
of the desired conjugate.
Thirteen molecules were tested in blood-brain barrier assays based on primary cells from
porcine brain endothelial microvessels. The tested chelators did not, however show greater
blood-brain barrier permeability when compared to similar non-glycosylated chelators.
Instead, permeability was low and correlated with the substances’ lipophilicity. This
indicates that glycosylation alone is not suﬃcient for the transport of the conjugates
and may hinder permeability. In order to increase a compound’s brain permeability by
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Neurological disorders are a class of disorders of the nervous system. They are a major
burden on modern society, aﬀecting one in four people worldwide.1 In Europe, neurological
disorders cause around 35% of years lost due to ill-health, disability or early death.2
A subset of neurological disorders are called neurodegenerative, because they are linked
to the progressive loss of neuronal function or structure. The primary risk factor for
neurodegenerative diseases (ND) is age. This will exacerbate the healthcare burden of
ND as the average age of the global population is expected to rise rapidly, especially
in countries with a high or rising life expectancy (i.e. developed or newly industrialised
countries).3 This is particularly true for the most common neurodegenerative diseases:
Alzheimer’s disease (AD) and Parkinson’s disease (PD).4
The underlying cause is only poorly understood in most ND, and the disease processes are
also often unclear. The diagnosis is based on empirical clinical criteria, but a deﬁnitive
diagnosis requires post-mortem autopsy.5 Interestingly, certain hallmarks and patterns
have been identiﬁed in the most important neurodegenerative diseases, including AD, PD,
amyotrophic lateral sclerosis, prion diseases and Huntington’s disease. They all show a
characteristic progressive loss of speciﬁc, localised cell populations and the pathological
accumulation and aggregation of certain proteins.3,6–8
1.1.1 Parkinson’s Disease
1.1.1.1 Epidemiology
Parkinson’s diseases was ﬁrst described by James Parkinson in 18179 and is the second
most common ND worldwide, after Alzheimer’s disease.7 The incidence rate of PD is
15
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estimated to be 8-18 cases per 100,000 persons per year, but varies from country to
country and is higher in populations with a higher average age.10 The prevalence of PD
in the UK was estimated to be around 125,000 cases in 2009, or 0.3% of the population.11
The prevalence estimate is based on existing medical records, it is therefore likely that a
signiﬁcant number of undiagnosed cases exist in addition to these recorded cases.11
The biggest risk factor for Parkinson’s disease is age, which is illustrated by the fact that
over 90% of patients are aged 60 or older.4,7,10 The average age at onset of the disease is
60 years. While some studies found that PD has a higher prevalence in men, others found
no diﬀerence between sexes.10 Most Western societies have a rapidly ageing population,
which will lead to an increase in PD cases in the future. For the UK, studies expect a 50%
increase of people aged 60 or over and accordingly a 25% increase of PD cases by 2020.11
Similarly, the number of cases for 15 of the world’s most populous nations is expected
to double by 2030, driven by a pronounced increase of cases in developing and newly
industrialised countries (China, India, Indonesia, Brazil, Pakistan, Bangladesh, Russia,
Nigeria).4 Other risk factors related to PD, such as a number of gene polymorphisms,
have been identiﬁed, but only a small number of cases can be attributed to genetic
factors. Mutations in genes such as SNCA (α-synuclein), LRRK2 (dardarin), PARK2
(parkin) or PINK1 have been shown to cause PD.12 Nevertheless, over 90% of PD cases
are idiopathic.10,13 Environmental factors – such as smoking, diet, exposure to certain
toxins, metals or herbicides – have been suggested as risk factors for PD, but their eﬀect
remains contested.10,14
1.1.1.2 Pathology and Symptoms
The pathology of PD is characterised by the loss of neurons in the nigrostriatal path-
way,7 and the presence of intracellular protein inclusions, so called Lewy bodies (see
Figure 1.1).15 The loss of neurons in PD is very speciﬁc and localised. It mainly aﬀects
the dopaminergic neurons projecting from the substantia nigra of the midbrain to the
striatum. The neurons projecting into the putamen are lost preferentially over the caudate
(Figure 1.1.A). At the time of death, up to 70-80% of neurons in that area are lost.7,16
The neuronal loss leads to a depletion of dopamine in the striatum, interrupting the signal
transduction to the areas responsible for motor control (Figure 1.1.B).17 This causes the
typical motor symptoms, such as resting tremors, stiﬀness and bradykinesia (slowness of
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movement) – non-motor symptoms also exist but their cause is not as clear.18 Interestingly,
a large population of dopaminergic neurons is lost before the onset of symptoms.7
The exact cause of neuronal loss is unknown, but protein aggregation (Lewy bodies,
Figure 1.1.C) and oxidative stress are known for their toxicity to cells, and both pro-
cesses have been shown to occur in PD brains.6,18,19 α-Synuclein is the main aggregating
protein in PD, but the role of α-synuclein in health and disease is unclear. While it is
neuroprotective for non-dopaminergic neurons, aggregates of soluble α-synuclein exhibit
toxicity in the presence of dopamine.20 Multiple mutations of the synuclein gene have
been shown to cause PD, or to constitute a risk factor for sporadic PD.12,16 Numer-
ous markers of oxidative stress and oxidative damage have been found in Parkinsonian
brains.6,21–23 The natural dopamine metabolism and dopamine auto-oxidation produce
highly reactive oxygen species, which cause oxidative stress. This requires a ﬁnely tuned
anti-oxidative system to be in place in dopaminergic neurons.18 Cell and animal models
of PD are frequently induced by treatment with the chemicals 6-hydroxydopamine and
1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP). MPTP is metabolised to 1-methyl-
4-phenylpyridinium (MPP+) in cells, which then acts as a complex I inhibitor in mito-
chondrial respiration.24–26 MPP+ also reportedly opens the mitochondrial permeability
transition pore, leading to the loss of membrane potential.27 The cell’s energy supply
therefore depletes and oxidative damage of the mitochondria and the whole cell increases.
MPP+ also appears to aﬀect the dopamine release and re-uptake systems, which may
play an additional role in the compound’s toxicity to dopaminergic neurons.28,29 Similarly,
6-hydroxydopamine also inhibits complex I of the mitochondrial respiratory chain and
thus aﬀects the energy metabolism of cells and increases oxidative damage, leading to cell
death.30–32
Elevated levels of iron and other metals have been found in the substantia nigra of PD
patients, often associated with protein aggregates, while the iron levels in other parts of
the brain were not elevated.21–23,33,34 Iron can participate in the Fenton reaction35 to
continually produce free radicals from hydrogen peroxide, which is mainly produced in
mitochondria as a by-product of the natural metabolism.36 The toxicity mediated by iron
in cells appears at least partly linked to the accumulation of oxidative damage in the
mitochondrial DNA, which leads to progressive mitochondrial dysfunction.37 α-Synuclein
misfolding and aggregation has also been shown to be enhanced by oxidative damage38
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and the presence of iron.39 It has been proposed that the dysregulated iron localisation
in PD exacerbates the stress on dopaminergic neurons caused by protein aggregates and
oxidative stress on multiple levels and may lead to the preferential death of dopaminergic
cells.3,7,18,21–23,33,36,37,40 The involvement of iron in these processes links it to Parkinson’s
disease and its progression. The removal of iron from PD brains therefore opens a novel
way for the development of PD drugs, which could lead to disease modifying agents.
1.1.1.3 Current Treatments
At the present time, there is no cure for Parkinson’s disease and existing treatment options
only help to manage the symptoms.16,18 The focus of current treatments is to alleviate the
severity of motor symptoms. Multiple drugs are on the market, aﬀecting diﬀerent target
proteins in order to increase the available dopamine in the striatum.18
Figure 1.1: Pathology of Parkinson’s Disease.
A. Normal nigrostriatal pathway in red. B. Nigrostriatal pathway in PD.
C. Immunostaining of Lewy Bodies in substantia nigra dopaminergic neurons.
(Reprinted by permission from Elsevier: Neuron, copyright 2003.)7










Figure 1.2: Structure of Dopamine and L-DOPA.
The primary treatment for PD patients is l-3,4-dihydroxyphenylalanine (L-DOPA, le-
vodopa, Figure 1.2), which is orally administered and transported into the brain, where
it is metabolised to dopamine.18 L-DOPA is very eﬀective, but when given over longer
time periods, patients tend to show resistance to L-DOPA treatment,7,18 or worse, start
to develop dyskinesia with hyperkinetic movements.41 Other drugs, such as dopamine
agonists or monoamine oxidase B inhibitors, which inhibit dopamine metabolism, are also
used for the management of PD.16 Additionally, surgical treatments are available. These
include lesioning of the aﬀected brain regions or deep brain stimulation with electrodes,
stimulating the neurons in the appropriate regions in order to facilitate the transduction
of motoric signals.16,18
1.1.1.4 Emerging Treatment Options
Symptomatic treatments for PD have been successfully used since the early 1960s,42
but drugs that aﬀect the progression of the disease have not been developed yet. The
involvement of iron in the pathological processes of PD via oxidative stress and increased
protein aggregation6,8,19,21–23,39 could be the basis for the development of the ﬁrst class of
disease modifying agents.16,36,40
A variety of studies investigated the eﬀect of iron on neuronal cells in vitro and in
vivo, as well as the eﬀect of iron removal by chelation. Zheng et al. showed that iron
chelators have an anti-oxidative eﬀect on iron-mediated lipid-peroxidation in brain homo-
genate.43 The group also found a marked neuroprotective eﬀect of iron chelators against
6-hydroxydopamine insult – a method commonly used to induce parkinsonism in an-
imal models – in an in vitro PD model, the pheochromocytoma cell line.43 In vivo
experiments performed by Dexter et al. showed that iron chelators were neuroprotective
in rats after administration of 6-hydroxydopamine, attenuating the loss of dopamine
















Figure 1.3: Structure of Deferiprone (CP20) and its Neutral 3:1 Complex with Fe3+.
levels and tyrosine hydroxylase-positive∗ neuronal cells.45 In this study, prior treatment
with deferiprone (Figure 1.3) greatly reduced 6-hydroxydopamine induced loss of tyrosine
hydroxylase positive neurons from 45% to only 15%, while other clinically used iron
chelators protected to a lesser extent (desferal: 25%, desferrioxamine: 35%). The positive
inﬂuence of deferiprone on iron-induced damage in cultured cortical neurons and human
neuroblastoma SHSY-5Y cells in vitro was illustrated by Molina-Holgado et al.46 They
also reported over 50% protection against cell death (induced by treatment with 100 µm
H2O2) by 100 µm deferiprone and a higher preservation of neuronal morphology than the
neuroprotective compound 2,2’-dipyridyl. Deferiprone at 10 and 30 µm concentrations
reduced cell death of SHSY-5Y cells caused by administation of 5mm 1-methyl-4-phenyl-
1,2,3,6-tetrahydropyridine (MPTP) 2-fold and 3-fold respectively. Similarly, the Bush
group showed that iron chelation strategies in a MPTP-induced PD mouse model – either
by administration of an orally available iron chelator, or by overexpression of ferritin –
protect nigral dopaminergic neurons and rescues the levels of dopamine and dopamine
metabolites.47 Transgenic mice, overexpressing the ferritin heavy subunit, showed an
increase in MRI signal intensity of ferric iron, while bioavailable ferrous iron was reduced
by 22%. In transgenic mice, the harmful eﬀect of MPTP administration on the number of
dopaminergic neurons, oxidative stress levels or dopamine levels was prevented. Chemical
chelation by a small molecular iron chelator clioquinol (30mg/kg) reduced total substantia
nigra iron content by about 30%, as determined by MRI and mass spectrometry. MPTP-
mediated motor deﬁcits and changes in oxidative stress (as measured by glutathione levels),
number of dopaminergic neurons in substantia nigra and dopamine levels in the striatum
were attenuated by clioquinol treatment.
∗Tyrosine hydroxylase is an enzyme involved in the biosynthesis of dopamine. It hydroxylates tyrosine
to L-DOPA using molecular oxygen.44
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Based on these results and other studies,8 two small clinical trials (40 and 22 patients)
were recently conducted in Lille, France48 and London, UK.49 The trials were investigating
the eﬀect of deferiprone treatment in PD patients in placebo-controlled, double-blinded
studies. The measured outcomes were removal of iron from the brain, as measured by
the change of T2*/R2* times in MRI scans, personal well-being and motor indicators of
disease progression. Both trials reported promising results for a 30mg/kg per day dosing
regime. In the French trial, the 40 patients’ brain iron levels were monitored by MRI
every 6 months. After 6 months of treatment, susbtantia nigra iron levels were signiﬁcantly
reduced and after 12 months, even more iron had been removed from the substantia nigra,
and a signiﬁcant change in putamen iron levels was also observed; serum and CSF ferritin
levels were also reduced. Motor performance improved for patients in the deferiprone-
treated group (change in UPDRS motor score of -2 points, compared to baseline at month
0), while it worsened in patients where the start of deferiprone treatment was delayed for
6 months. Deferiprone treatment also slowed the gradual worsening of motor performance
over time. In the patient group which stopped treatment 6 months earlier than the rest, the
motor performance deprecated more rapidly than for patients with prolonged treatment.48
Additionally, patients improved in their motor scores and well-being even before a removal
of iron from the brain could be observed by MRI.50 These results prompted the French
group to plan another trial with 300 to 400 patients.50
While deferiprone showed promising results in these trials, its known disadvantages are
its relatively low brain penetration,51 its fast metabolism –52,53 and the occurrence of
some dangerous – albeit rare and transient – side eﬀects, such as agranulocytosis, which
requires constant monitoring.54 If the brain permeability of deferiprone could be improved,
the impact of the rate of metabolism and the side eﬀects would be reduced due to the
lower drug concentrations needed in systemic circulation.
1.2 Delivery of Drugs to the Brain
Drugs active in the central nervous system (CNS) need to enter the brain to achieve their
desired eﬀect. Therefore, the delivery of drugs to the brain has been an important research
area for many years.55 The principle factor limiting the entry of drugs into the brain is the
blood-brain barrier (BBB). Its existence was ﬁrst experimentally conﬁrmed by Goldmann
in 1909.56
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Only a small subset of drugs are able to penetrate the blood-brain barrier. In 1999, Ghose
et al. analysed over 7000 drugs from the Comprehensive Medicinal Chemistry database
and found that only 5% of them were CNS active drugs.57 Of these drugs, all are used
for the treatment of depression, schizophrenia and other mental disorders, but none for
the treatment of neurodegenerative diseases.57 CNS active drugs tend to be small, with a
molecular weight (MW) <400Da, but not all drugs with a low MW automatically enter
the brain.58 Drug molecules need to have a certain set of properties to enter the CNS,59,60
which are dictated by the properties of the BBB. The development of eﬃcient strategies
for drug delivery to the brain therefore requires a profound understanding of the BBB.
1.2.1 The Blood-Brain Barrier
The blood-brain barrier is a multicellular structure (Figure 1.4) that exists in all species
with a well developed CNS (all vertebrates and some invertebrates).61 The BBB separates
the brain from the systemic blood circulation and thus maintains homeostasis of the CNS
for optimal neuronal function and synaptic signalling.62,63 It functions as a combination
of a physical, a transport and a metabolic barrier.
Figure 1.4: Cell Associations at the BBB. (Reprinted by permission from Macmillan
Publishers Ltd: Nature Medicine, copyright 2013.)63
In mammals, the physical barrier of the BBB is formed by the endothelial cells of the
cerebral capillaries.61–63 In contrast to peripheral blood vessels, the endothelium of the
brain vasculature is not leaky due to the lack of fenestrations and the formation of tight
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junctions between the cells. These tight junctions prevent plasma proteins or other solutes
in the blood from entering the brain by paracellular diﬀusion, i.e. via gaps between the
cells.64 Any substance that needs to get into or out of the brain therefore has to pass
transcellularly through the endothelium (see Figure 1.5). The metabolic barrier of the
BBB is comprised of metabolic enzymes in the cells of the BBB that degrade or detoxify
potentially harmful substances during their transit, for example multiple cytochrome
P450 enzymes, tranaminases, monoamine oxidases or UDP glucuronosyltransferases.65
The transport barrier is comprised of transport systems (Figure 1.5), which eﬄux solutes
entering endothelia back into the blood. These will be discussed in more detail in sec-
tion 1.2.2.3.
Other CNS barriers – such as the blood-cerebrospinal ﬂuid barriers at the choroid plexuses
in cerebral ventricles and the arachnoid membrane under the dura mater – have a much
smaller surface area and play a minor and more localised role in transport processes.62
Figure 1.5: Transport Routes in the Blood-Brain Barrier. (Adapted by permission
from Elsevier: Neurobiology of Disease, copyright 2010.)62
1.2.2 Overcoming the Blood-Brain Barrier
Multiple strategies to overcome the BBB exist includin for example, direct injection of
drugs into the CNS (intrathecal) or nanoparticle carrier systems for large drug delivery,
and chemical modiﬁcation of drugs to improve small drug delivery. For small molecules
such as deferiprone, the main strategies are either to modify the lipophilicity of molecules –
thus changing their propensity to cross the BBB by passive diﬀusion – or to take advantage
of the active or energy-independent transport systems at the BBB.55
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1.2.2.1 Passive Diffusion
Passive diﬀusion across the blood brain barrier is limited by the molecules’ ability to cross
the lipid bilayers of the cell membrane. The movement of molecules is driven by the
gradient between the extracellular and intracellular concentration.66
The permeability of molecules is mainly governed by their lipophilicity, polarity and size.
Lipinski proposed a set of guidelines for drug discovery and development, termed the ‘Rule
of Five’: 5 or fewer hydrogen bond donors, 10 or fewer hydrogen bond acceptors, a logP
small than 5 and a molecular weight small than 500 (see Table 1.1).66 Lipinski states,
that poor oral absorption is more likely when the molecule breaks one or more of the
rules.66 While the ‘Rule of Five’ was developed to improve oral absorption of drugs, these
parameters are often also applied as a guideline for CNS drug-delivery.67,68 This principle
is valid, because a main determinant of both oral absorption and CNS permeability is the
ability to overcome cell membranes.66,69
Large molecules are unlikely to cross biological membranes by diﬀusion, because they
need to displace a large number of lipid molecules in the membrane, which is energetically
disfavoured.70,71 The diﬀusion rate of molecules† is inversely related to their size72 or
cross-sectional area.70 These properties can only be determined experimentally, while the
molecular weight is easily calculated from the formula and thus used as a substitute for
molecular size. Fischer et al. estimated the upper limit for the cross-sectional area for
passive diﬀusion to be around 80Å2,70 which corresponds to a molecular weight of 300–
400Da.55 A molecular weight ≤ 500Da is suggested for good permeability by Lipinski and
other groups.66,73
A hydrophilic molecule is unlikely to partition into the hydrophobic core of the membrane’s
lipid bilayer. High lipophilicity increases a molecule’s membrane permeability,74 but also
reduces its solubility in aqueous media. It may also lead to low absorption and high
plasma protein binding.73,74 The free drug concentration in the plasma will therefore be
low, resulting in a ﬂat concentration gradient and slow diﬀusion rate.74 Lipinski therefore
suggests a logP ≤ 5 in order to achieve good bioavailability.66
The polarity of molecules, or rather polar surface area (PSA), is the sum of the surface
of all polar atoms in a molecule. Hydrogen bond donors (HBD) and hydrogen bond
acceptors (HBA) increase the polarity of a molecule and its solubility in water and polar
†Diffusion into and through the lipid bilayer, in this case.
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environments, but limit its solubility in apolar environments, such as lipids.68 Lipinski’s
rules suggest to limit the number of HBD and HBA to 10 and 5 respectively, for oral
bioavailability.66
Table 1.1: Physicochemical Property Ranges
Suggested for Increased CNS Permeability.
Property Lipinski66 Hitchcock73
PSA (Å2) — < 90
HBD ≤ 5 < 3
HBA ≤ 10 —
logP ≤ 5 2–5
MW (Da) ≤ 500 < 500
To increase BBB penetration, Hitchcock et al. suggested more stringent limits than spe-
ciﬁed in Lipinski’s rules (see Table 1.1).73 Norinder et al. reported another facile method
to determine whether a molecule is likely to enter the CNS: the sum of nitrogen and oxygen
atoms should be ≤ 5 and logP minus the sum of N+O atoms > 0.60
Even though violating these rules will negatively aﬀect a molecule’s ability to permeate
the brain, they should be regarded as a ‘rule of thumb’, as compounds breaking one or
more rules are known to enter the CNS.75
Habgood and colleagues found that the brain uptake of 3-hydroxypyridin-4-ones (HPOs)
with varying chain length of the N -substituent correlated with their logP.76 Lengthening
the N -alkyl chain increased logP and thus brain penetration. In contrast, the introduction
of an hydroxyl group almost entirely abolished the entry of HPOs into the brain, while
non-hydroxylated derivatives with similar logP values entered the brain more easily.76
The more lipophilic HPOs were not advanced further however, because their lipophilicity
lead to higher partitioning into other organs such as the liver, where HPOs are rapidly
metabolised and excreted.52
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1.2.2.2 Prodrugs
Prodrugs are derivatives of drugs in which part of the active group is conjugated with a
pro-moiety in order to avoid peripheral metabolism and/or improve uptake in the target
tissue. The pro-moiety is then cleaved in the target tissue, releasing the active drug.77,78
A common strategy to improve the permeability of a drug is to mask their polar groups
– these may act as hydrogen bond donors – with non-polar groups.68,69,77 This increases
the drug’s lipophilicity, facilitating permeability across the BBB. The prodrug enters the
brain and the active drug is released by bioconversion.77,78
Hydroxyl and acid groups are often masked as esters by reaction with acids or alcohol
respectively, which can be cleaved by esterases in the brain.68 One of the most successful
example for this strategy is heroin, which is the diacetylated derivative of morphine. The
diacetylation increases brain penetration, while esterase activity in the brain eﬀectively
locks in the deacetylated product (morphine) due to its lower lipophilicity.74
L-DOPA is a prodrug of dopamine – while dopamine does not enter the brain, L-DOPA
is transported by the large neutral amino acid transporter 1 (LAT1).73,79 It is then
metabolised by DOPA decarboxylase to release dopamine.73,80 A pro-moiety may also
be used to direct the drug to its intended target via one of the endogenous transport
systems.78 Examples for this strategy will be discussed in section 1.2.2.3.
1.2.2.3 Transport Processes
The blood-brain barrier uses a multitude of diﬀerent transport systems (Figure 1.6) to
supply the brain with nutrients, remove metabolites and prevent the entry of foreign
substances and toxins.62,81 These transport systems are relevant for drug delivery and
may even be targeted to increase drugs’ BBB permeability.82–85
Active eﬄux transporters (AET) export molecules from the brain endothelium, often
by using energy in the form of ATP or sodium-dependent co-transport.55,62 Notable
members are P-glycoprotein (P-gp), breast cancer resistance protein (BCRP) and the
multidrug resistance-associated proteins (MRP 1–5). AETs preferentially transport lipo-
philic molecules and increasing lipophilicity makes molecules a more likely substrate of
active eﬄux transporters.67,78
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While AETs cannot be used to target molecules to the brain, they should be considered
in the design of molecules, because AETs can severely limit a molecule’s ability to reach
eﬀective concentrations in the brain.85 Azidothymidine (AZT) and other drugs used in
the treatment of AIDS are ineﬀective at penetrating the brain as a result of AET eﬄux,
resulting in a sanctuary for HIV.86 The responsible transporter was only identiﬁed in 2007
by Pan et al.87 The group found that transfection of canine kidney cells with Bcrp1 (the
mouse homologue of BCRP) signiﬁcantly reduced the intracellular accumulation, as well
as basolateral to apical ﬂux of AZT and acabavir, when compared to wild-type cells. This
eﬀect was abolished by co-administration of BCRP inhibitors GF120918 or Ko143.87
AETs can also be used as a means to reduce undesirable brain penetration in peripheral
drugs.88 Loperamide is a opioid-receptor agonist, which is used for the treatment of
diarrhoea. It is a Pgp substrate, which means that the brain is shielded from its CNS opioid
eﬀect under normal conditions.89 When a Pgp inhibitor was co-administered, loperamide
caused respiratory depression via its central opioid action.89
Receptor-mediated transcytosis (RMT). Large endogenous molecules, such as sig-
nalling peptides or proteins, may be transported across the BBB in vesicles by speciﬁc and
non-speciﬁc transcytotic systems.62 Non-speciﬁc transport occurs by adsorptive-mediated
transcytosis (AMT), wherein a positively charged macromolecule adsorbs onto the cell
membrane and the interaction with cell surface binding sites triggers the internalisation
via the formation of a vesicle, which is then transported across the cell.62 Contrarily,
Figure 1.6: Transport Systems found in the BBB Endothelium. (Reprinted by
permission from ASPET: Molecular Interventions, copyright 2003.)55
Chapter 1 – Introduction 28
in receptor-mediated transcytosis (RMT), a speciﬁc ligand binds its receptor on the en-
dothelial cell membrane and triggers the endocytosis of the ligand-receptor complex.90,91
During RMT, a caveolus is formed, which internalises the ligand-receptor complex within
a vesicle. This vesicle is transported across Receptor-ligand pairs undergoing RMT include
insulin, transferrin, insulin-like growth factor and LDL.55,62,67,78,81,84,92 This system can be
used to transport drugs, in particular large molecules, as a ‘Trojan horse’ across the BBB.
This Trojan horse can be the natural ligand of the receptor, which has been conjugated to
the drug, or polypeptides, often a monoclonal antibody. These bind to an exofacial epitope
of the receptor, distinct from the natural ligand-binding site and thus do not interfere with
the transport of the endogenous ligand.55,68
The transferrin receptor (TfR) has been used for the delivery of molecules across the BBB
using either strategy. Yan et al. studied ﬂuorescence-labelled iron nanoparticles, which had
been conjugated to transferrin (Tf). While the in vivo uptake of nanoparticles without Tf
was very low, the Tf-coated nanoparticles entered the brain in abundance.93 Niewoehner
et al. produced constructs between anti-amyloid beta antibodies (mAb31) and monoclonal
anti-TfR Fab fragments. Up to 50% of the given dose of these constructs passed the BBB in
an in vitro model, and the constructs showed up to 55-fold higher binding of amyloid beta
plaques than the untargeted antibody in mice after i.v. administration of the antibodies.94
Carrier mediated transport (CMT). In order to supply the brain with the nutrients
it needs for metabolism, the brain endothelium contains an array of carrier proteins,
which are specialised to transport speciﬁc classes of nutrients.62,83,84 Transported sub-
strates include glucose, amino acids, nucleosides, nucleotides and nucleobases, choline and
thyroid hormone.62,83 The transport can be facilitative, sodium-dependent or driven by an
exchange with other ions.62 Numerous drugs (Table 1.2) are known to enter the brain by
CMT. These include L-DOPA, valproic acid, gabapentin, the lactone-opened metabolites
of simvastatin and lovastatin, lidocaine or morphine glucuronide.77,85,95
The large neutral amino acid transporter 1 (LAT1) is one of few transporters which are
already used for the drug delivery. LAT1 is involved in the transport of a number of
drugs (Table 1.2).97 These include L-DOPA,98 phosphonoformate-tyrosine conjugate,99
gabapentin,100,101 melphalan102 and 4-chlorokynurenine103 (Figure 1.7).
LAT1 is a facilitative (sodium-independent, bidirectional) transporter found on the apical
and basolateral membrane of the brain endothelium. LAT1 transports large α-amino
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Table 1.2: Examples of Drugs Transported into the CNS by CMT (from Begley85).
Drug Transporter
Valproic acid MC fatty acid carriera
DHA-taxolb MC fatty acid carrier


















Oxazolamine COR3224 Purine carrier
Abacivir Nucleoside carrier
Morphine glucuronide Hexose carrier
a Medium-chain fatty acid carrier.96
b DHA = Docosahexaenoic acid.
c Large neutral amino acid transporter 1.
d NAM = 2-Amino-7-bis[(2-chloroethyl)amino]-1,2,3,4-
tetrahydro-2-naphthoic acid.
e Open lactone-form.
f Monocarboxylic acid transporter 1.
g Organic cation transporter.




































Figure 1.7: Structures of LAT1-transported molecules.
acids, such as tyrosine, phenylalanine or leucine.62,68,97 Transported drugs, with the
exception of gabapentin, are α-l-amino acids and therefore resemble the natural substrates.
Gabapentin’s cyclic structure and restricted conformation bring the amino and carboxy
groups in close proximity however, allowing recognition and transport by LAT1.84 Some
of these drugs are only delivered to the brain, while others act as prodrugs that are
metabolised to their active form in the brain and thus eﬀectively trapped.68,78 Examples
include L-DOPA, which is decarboxylated to dopamine,84 and 4-chlorokynurenine, which
is cyclised to 7-chlorokynurenic acid.103
Other CMTs have also been suggested as facilitators of brain-directed drug delivery.5,84,85,95
Attempts to utilise the glucose transporter GLUT1 will be discussed below.
1.2.3 GLUT1 Mediated Transport
1.2.3.1 Glucose transporter GLUT1
In mammalian cells, two groups of transporters are responsible for the transport of glucose.
The sodium-dependent glucose co-transport proteins (SGLT) – responsible for dietary
glucose uptake in the intestine and glucose reuptake in the nephron104 – and the sodium-
independent facilitative glucose transporters (GLUT).104–106 Glucose transporter GLUT1
belongs to the latter family. In the brain, it is found almost exclusively and abundantly at
the blood-brain barrier, while other members of the GLUT family are found in astrocytes
and neurons.106–109 GLUT1 is also localised in erythrocyte membranes, the retina, testes
and the placenta.110,111 The endogenous substrate of GLUT1 is d-glucose but not l-glucose.
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l-Ascorbic acid is also transported by GLUT1 in its oxidised form (dehydroascorbic
acid).112,113
Structure. GLUT1 is part of the major facilitator superfamily (MFS), a very large
transporter superfamily.110,114–116 Transporters of the MFS share a common core structure,
comprised of 12 transmembrane domains.115,117–119 This structure (Figure 1.8) has also
been suggested for GLUT1 through sequence analysis,105,120 CD spectroscopy110 and
comparison with bacterial homologues.118,121
The crystal structure of XylE, a bacterial homologue of GLUT1, was published in 2012 by
Yan and coworkers.122 This structure was then used as the basis to model the 3D structure
of GLUT1. XylE is a xylose/H+ symporter isolated from Escherichia coli. The protein has
a sequence identity of around 30% with GLUT1–4 and sequence similarity around 50%.122
This low identity may be excepted from the comparison of a bacterial and a mammalian
protein. However, members of MFS are known to have high sequence diﬀerence to each
other, while retaining homologous secondary structure and helical packing.121 Most amino
acid residues involved in substrate binding and a number of diseases-related residues in
GLUT1 are invariant in XylE and GLUT1 (Figure 1.8),122,123 which justiﬁes the use of
XylE as scaﬀold for the modelled structure of GLUT1. In early 2013, Quistgaard et
al. reported two more crystal structures of XylE.123 The protein was crystallised in the
inward open and partially occluded inward open conformations. These supplement the
structure by the Yan group, allowing closer study of the protein’s transport cycle. The
Figure 1.8: Predicted Secondary Structural Elements of GLUT1.
Polar and aromatic residues predicted to be involved in d-glucose binding are shaded red
and yellow, respectively. The residues whose mutations were found in GLUT1 deficiency
syndrome are shaded purple and blue for invariant and variant residues, respectively.
(TM, Transmembrane Domain; IC, Intracellular Helix; Adapted by permission from
Macmillan Publishers Ltd: Nature, copyright 2012.)122
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crystal structures suggest a single binding site, which is alternatively accessible from the
extracellular space in the outward open conformation and the intracellular space in the
inward open conformation.124
In 2014, the Yan group ﬁnally reported the crystal structure of GLUT1, making it the
ﬁrst reported structure of a eukaryotic sugar transporter.124 The protein was crystallised
in the inward open conformation (Figure 1.9) and it closely matches the structure of
XylE. The group found some diﬀerences in the length and arrangement of the intracellular
helices (IC1–3, cf. Figure 1.8 and Figure 1.9) in the loop between transmembrane domains
6 and 7 and high similarity in the substrate binding transmembrane domains.124 The
intracellular helices between transmembrane domains 6 and 7 separate the protein into
a C and a N domain. A central cavity is present in GLUT1, which appears to be the
binding site for the co-crystallised nonyl-β-d-glucoside. The interactions of the protein
with the glucoside includes multiple residues which are associated with GLUT1 deﬁciency
syndrome.124 GLUT1 is thought to transport substrates through the membrane by a series
of conformation changes,125 alternately making the substrate binding site available to one
side of the membrane.110,126 This is supported by the published crystal structures, which
show a movement of the C and N domains relative to each other, exposing the binding
site either to the extra- or intracellular side.122–124 The intracellular helices are thought
to close oﬀ access to the binding site during the transport cycle.124
Figure 1.9: Overall Structure of the Human Glucose Transporter GLUT1.
The structure of full-length human GLUT1 containing two point mutations (N45T,
E329Q) was determined in an inward-open conformation. The corresponding transmem-
brane segments in the four 3-helix repeats are coloured the same. A cut-open view of
the surface electrostatic potential is shown in the centre, a ribbon schematic bound to
nonyl-β-d-glucoside (NG) on the right. (IC, Intracellular Helix; Adapted by permission
from Macmillan Publishers Ltd: Nature, copyright 2014.)124
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Substrate Specificity. Studies of GLUT1 by Barnett et al. and Pardridge focused
on the substrate binding properties and transport kinetics and inhibition.127–129 These
studies showed that the interactions of glucose derivatives with GLUT1 depend to a large
extent on the position of the modiﬁcation, as well as steric eﬀects and hydrogen bonds
(Table 1.3).127–129
Modiﬁcations in position 1 are badly tolerated. The β-ﬂuoride is half as active as glucose
(d-Glucose: Ki = 8mm), while the Ki for the α-ﬂuoride is an order of a magnitude greater.
1-Alkylated derivatives lacking a hydroxyl group in position 1 have a 3–10 times higher
Ki than glucose. This indicates that position 1 plays an important role in substrate
recognition, leaving little room for modiﬁcations.
2-Deoxyglucose and 2-chloro-2-deoxyglucose have a similar Ki to glucose, while the C-2
epimer mannose is slightly less active. 2-O-Methylglucose is 15 times less active than
glucose, indicating that substituents in position 2 are not tolerated due to steric hindrance.
For positon 3, a hydrogen bond acceptor in equatorial position appears to be required for
high binding aﬃnity. 3-Deoxyglucose had a high Ki of 70mm and allose, the C-3 epimer,
did not show any inhibitory eﬀect. The Ki of 3-O-alkylglucoses decreased with increasing
size of the substituent. The ﬂuorine atom in 3-deoxy-3-ﬂuoroglucose can accept a hydrogen
bond and thus has a similar Ki to glucose, while the chloro and bromo derivatives are 4
times weaker inhibitors.
The introduction of alkyl substitutents in positions 4 and 6 appears to be well tolerated,
with 6-O-pentylglucose, 6-O-pentylgalactose and 6-O-benzylgalactose showing a higher
aﬃnity for the transporter than glucose. The absence of a hydrogen bond in position 6
(6-deoxyglucose and xylose) increased the Ki over 9-fold, while a ﬂuorine atom, which
acts as hydrogen bond acceptor, but not donor, conferred a much lower Ki than glucose.
The introduction of a cationic or anionic group (6-aminoglucose and glucose 6-phosphate,
respectively), completely abolished inhibitory activity. Position 6 therefore apparently
interacts with a mainly hydrophobic region of the binding pocket, which nevertheless
requires the presence of a hydrogen bond acceptor for high aﬃnity binding.
Galactose, the C-4 epimer, and its derivatives have a lower aﬃnity than the respective
glucose derivatives, indicating the requirement for the 4-hydroxyl group or its substituents
to be in the equatorial position.
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Table 1.3: GLUT1 Inhibition Constants (Ki) of Sugar Derivatives.
a









9 ref. [127] 3-Deoxy-3-fluoroglucose 7 ref. [128]
7 ref. [128] 3-Chloro-3-deoxyglucose 33 ref. [128]
1-Deoxyglucose 77–81 ref. [128] 3-Bromo-3-deoxyglucose 33 ref. [128]
1,2-Dideoxyglucose 38 ref. [128]
Glucal 27 ref. [128] 4-O-Propylglucose 10 ref. [128]
α-Glucopyranosyl fluoride 77–80 ref. [128]
β-Glucopyranosyl fluoride 15 ref. [128] 6-Deoxyglucose 77–80 ref. [128]
Methyl α-glucopyranoside NDb ref. [128] Xylose 70 ref. [128]
Methyl β-glucopyranoside ND ref. [128] 6-O-Propylglucose 17 ref. [129]
Propyl β-glucopyranoside ND ref. [129] 90c ref. [129]
9c ref. [129] 6-O-Pentylglucose 1 ref. [129]
Phenyl β-glucopyranoside 6 ref. [129] 6-Amino-6-deoxyglucose ND ref. [128]
0.5c ref. [129] Glucose 6-phosphate ND ref. [128]
6-Deoxy-6-fluoroglucose 1 ref. [128]
2-Deoxyglucose 6 ref. [127]
3 ref. [128] Galactose 40d ref. [127]
Mannose 22d ref. [127] 85–90 ref. [128]
20 ref. [128] Propyl β-galactopyranoside ND ref. [129]
2-O-Methylglucose 119 ref. [128] 90c ref. [129]
2-Chloro-2-deoxyglucose 8 ref. [128] 6-Deoxygalactose 50 ref. [128]
6-O-Methylgalactose 45 ref. [128]
3-Deoxyglucose 70 ref. [128] 6-O-Propylgalactose 17 ref. [129]
Allose ND ref. [128] NDc ref. [129]
3-O-Methylglucose 10 ref. [127] 6-O-Pentylgalactose 1.5 ref. [129]
12–14 ref. [128] 6-O-Benzylgalactose 1.2 ref. [129]
13 ref. [130] 6c ref. [129]
3-O-Ethylglucose 48 ref. [128] 6-Deoxy-6-fluorogalactose 7 ref. [128]
3-O-Propylglucose 59 ref. [128] 6-Deoxy-6-iodogalactose 8 ref. [128]
3-O-Allylglucose 25 ref. [128]
a Compounds were tested for the inhibition of i) l-sorbose entry into human erythrocytes128,129
ii) brain uptake of d-[14C]-glucose in rats127 or iii) 3-O-[3H]methyl-d-glucose uptake into a mono-
layer of bovine brain microvessel endothelial cells (BMEC).130 All tested compounds were the d-isomer.
b No inhibition detected.
c Inhibitor present on intracellular side.
d Ki ≈ Km
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Interestingly, the eﬀect of derivatives was very diﬀerent when they were present intracellu-
larly, rather than on the outside.129 Glucosides, which previously had a very limited eﬀect,
showed very high inhibitory activity inside the cell. This is in contrast to 6-alkylated
sugars, which were very active outside the cell, but when applied to the inside, they
show little to no inhibition to the transport activity of GLUT1. This data suggests
that GLUT1 forms diﬀerent interactions with glucose, depending on the orientation of
the protein,126,129 allowing alternating access to the substrate-binding site. Since the
studies reported Ki and not Km of the sugar derivatives, no direct assessment about the
transportability can be made. A high inhibition constant signiﬁes low binding and thus
low likelihood of transport. The inverse assumption, that tightly bound compounds are
better transported by GLUT1, is not true however, because the compounds may be non-
transportable inhibitors. Nevertheless, binding is a prerequisite for transport.
The GLUT1 crystal structure (Figure 1.9) shows a central cavity – the putative binding
site. It is accessible alternatively from the intra- or extracellular side.124 Furthermore,
GLUT1 was co-crystallised with nonyl-β-d-glucoside in an inward-facing conformation.
The sugar was sitting in the binding pocket, with the nonyl-chain protruding towards
the intracellular side.124 All this information supports the described substrate-binding
model and explains the distinct behaviour exhibited by 1- and 6-modiﬁed sugars. When
the transporter is facing outwards, the ‘front’ of the sugar with position 1 is entering
the binding pocket ﬁrst, thus requiring an unsubstituted position 1 interacting with
the transporter, while position 6 may have less interactions with the protein in this
conformation. Conversely, in the inward facing conformation, position 6 is the ﬁrst to
interact with the binding pocket, while there remains space for substituents in position 1,
e.g. the nonyl group in the crystal structure.
The information gained by these studies regarding the structural requirements for GLUT1
binding is therefore very useful for the design-considerations of GLUT1 transportable
compounds.
1.2.3.2 Use of GLUT1 for Drug Targeting
Targeting glucose transporter GLUT1 has been suggested as potential strategy to deliver
drugs to the CNS.5,67,68,78,81,84,131
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Peptides. It has been speculated that glycosylation of peptides can improve their bioavail-
ability and delivery to the brain.68,131–133 A particular eﬀort was made in the synthesis of
glucosylated opioid peptides, such as enkephalins or dermorphin.134–154 Two studies meas-
ured the in vivo pharmacological eﬀect of these constructs.137,138 They found improved
bioavailability and CNS eﬀects compared to the parent peptide, but did not attribute
this to transport by GLUT1.137,138 A recent study investigated the eﬀect of enkephalin
glycosylation on the permeability across a Caco-2 cell monolayer. The parent peptide did
not cross the monolayer due to rapid degradation, while the glucosylated derivatives were
able to cross the cell monolayer intact.154 Only some Caco-2 cell clones express GLUT1,
while all carry the sodium glucose co-transporter SGLT1.104,155 Only a single study could
be identiﬁed, which directly investigated the involvement of GLUT1 in the uptake process
of a glucosylated peptide.156 Williams et al. elegantly compared a d-glucosylated peptide
with its l-glucose analogue using in situ rat brain perfusion of the radiolabelled peptides,
while it was known that the unglycosylated peptide does not enter the brain. They
found that this replacement did not aﬀect CNS uptake, thus ruling out GLUT1 mediated
transport. The Polt group speculated that glycopeptides are transported by adsorptive-
mediated transcytosis.137,138,147 The uptake mechanism for glycosylated peptides remains
unclear and warrants further investigations.68 Peptides are of lesser relevance to the present
work, however, and will therefore not be discussed in more detail.‡
Small Molecules. Small molecules are the main focus of drug delivery eﬀorts based on
glycosylation. This strategy has been applied to develop or modify drugs from classes
including chemotherapeutics, anti-inﬂammatory, anti-retroviral and PD drugs.
The delivery of anti-retroviral drugs to the brain is pursued, because the brain can serve
as a reservoir for HIV.157 Bonina et al. reported two glycosylated derivatives of azido-
thymidine (AZT, 1, see Figure 1.11), a reverse-transcriptase inhibitor, and investigated
the plasma concentration and release of free AZT in rats.158 The total AUC was lower for
both glycosylated drugs, but 6-galactosyl ester 1b released AZT slower and over a longer
period of time. Data on the drugs’ brain penetration was not presented. Rouquayrol et al.
synthesised 3-glucosyl esters of HIV protease inhibitors saquinavir (2), indinavir (3) and
nelﬁnavir (4).159 The group tested the permeability of the glucosylated drugs through a
Caco-2 monolayer in both directions (apical to basolateral and basolateral to apical).160
‡For a review on glycosylated neuropeptides, see ref. [132].




















































Figure 1.10: Sugar Fragments Used in Glycosylated Drugs. Wavy line indicates point
of attachment.
Conjugates 3c and 4a showed comparable uptake to the respective parent drugs, while
the uptake of the other conjugates that were tested (2a,c and 3a) was much lower. Eﬄux
rates were diﬀerent to the uptake data, some were higher (2c), comparable (4a) or lower
(2a and 3a,c) than the parent drugs’ eﬄux.160 These results indicate that glucosylation
does not improve the intestinal absorption of these anti-retroviral drugs, and its eﬀect for
transport by GLUT1 remains questionable.160
Recently, a number of glucosylated non-steroidal anti-inﬂammatory drugs (Figure 1.12)
have been reported. Jacob and Tazawa synthesised a 3-glucosyl derivative of aspirin (5)
and tested its cytotoxic eﬀect against cancer cell lines, but did not report permeability
data.161 Chen et al. aimed to improve the brain drug delivery of ibuprofen by glucosylation.
They formed an ester bond between ibuprofen and glucose in positions 2, 3, 4 and 6 (6a–
d) and tested the resulting conjugates for their pharmacokinetic behaviour.162 The tissue
distribution of ibuprofen and the conjugates was measured 60 min after i.v. injection and
about 15–25µg/g was found in the brain for ibuprofen and ibuprofen conjugates 6a–c,
while the brain concentration of the 6-linked conjugate 6d was found to be 55 µg/g. The
group did not investigate whether GLUT1 is directly involved in the results they found, but
explained their ﬁndings with GLUT1’s substrate speciﬁcity and tolerance to modiﬁcations
in certain positions.162 The Gynther group reported the synthesis and investigation of the
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Figure 1.11: Structures of Glycosylated Anti-Retroviral Drugs. Azidothymidine (1),
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Figure 1.12: Structures of Glucosylated Non-Steroidal Anti-Inflammatory Drugs.
Acetylsalicylic acid (Aspirin, 5), Ibuprofen (6), Ketoprofen (7), Indomethacin (8 and 9).
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brain uptake of ketoprofen and indomethacin 6-linked glucoconjugates (7, 8 and 9).163
In situ rat brain perfusion was used to study the brain uptake of ketoprofen derivative 7
and indomethacin derivative 8. The uptake of the ketoprofen conjugate was reduced
in the presence of 50mm glucose, but no such eﬀect was seen for the indomethacin
conjugate. Incubation at 5 ◦C reduced the uptake of both glycoconjugates. Further
experiments measured the inhibition of d-[14C]glucose uptake in the presence of 20mm
glucose, compounds 7 and 8 (80 µm), at 5 ◦C or after preincubation with the conjugates
followed by a wash step. Glucose, reduced temperature and ketoprofen derivative 7 all
inhibited d-[14C]glucose uptake by 75%, while the indomethacin derivative 8 inhibited over
95% of uptake. Inhibition was reversible, as washing the compounds from the capillaries
restored d-[14C]glucose uptake to 75–80% of the baseline. Furthermore, the IC50 values
for 7 and 8 were determined to be 33 µm and 0.71 µm, respectively. These results indicate
that 6-glucosylated ketoprofen 7 is transported into the brain by GLUT1. While the
indomethacin derivative 8 has similarly high uptake into the brain, it is not inhibited by
50mm glucose. This could signify that 8 is a non-transportable inhibitor and enters the
brain via passive diﬀusion. It is, however, more probable that glucose does not inhibit the
uptake of 8, because of the compound’s much higher aﬃnity for the binding site compared
to glucose.163
Halmos et al. studied glucose methanesulfonate esters as potential brain-targeted alkylat-
ing agents.164 The compounds were tested for their inhibition (IC50) of d-[14C]glucose
uptake by GLUT1. The IC50 values for glucose and its 3-mesylated, 4-mesylated, 6-
mesylated, 3,6-dimesylated and 4,6-dimesylated derivatives were determined to be 10mm,
>100mm, 32mm, 52mm, >100mm and 42mm, respectively. The study did not report
whether the compounds enter the brain.164 In an earlier study, Halmos et al. reported the
synthesis of glucosylated chlorambucil derivatives (10, Figure 1.13) and their inhibition
of d-[14C]glucose transport by GLUT1.165 The conjugates are 6-linked esters (10a) and
amides (10b) of chlorambucil and glucose or methyl glucosides (10c,d). Conjugates
were tested for their inhibition of d-[14C]glucose uptake into erythrocytes. Both methyl
glucosides (10c,d) had an IC50 of 3mm, amide 10b was inactive below 4mm and ester
10a was a strong inhibitor with an IC50 of 0.065mm. This inhibition was determined
to be reversible. Additionally, compound 10a inhibited binding of [3H]cytochalasin B,
an allosteric GLUT1 inhibitor, to the transporter. The group also measured association
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of carbon-14 labelled compound 10a to erythrocytes and open erythrocyte membranes.
The compound’s binding was independent of the presence of cytochalasin B, and showed
only a slight temperature dependence, while glucose transport was largely abolished by low
temperatures.165 The compound accumulated to the same extent in erthyrocytes and open
erythrocyte membranes. These results taken together, indicate that compound 10a is a
high aﬃnity, reversible, non-transported inhibitor of GLUT1. Uriel et al. conjugated keto-
C-glycosides with various sugars and evaluated their potential as anti-cancer agents.166
The compounds (11, Figure 1.13) were also tested for their inhibition of d-[14C]glucose
uptake into erythrocytes. The glucose and galactose derivatives had IC50 between 1.5
and 4.5mm, while the xylose and l-rhamnose derivatives were much worse inhibitors. No
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Figure 1.13: Structures of Other Glycosylated Molecules. Chlorambucil (10), Keto-
C-glycosides 11, Morphine (12), 7-Chlorokynurenic acid (13), 6-Deoxy-N -(7-nitrobenz-
2-oxa-1,3-diazol-4-yl)-aminoglucose (NBDG, 14).
Glucuronidation generally is used by the body to detoxify compounds, by increasing their
solubility in blood and thus allowing excretion from the body via the kidneys. Glucuronid-
ated substances were also found to be substrates of ATP-dependent eﬄux transporters,
in particular the multidrug resistance-associated proteins (MRPs).167,168 Several studies
found an interplay between glucuronosyltransferase enzymes, in particular from the UDP
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glucuronosyltransferase 1 family, and the expression and activity of MRPs.169–171 In view
of these ﬁndings, the glucuronidation of morphine has the interesting eﬀect that it increases
morphine’s in vivo activity,172 despite a 30-fold reduction of its brain uptake (%ID/g) in
rats and a 60-fold reduction of its permeability surface area product (PS), compared to
morphine.173 Morphine (12a) and its glucuronide 12b, glucoside 12c, galactoside 12d
and other sugar derivatives have been studied regarding their opioid receptor binding and
anti-nociceptive eﬀect in rats.174 The galactoside 12d was much weaker, the glucuronide
12b slightly weaker in their eﬀect compared to morphine, while glucoside 12c had a higher
anti-nociceptive eﬀect. The glucuronide and glucoside of 7,8-dihydromorphine showed the
strongest anti-nociceptive eﬀect.174 A separate publication compared morphine mannoside
12e to morphine and the glucuronide and found the mannoside to possess a much higher
anti-nociceptive activity in vivo.175 Neither of the studies tried to elucidate the mechanism
of brain penetration, but a study by Bourasset et al. investigated the involvement of various
transport proteins in morphine glucuronide (12b) brain uptake in mice.176 The group
found that knocking out mdr1a (PgP) did not aﬀect the uptake of radiolabelled 12b, but
co-administration of glucose (30mm), digoxin or PSC833 reduced the uptake to a third.
Digoxin and PSC833 are inhibitors of PgP and the organic anion transport protein (OATP)
family. These results indicate that 12b is transported both by GLUT1 and a member of
the OATP family.176 In a more recent study however, Sattari et al. looked at the transport
of 12b in canine kidney cell lines MDCKII and MDCK-PGP (MDCK-MDR1), the latter of
which over-expresses the PgP eﬄux transporter.177 The group found that the transport of
12b is increased by the PgP-inhibitor cyclosporin, in particular in MDCK-PGP cells, but
reduced by PgP- and OATP-inhibitor digoxin. Treatment with probenecid, an inhibitor of
OATP, did not have an eﬀect, but partially inhibited by glucose. In summary, the authors
of the study suggested, that morphine glucuronide 12b is indeed subjected to PgP-eﬄux,
but transported by GLUT1 and possibly members of the OATP transporter family.177
Sugar conjugates of 7-chlorokynurenic acid, a potential anti-convulsant, were reported
by Battaglia et al.178 The parent drug and the galactose derivative 13c did not show
anti-convulsant activity, while both glucose derivatives were active. Drug delivery to the
brain was measured by continuous brain microdialysis in rats. Up to 1000-fold increased
levels of conjugate 13b and its metabolites were detected in the brain, when compared to
unconjugated 7-chlorokynurenic acid, data for the other conjugates was not presented.178





















dopamine H OH OH
15a A-Glc1b OH OH
15b A-Glc3 OH OH
15c A-Glc4 OH OH
15d A-Glc6 OH OH
15e A-Gal6 OH OH
16a B-Glc1a OH OH
16b B-Glc1b OH OH
16c B-Glc3 OH OH
16d B-Glc6 OH OH
16e B-Glc6 OCH3 OCH3
16f B-Glc6 OAc OAc
16g B-Glc6 methylenedioxy
16h B-Glc6 H H
17 C-Glc6 OH OH
18a H O-Glc1b OH
18b H OH O-Glc1b
18c H O-A-Glc6 OH
18d H OH O-A-Glc6
18e H O-A-Glc6 O-A-Glc6
Figure 1.14: Structures of Dopamine-Sugar Conjugates.
A ﬂuorescent glucose derivative, 6-deoxy-N -(7-nitrobenz-2-oxa-1,3-diazol-4-yl)-aminoglu-
cose (14, NBDG) was ﬁrst synthesised by Speizer et al.179 The group found that NBDG
(14) accumulates in erythrocytes and that its entry is inhibitied by glucose and cytochalasin
B and is temperature dependent. This indicates transport by GLUT1.179 Interestingly, its
exit was uninﬂuenced by glucose but inhibited by cytochalasin B, while d- and l-glucose
partially inhibit exit from erythrocyte ghosts. The authors speculated that uptake is in
part mediated by GLUT1, while the exit was by passive diﬀusion.179 Barros et al. showed
that uptake of 14 is a slow process, which is due to a low transport rate.180 A high
binding aﬃnity to GLUT1, which was calculated to be two orders of magnitude lower
than glucose,180 can explain the low inhibition by glucose, which was reported by Speizer.
If the aﬃnity of 14 to bind the inward facing conformation of GLUT1 is too low, it could
be an explanation why it is not exported by GLUT1.
Dopamine and dopamine analogues have been conjugated to sugars in numerous ways
(Figure 1.14, Figure 1.15). Bonina et al. synthesised dopamine and L-DOPA sugar conjug-
ates 15b,e and 19a,b and evaluated them for their activity in vivo.181 While dopamine
normally does not enter the brain, its galactosyl derivative 15e showed a higher activity
than L-DOPA. The 3-glucosyl conjugate 15b was also active, but to a lesser extent. The
activity of L-DOPA, which is centrally active, was increased by conjugation to glucose






























Figure 1.15: Structures of Glycosylated L-DOPA and Dopamine Analogues.
(19a), while the 6-galactosyl derivative 19b had roughly the same activity as the parent
drug.181 The uptake of the compounds was not directly measured. Fernandez-Mayoralas
and co-workers reported the synthesis of a large number of dopamine conjugates, including
succinyl- (15 and 18), carbamate- (16) and peptide-linked (17) derivatives,182–184 as well
as structurally related sugar conjugates 20 and 21 (Figure 1.15).184 The group determined
the uptake into erythrocytes,184 inhibition of glucose uptake by erythrocytes,183 and the
in vivo eﬀect182 of some of these conjugates. Compounds 15a,d,e and 18a,b were tested
for their ability to recover motor activity in reserpinised mice.182 The 6-linked derivative
15d and β-glucoside 18b were the most active compounds, but at the tested dose, they
were only half as eﬀective as amphetamine, while the other compounds showed even less
modiﬁcation of motor activity.182 Compounds 15a,d,e, 16a–d, 17 and 18a were tested
for their eﬀect on d-[14C]glucose uptake into erythrocytes.183 Glucosides 15a and 18a
and galactose derivative 15e were inactive, compounds 16a–c had IC50 values of 50, 31
and 60mm, respectively. Only conjugates that were linked in position 6 of glucose, had
IC50 values around or lower than glucose: Values for 15d, 16d and 17 were 12, 1.5 and
2.2mm, respectively.183 The uptake into erythrocytes was evaluated for 16d, along with
6-linked glucoconjugates 16e–h, 20 and 21.184 No uptake was detected for the compound
with the highest GLUT1 inhibition (16d), its O-acetyl derivative 16f and compound 21.
Dopamine derivatives 16e, 16g and 16h were taken up by erythrocytes (0.8, 1.8 and
2.5mmol/l erythrocytes), as was compound 20 (4.9mmol/l erythrocytes). Their uptake
does not appear to be GLUT1 dependent, however, since co-incubation with reversible
and irreversible GLUT1 inhibitors did not change the uptake of these compounds.184









































Figure 1.16: Structures of Glycosylated Metal Chelators.
Orvig and co-workers recently published the synthesis of glucosylated metal chelators of the
hydroxypyridinone 22 and tetrahydrosalen 23 classes (Figure 1.16),185–188 and speculated
that this glucosylation results in directed uptake into the brain.186,187 Hydroxypyridinone
glucosides were tested for their use as prodrugs for the treatment of Alzheimer’s disease by
copper chelation. Furthermore, the uptake of radioiodinated compounds was tested in a
rat brain perfusion assay.186,187 The permeability of 24 was found to be 0.5 µl s−1 g−1,186 a
structurally related radioiodinated glucoconjugate had a permeability of 0.9±0.4 µl s−1 g−1,
which is comparable to thiourea and lower than caﬀeine.187 The group speculated that
this uptake is due to GLUT1 transport.
Roy et al. synthesised glucosylated deferiprone (25), which is structurally closely related
to pyridinone 24. Brain uptake of 25 was measured by in situ brain perfusion of guinea
pigs, but HPLC could not detect the compound in the brain.51
While many studies investigated the synthesis and activity of glycosylated molecules,
which are purportedly transported by GLUT1, only few studies measured the compounds’
interaction with and inhibition of the glucose transporter and even fewer measured the
substances’ uptake.
In the work published by the Orvig group, for example, rat brains were perfused via the
common carotid artery with physiological perfusion ﬂuid containing [3H]-choline and the
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radioiodinated HPO-glucoside 24 (Figure 1.16).186,187 The brains were perfused for 60
seconds at 10ml/min, resulting in an arterial pressure of 120 mmHg. After decapitation,
the brains were isolated and cleaned of meningeal vessels and the arachnoid membrane.
The perfused hemispheres were then dissected. The protocol mentions the digestion of
‘brain regions’ before scintillation counting, but no further details regarding the speciﬁc re-
gions is given and only one permeability value is reported (presumably for the whole brain).
The permeability was calculated (Kin) via the Crone-Renkin equation and corrected for
the brain vascular space, which was estimated in separate experiments. While the design
of the experiment is relatively solid, a more reliable Kin could have been calculated from
linear regression if the uptake had been measured at multiple time points. Potentially,
the radiolabel had partly dissociated § and diﬀused as iodide ion across the BBB, rather
than the intact molecule, skewing the measured results towards a higher permeability.
The direct measurement of a compound by HPLC/GC, or the use of stable radiolabels
(tritium or carbon-14) would therefore be preferable. The main issue with these studies
are that the presentation and interpretation of the data could be improved. The standard
deviation or standard error or sample size for the experiments was not given, and the use
of choline in the perfusion ﬂuid is not explained or mentioned further. The authors of the
studies interpret the uptake of the radioiodinated compound at levels lower than expected
by passive diﬀusion as a sign that the compound is plausibly entering the brain through
carrier-mediated transport. This conclusion is questionable, as GLUT1 transport or other
carrier-mediated transport would increase the brain uptake of molecules in addition to
their passive diﬀusion, rather than reduce the extent of passive diﬀusion. Active-eﬄux
transport might be a better explanation for the low permeability found for the glucosylated
compound.
In contrast, Halmos et al. studied glucosylated chlorambucil derivatives (10, Figure 1.13)
in human erythrocytes and erythrocyte membranes.165 Erythrocytes were isolated from
fresh blood in citrate buﬀer by removal of platelets and leukocytes. The cells were washed
by multiple centrifugation (2500 g) and resuspension steps in phosphate buﬀered saline
and stored at a hematocrit of 30%. Erythrocyte membranes were prepared by hemolysis
of erythrocytes in sodium phosphate solution followed by centrifugation (22000 g) and
§Iodinated compounds may dissociate due to the relatively low bond dissociation energy (under
60 kcal/mol for a carbon-iodine bond, carbon-bromine and carbon-hydrogen bonds are around 72 kcal/mol
and 100 kcal/mol, respectively).189
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multiple washings. The inhibition of [14C]-glucose uptake (IC50) into erythrocytes by
glucose, methyl-β-glucopyranoside, 3-O-methylglucose and chlorambucil derivatives was
determined at 8 seconds incubation time¶ and stopped by an ice-cold buﬀer with inhibitors
(phloretin, cytochalasin B and HgCl2). The 6-amide-linked conjugate 10b was found to
have an IC50 value larger than the highest tested concentration (4mm) and the 6-linked
methylglucosides 10c,d were relatively inactive (3.0±0.3 and 3.0±0.9 mm). The 6-ester-
linked conjugate 10a, however, was about 50-times better as an inhibitor of glucose uptake
(IC50: 65±15 µm). Conjugate 10a was thus studied further. The inhibiton of glucose
uptake by 10a or cytochalasin B pre-incubation of 20 min was reversible by washing
of the erythrocytes with PBS after the pre-incubation, eliminating the possibility that
the inhibitory eﬀect was due to alkylation of GLUT1. Similarly to the inhibiton of
glucose uptake, the binding of tritium-labelled cytochalasin B to GLUT1 was inhibited
by conjugate 10a in a competitive manner. Finally, [14C]-compound 10a was incubated
with erythrocytes over a range of times (up to 1 hour) and concentrations. The uptake of
the compound was independent of saturating concentrations of glucose or cytochalasin
B and independent of the temperature, thus suggesting non-speciﬁc binding to some
component of the cells. This was conﬁrmed by an experiment measuring the association of
the compound to open erythrocyte membranes, which found the similar levels of binding as
for intact erythrocytes. The authors therefore concluded that the conjugate 10a interacts
with GLUT1 as a non-transported inhibitor.165 Halmos et al. tested the uptake of 10a
thoroughly, and drew the correct conclusions from the data that they had obtained from
multiple well designed experiments, each with a speciﬁc intention.
Overall, certain trends in the literature could be identiﬁed. Sugars other than glucose
are not very well tolerated by GLUT1. Inhibition of GLUT1 is not suﬃcient to indicate
transport of the substance. All conjugates that were convincingly proven to be transported
by GLUT1 are linked in position 6, and the drugs that have been linked are relatively small
and lipophilic. The ﬁndings are in agreement with the studies on substrate speciﬁcity of
GLUT1 (see 1.2.3.1).
The evidence base for GLUT1 transported drugs currently remains narrow, generalisations
should therefore be avoided. Each compound class needs to be evaluated not through
¶Glucose uptake was previously determined to be linear up to this time point.
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inference from other compound’s results, but tested rigorously before conclusion about
GLUT1-mediated transport are drawn.
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1.3 Objectives
The use of iron chelators for the treatment of PD is a promising strategy, but the drugs
currently being investigated rely on passive diﬀusion across the BBB. It was hypothesised
that the conjugation of iron chelators with sugars could target them to the brain and
enhance their uptake.
The aim of this project is therefore to investigate the BBB permeability of known and novel
iron chelators of the 3-hydroxypyridin-4(1H )-one class. The focus is to study whether
sugar conjugates can overcome the BBB, and whether this is facilitated by GLUT1.
The main objective is to investigate how diﬀerent linkers, points of attachment on the
HPO moiety and the sugar moiety aﬀect the molecules’ aﬃnity for and transportability
by GLUT1. Potential conjugates (Figure 1.17) can be linked in positions 1, 2 and 3 of the
HPO moiety. Accessible linkers for the conjugation are amides, ester, ethers or triazoles,
which could be linked in any position of the sugar. Due to the structural requirements
for substrate recognition of GLUT1, conjugates linked in position 6 of the sugar are of
particular interest.
Iron chelator glucosides have been reported previously, but the extent of their BBB
permeability remains debated.51,186 Further investigations into these conﬂicting ﬁndings
are the second objective.
The third objective of this work is the development of a suitable cell-based assay, which
can be used for the determination of BBB permeability, speciﬁcally with regards to the
































Figure 1.17: General Structure of Sugar-Hydroxypyridinone Conjugates.
Linker = Amide, Ester, Ether, Triazole.
Chapter 2
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Reports regarding the blood-brain barrier permeability of HPO glucosides 24 and 25
(Figure 2.1) were published by Orvig’s and Hider’s groups, respectively.51,186 Schugar et
al. reported that the radiolabelled molecule 24 could be detected in the brain of rats by
scintillation counting.186 Roy et al. measured the permeability of N -methyl pyridinone
25 in guinea pigs, but could not detect any compound by HPLC analysis of the brain
homogenate.51
In order to investigate this intriguing diﬀerence in BBB permeability further, the synthesis
of the non-radiolabelled analogue of compound 24 and its close structural analogues 26



























Figure 2.1: Structures of 3-(β-d-Glucopyranosyloxy)-pyridin-4-ones.51,186
Maltol (27, Scheme 2.1) was reacted with aniline (28a) and 4-bromoaniline (28b) to give
N -arylpyridinones 29a and 29b in 60% and 33% yield, respectively. This diﬀerence in
reactivity may be explained by the electronic eﬀect the bromo-substituent has on the
aromatic amine. Pyridinones 29 were then glucosylated with 2,3,4,6-tetra-O-acetyl-α-d-
glucopyranosyl bromide (30, 1-bromo-α-d-glucose tetraacetate, which may be synthesised
as described in Scheme 4.3) in the presence of sodium hydroxide in a biphasic reaction
mixture, with tetrabutylammonium bromide or hydrogen sulfate as phase transfer agent.
Protected glucosides 31a and 31b were obtained in 40% and 44% yield exclusively as
49
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the β-anomers. This substitution reaction proceeds via elimination of the bromide and
attack by the carbonyl oxygen of the adjacent acetyl group. The resulting α-conﬁgured
oxocarbenium ion is attacked by the alcohol, resulting in the β-conﬁguration of the
product.190 This is also conﬁrmed by the 1H-NMR signal of the anomeric proton. In
α-conﬁgured glucosyl bromide 30, the signal is at δ 6.61ppm and the coupling constant
is 4.0Hz, while in glucosides 31a and 31b the coupling constant is 7.9Hz (chemical shift:
5.70 ppm and 5.69 ppm respectively). These values match the coupling constants for β-
conﬁgured glucopyranoses (around 8Hz), which have been determined experimentally,191
while the anomeric proton of α-conﬁgured glucopyranoses has a coupling constant around
4Hz.191 Deprotection of the sugar with sodium methoxide in dry methanol ﬁnally gave the
desired glucosides 26a in 74% yield and 26b in 60% yield. The purity of these compounds
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Scheme 2.1: Synthesis of 3-(β-d-Glucopyranosyloxy)-1-phenylpyridin-4-ones. Re-
agents and Conditions: i) HCl, H2O, reflux, 29a: 60%, 29b: 33%; ii) 1-bromo-α-d-
glucose tetraacetate 30, TBAB or TBAS, NaOH, DCM/H2O, 35
◦C, 31a: 40%, 31b:
44%; iii) NaOMe, dry MeOH, rt, 26a: 74%, 26b: 60% .
Following the procedure for the synthesis of [125I]pyridinone 24, described by Schugar et al.,
the 4-brominated glucoside 31b was transformed to arylstannane 31c with bis(tributyltin)
and tetrakis(triphenylphosphine)palladium in 13% yield (Scheme 2.2, literature:186 38%).
A potential reason for the lower yield could be that the anhydrous reaction conditions were
not maintained as rigorously as it might be necessary. The next step, replacement of the
tributylstannyl group with the radioisotope – or ‘cold’ iodine in this case – was eﬀected
by sodium iodide, chloramine T and dilute phosphoric acid. Schugar et al. report the
successful transformation to the radioiodinated product and its subsequent deprotection
to glucoside 24. Despite exactly replicating the reported procedure, the reaction did not
yield the desired 31d, but rather starting materials and decomposition products. After
column chromatography, some decomposition products could be identiﬁed as (partially)
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deacetylated starting material due to their NMR spectra, which showed one or two acetyl



























31b 31c 31d 26c
Scheme 2.2: Attempted Synthesis of 3-(2,3,4,6-Tetra-O-acetyl-β-d-glucopyranosyl-
oxy)-1-(4-iodophenyl)-2-methylpyridin-4(1H )-one. Reagents and Conditions: i) Bis(tri-
butyltin), Pd(PPh3)4, dry toluene, N2 atmosphere, reflux, 13%; ii) NaI, chloramine T,
H2PO4, EtOH/H2O, rt.
Alternative Routes to 1-(4-Iodophenyl)-Pyridin-4-ones
Attempts were made to obtain 31d via other synthetic routes. The reaction conditions,
which were previously used for the double Michael addition of an aromatic amine to maltol
(Scheme 2.1), gave the expected pyridinones 29a and 29b from aniline and 4-bromoaniline.
When 4-iodoaniline (28c) was used as reagent however (Scheme 2.3), extensive polymer-
isation was observed and no product could be identiﬁed or isolated, while unreacted maltol
was partly recovered. Reversal of the reaction steps, thus glucosylating maltol ﬁrst, yielded
pyranone 32 (30%). The double Michael addition of 4-iodoaniline under acidic conditions
again resulted in polymerisation of 4-iodoaniline and some decomposition of glucoside 32
(partial deacetylation of the glucoside). Saghaie et al. reported that the reaction between
pyranone and aniline proceeds without addition of acid, but at high temperatures (150 ◦C
to 160 ◦C) in a sealed pressure tube.192 Under these conditions, no reaction was observed
even after prolonged reaction times, and the unmodiﬁed starting materials were recovered
(Scheme 2.3).
After reactions with 4-iodoaniline did not yield iodinated pyridinones, other possibilities
to introduce iodine to an aromatic ring were investigated. Buchwald’s group published a
facile and high yielding method for the exchange of aromatic bromides via an aromatic
Finkelstein reaction.193 For this, the aromatic bromide, sodium iodide, a catalytic amount
of copper(I) iodide and a simple diamine ligand are heated to reﬂux in a protic or non-
protic, polar solvent (or solvent mixture), generally for 12–24 hours.193

































Scheme 2.3: Attempted Synthesis of 1-(4-Iodophenyl)-pyridin-4-ones. Reagents and
Conditions: i) 4-iodoaniline 28c, HCl, MeOH/H2O, reflux; ii) glucosyl bromide 30,
TBAB, NaOH, DCM/H2O, 35
◦C, 30%; iii) 4-iodoaniline 28c, MeOH/H2O, 150
◦C,
sealed tube.
The feasibility of this reaction was explored in a set of trial experiments using less complex
starting materials. HPOs have a high aﬃnity to chelate copper,194,195 which would lead
to the chelation of the catalyst for the transhalogenation. The iron chelating part of the
molecule (3-hydroxy and 4-oxo groups) therefore had to be masked to prevent chelation
of the catalyst. Benzylated maltol 33 (Scheme 2.4) was thus synthesised from maltol
and benzyl bromide in excellent yield. Pyranone 33 was then transformed to pyridinone
34a by reaction with 4-bromoaniline (yield: 79%), as described for the non-benzylated
pyridinones 29. The transhalogenation reaction was then attempted on benzylated bro-
mopyridinone 34a. For this, the pyridinone 34a, sodium iodide, copper(I) iodide, N,N’ -
dimethylethylenediamine and dioxane were added to a sealed tube and heated to 110 ◦C
for 24 hours. The crude product was isolated and analysed by 1H-NMR spectroscopic
analysis, which showed that the reaction successfully produced 34b, but some unreacted
starting material remained (5/1 ratio 34b/34a; yield by NMR: 64%). The product was



















Scheme 2.4: Synthesis of 3-(Benzyloxy)-1-(4-iodophenyl)-2-methylpyridin-4(1H )-one.
Reagents and Conditions: i) Benzyl bromide, NaOH, MeOH/water, reflux, 92%; ii) 4-
bromoaniline 28b, HCl, MeOH/H2O, reflux, 79%; iii) NaI, CuI, N,N’ -dimethylethylene-
diamine, dry dioxane, 110 ◦C, sealed tube, 64%.




























29b 29c 31b 31d
Scheme 2.5: Attempted Transhalogenation of 1-(4-Bromophenyl)-pyridin-4-ones.
Reagents and Conditions: i) NaI, CuI, N,N’ -dimethylethylenediamine, dry dioxane,
110 ◦C, sealed tube.
the halogen substituent). In the 4-bromo substituted HPO 34a, these signals are doublets
with a chemical shift of 7.73ppm and 7.28 ppm, while the iodinated product 34b lacks
these peaks and shows doublets at 7.83ppm and 6.93 ppm, instead, which can be explained
by the stronger electronic eﬀect of the iodine substituent.
When the same reaction conditions were used for the transhalogenation of 3-hydroxy-
pyridinone 29b (Scheme 2.5), no reaction was observed, however, and the starting mater-
ials were recovered. This result was expected as the compound presumably sequestered
the copper catalyst, preventing any reaction. In the glucosylated pyridinone 31b, the
glucoside masks the 3-hydroxy group, which should prevent chelation of the catalyst. Sur-
prisingly, after column chromatography we mainly isolated unreacted 31b, some partially
deacetylated starting material and other unidentiﬁed side products. This lack of reactivity
could not be explained in view of the previous experiments, however.
At this point, no further attempts towards the synthesis of pyridinone 26c (Scheme 2.2)
were made, and the blood-brain barrier permeability assays were carried out with the
non-iodinated analogues 26a and 26b.
Spectroscopic Investigations
The spectroscopic investigations for the structure elucidation of glucoside 26a (Figure 2.2)
and full assignment of all 1H- and 13C-resonances – and 1H,1H-coupling constants where
possible – are presented here (Table 2.1), in order to demonstrate the general approach
taken to ascertain that the isolated compounds are of the expected structure.
Reliable and unambiguously assigned chemical shift data are important reference material
for NMR prediction programs, such as CSEARCH196/NMRPREDICT197 (part of the



















Figure 2.2: Structure and Numbering of Glucoside 26a.
Mnova package) and ACD/NMR Predictors.198 NMR prediction programs have become
very popular in the last few years, particularly for predicting 13C-NMR chemical shifts.
However, the quality of such predictions is highly dependent on the availability of authentic
reference data from related structures.
Glucoside 26a is a pale tan solid, which decomposes at 198 ◦C. High resolution mass
spectrometry found the parent ion plus chloride ([M+Cl–]) at m/z 398.1007/400.0973 amu,
which is within ±0.01 amu of the calculated values for expected parent ion plus chloride.
This indicates, that the molecule has the same molecular formula as the expected product
(C18H21NO7+Cl
–).
Multiple NMR spectra of 26a in deuterated methanol were recorded for the structure
elucidation: 1H-NMR, proton decoupled 13C-NMR, DEPT135, 1H,13C-HSQC, 1H,13C-
HMBC and 1H,1H-COSY. Certain signals are unique in this compound and can be assigned
directly, such as the singlet at 2.25 ppm (2-CH3) and the two doublets at 7.75 and 6.57
ppm, which are the pyridinone ring hydrogens (H-5 and H-6). The COSY spectrum allows
the assignment of the network of hydrogen atoms that couple with each other. Starting
from proton signals which are very distinct, such as the doublet of H-1” (4.73 ppm), the
anomeric centre of the sugar, the remaining signals of the sugar part of the molecule
(between 3 and 4 ppm) are easily assigned (Table 2.1). The signals of the phenyl ring
appear as two multiplets: 7.63–7.57 ppm for H-3’,4’,5’ and 7.47–7.41 ppm for H-2’,6’.
The proton decoupled 13C-NMR spectrum shows all carbon signals, while the DEPT135
spectrum shows only carbon atoms which are bonded to at least one hydrogen atom.
DEPT135 also shows whether a carbon is connected to an even or odd number of hydrogen
atoms. Signals that do not appear in the DEPT135 spectrum, but are present in the
decoupled carbon NMR spectrum, must stem from quaternary carbon atoms. The HSQC
spectrum allows the assignment of the proton signals to the carbon atoms to which the
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protons are attached to, so that the quaternary carbon signals are the only signals that
have not been assigned at this point (Table 2.1).
The 1H,13C-HMBC spectrum contains a large amount of information about the connectiv-
ity within a molecule and is a very powerful and important NMR technique for structure
elucidation. Since the signal at 145.91 ppm correlates with the signal of H-1” (4.73 ppm),
this carbon must be C-3 (Figure 2.3.a). H-5 may also be identiﬁed from its correlation
with the signal from C-3, and its shift is therefore 6.57 ppm. C-3 also correlates with
the 2-methyl group (2.25 ppm). The other quaternary carbon (146.76 ppm) the 2-methyl
group has a correlation with, must thus be C-2 (Figure 2.3.b). The correlation of C-2 with
the signal of H-6 (7.75 ppm) conﬁrms the previous assignment of H-5. H-5 and H-6 both
correlate with the carbonyl signal at 174.86 (C-4, Figure 2.3.c), while only H-6 correlates
with C-1’ of the N -phenyl ring. Three-bond correlations were observed (H-2’,6’ with C-4’
(131.16 ppm), H-3’,5’ with C-1’ and H-4’ with C-2’,6’), while two-bond correlations were
too weak to be observed.
To summarise, a combination of standard 1D and 2D NMR techniques was suﬃcient to











































































Figure 2.3: HMBC Correlations in Glucoside 26a.
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Table 2.1: Proton and Carbon NMR Signals of 26a in CD3OD. Shifts given as δ ppm,
relative to TMS.
Position 1H Shift 13C Shift Signal Typea
2 – 146.76 Cq
3 – 145.91 Cq
4 – 174.86 Cq
5 6.57 116.89 CH, d
6 7.75 142.3 CH, d
2-CH3 2.25 15.74 CH3, s
1’ – 143.05 Cq
2’,6’ 7.47–7.41 127.99 CH, m
3’,5’ 7.63–7.57 131.23 CH, m
4’ 7.63–7.57 131.16 CH, m
1” 4.73 107.06 CH, d
2” 3.47–3.40 75.58 CH, m
3” 3.47–3.40 78.48 CH, m
4” 3.34 71.11 CH, ‘t’
5” 3.27 78.72 CH, ddd
6a” 3.84 62.63 CH, dd
6b” 3.66 62.63 CH, dd
a Type of carbon signal: Cq – quaternary carbon.
Multiplicity: s – singlet, d – doublet, t – triplet, m –
multiplet.
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The second aim of this project – in addition to the preparation of HPO-glucosides 26
discussed in the previous chapter – was to obtain conjugates which are linked in other
positions, particularly positions 2 and 6 of the sugar moiety. These positions are expected
to facilitate the recognition and transport of sugar conjugates by GLUT1, as discussed in
Section 1.2.3.2.
In this chapter, the synthesis of amide-linked conjugates is described. Amide-linked
conjugates were designed, because amides are relatively facile to form, while at the same
time stable enough to withstand the esterases and general milieu found in blood. The
starting materials for the formation of an amide are commonly a carboxylic acid and an
amine. This allows two distinct strategies for HPO-sugar conjugates (Figure 3.1). On the
one hand an amino sugar could be coupled with an HPO with a carboxylic acid moiety,
and on the other hand a sugar bearing an acid group could be attached to an HPO with
a free amino group. Both routes are described in this chapter.
Additionally, 3-hydroxypyridin-4-ones can be conveniently functionalised on two parts of
the molecule: A substituent with the desired functional group may be introduced on the
































Figure 3.1: Routes towards Amide-linked Conjugates.
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3.1 Preparation of Conjugates with Glucosamine
3.1.1 Synthesis of ω-(4-Oxopyridin-1-yl)carboxylic acids
This section covers the preparation of HPOs with N -alkyl substituents bearing a carboxylic
acid group.
Maltol (27), protected maltol 35 or other pyran-4-ones are readily transformed into their
respective pyridin-4-ones 36 (Scheme 3.1) via a double Michael addition of alkylamines,
amino alcohols, amino acids and most other aliphatic primary amines under basic condi-
tions, as demonstrated by Dobbin et al.199 Alternatively, N -unsubstituted HPOs 37 may


















Scheme 3.1: Synthesis of N -substituted 3-Hydroxypyridin-4-ones.199–201 Reagents
and Conditions: R = H, Me, Bn; R’ = alkyl, hydroxyalkyl, carboxylic acid, aminoalkyl;
R” = alkyl, acyl.
In order to obtain the desired HPOs, the protocol described by Dobbin et al. was followed.
The 3-hydroxy group of maltol was ﬁrst benzylated to give pyranone 33 in 92% yield
(Scheme 3.2). Reaction of this intermediate with glycine, β-alanine or γ-aminobutyric
acid transformed the protected pyranone into pyridinones 39a, 39b and 39c, respectively,
in good to excellent yield (71–98%). This reaction proceeds via a double Michael addition





















Scheme 3.2: Synthesis of ω-(4-Oxopyridin-1-yl)carboxylic acids. Reagents and
Conditions: i) Benzyl bromide, NaOH, MeOH/water, reflux, 92%; ii) glycine or β-alanine
or γ-aminobutyric acid, NaOH, MeOH/water, reflux, 39a: 94%, 39b: 71%, 39c: 98% .





































Scheme 3.3: Reaction Mechanism of Double Michael Addition to Pyran-4-ones.
3.1.2 Preparation of 2-Carboxypyridin-4-ones
HPOs bearing functional groups in position 2 have been described in the literature, but
their synthesis typically involved numerous steps to introduce an oxygen on the substituent
on position 2, which was then oxidised further.
For example, Liu et al. prepared pyromeconic acid (40, R=H, Scheme 3.4) from furfuryl
alcohol in 4 steps (40% overall yield).203 Pyromeconic acid or its 6-substituted analogues
were then reacted with an aldehyde, in a reaction analogous to an aldol condensation. This
was followed by the protection of both hydroxy groups as a benzylidene acetal, to give
pyranones 41. These intermediates were transformed to the respective pyridinone 42 via
double Michael addition of a primary amine R”-NH2. The 2-hydroxyalkyl group was then
deprotected by catalytic hydrogenolysis to furnish pyridinones 43.203 Such pyridinones 43,
where R’=H, are suitable starting materials for the further oxidation of the alcohol func-



























40 41 42 43
Scheme 3.4: Published Synthesis of 2-(1’-Hydroxyalkyl)-3-hydroxypyridin-4-ones.203
Reagents and Conditions: i) R’-CHO, water, pH 10.5, rt, then HCl, 47%; ii) benzaldehyde
dimethyl acetal, p-TsOH, DMF, 80 ◦C, 82%; iii) R”-NH2, 2M NaOH, EtOH/water (1/1),
70 ◦C, 40–79%; iv) Pd/C (5%), H2, EtOH, pH 1, rt, 73–88%.
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An alternative route for the synthesis of HPOs with a carboxy group in position 2 was
reported by Piyamongkol et al. and starts from maltol (Scheme 3.5).204 First, the 3-hydr-
oxy group was benzylated, followed by the double Michael addition of ammonia to furnish
pyridinone 44. The carbonyl group in position 4 was then benzylated in a Mitsunobu
reaction using benzyl alcohol to give 3,4-bis(benzyloxy)-2-methylpyridine, which in turn
was oxidised to its N -oxide 45 with m-chloroperoxybenzoic acid in DCM. The N -oxide
was acetylated with acetic anhydride, which re-arranges to give ester 46. The ester was
hydrolysed and the resulting hydroxide transformed to the aldehyde with a Parikh-Doering
oxidation. 3,4-Bis(benzyloxy)picolinic acid (47) is ﬁnally obtained in 14% overall yield by
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Scheme 3.5: Synthesis of 3,4-Bis(benzyloxy)picolinic acid.204 Reagents and Condi-
tions: i) BnBr, NaOH, EtOH, reflux, 80%; ii) NH3, EtOH, reflux, 75%; iii) TPP, DEAD,
BnOH, THF, reflux, 79%; iv) MCPBA, DCM, rt, 77%; v) acetic anhydride, reflux; vi)
2M NaOH, reflux, 81% (two steps); vii) DMSO, Py−SO3, TEA, chloroform, rt, 62%; viii)
NaClO2, H2NSO3H, acetone/water (1/1), rt, 77%.
In general, the desired carboxylic acid (48, see Scheme 3.6) could be obtained from the
oxidation of pyridinone 49 or from the double Michael addition of methylamine to an
oxidised pyranone, e.g. carboxylic acid 50. The latter route was chosen, avoiding the





















Scheme 3.6: Retrosynthetic Analysis of 3-(Benzyloxy)-2-carboxypyridin-4-one.












Scheme 3.7: Synthesis of 3-(Benzyloxy)-2-formylpyran-4-one.205
Pace et al. reported the facile oxidation of 3-benzyloxy maltol (33) with selenium dioxide
in reﬂuxing bromobenzene in good yield (Scheme 3.7).205
Replicating the published procedure, the reaction proceeded without side products, but full
conversion of the starting material could not be achieved – about half the starting material
remained unreacted. The product 51 has a very similar Rf value (Rf = 0.50, Ethyl
acetate/Hexane: 2/1) to the starting material (Rf = 0.54) on thin layer chromatographic
(TLC) plates, which made the puriﬁcation by column chromatography diﬃcult. Numerous
eluent mixtures were investigated, but none allowed a signiﬁcantly better separation than
ethyl acetate/hexane mixtures.
Therefore, attempts were made to optimise the reaction (see Table 3.1). First, the inﬂuence
of temperature was investigated (entries 1–5). The crude material was analysed by 1H-
NMR and the amount of aldehyde quantiﬁed via the intensity of the characteristic signal
of the aldehyde proton at δ 9.87 ppm. At low temperatures (20 ◦C and 40 ◦C), no peak
could be observed. The peak was only detected at higher temperatures: barely noticeable
at 80 ◦C and 120 ◦C, but distinct and strong at reﬂux temperature (160 ◦C). However,
even when the reaction was heated to reﬂux, only half of the material had been converted
to the desired aldehyde 51 and the other half was the unchanged starting material, as
determined by NMR. Varying the amount of selenium dioxide used in the reaction did not
seem to have a large eﬀect, where reactions with around 2 equivalents (entries 6–8) gave
yields between 35–43%, while 4 equivalents (entry 9) reduced the yield to 20% and multiple
additions of reagent (entry 10) also appeared to have a detrimental eﬀect. The choice of
solvent seemed to be limited to bromobenzene, because the use of other solvents, which
had previously been reported to work with selenium dioxide, prevented the formation of
product in this instance: When reﬂuxing acetic acid/acetic anhydride was used,206 no
turnover was observed, while reﬂuxing DMF207 led to a complex mixture, which could not
be puriﬁed. DABCO and copper(I)bromide-dimethylsulﬁde complex (entry 13), which
had been published by Wang et al. as reagent for the oxidation of heteroaromatic methyl
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groups,208 did not result in any turnover of starting material.
Because no signiﬁcant improvement had been achieved at this point, it was decided to
purify the aldehyde 51 by repeated column chromatography and proceed by converting
51 into pyridinone 52 (Scheme 3.8). Unexpectedly, the usual reaction conditions (as
described for compounds 39, Scheme 3.2) only returned the unreacted starting material.
The electronic eﬀect of the aldehyde group may interfere with the double Michael addition,
which could explain that the reaction did not proceed. Thus, the aldehyde group was
protected as dimethyl acetal 53, which gave pyridinone 54 in 75% yield by reaction with
methylamine. The deprotection of the pyridinone acetal to aldehyde 52 was attempted
with a range of acidic conditions (e.g. HCl or TFA), but no reaction was observed, when
monitored by TLC.
Instead, maltol aldehyde 51 was oxidised to pyranone acid 50 with sodium chlorite and
sulfamic acid in fair yield (Scheme 3.9), following the protocol by Piyamongkol.204 Then,
the transformation of acid 50 into pyridinone acid 48 via double Michael addition was
attempted. The reaction did not proceed when heated to reﬂux at atmospheric pressure,
but only when heated to high temperatures (110 ◦C) in a sealed tube. This aﬀorded the
desired carboxylic acid 48 in 70% yield. An advantage of this route is that the troublesome
puriﬁcation of aldehyde 51 is not necessary, because the crude product could be directly
oxidised to carboxylic acid 50. Any remaining benzylated maltol (33) was readily removed
during work up, when the product was washed with acetone.
Overall, this synthetic route shortens the 8-step synthesis by Piyamongkol et al. to a 4-step
route. All steps are synthetically facile, do not require exclusion of moisture of air and
do not involve puriﬁcation by column chromatography – only the ﬁrst intermediate 33 is
puriﬁed by recrystallisation. The overall yield is comparable to the published procedure
(14% vs 17%), but could be greatly increased, if full conversion in the oxidation with
selenium dioxide was achieved.
3.1.3 Formation of Selectively Protected Glucosamine Derivatives
Glucosamine was chosen as the amino sugar for the coupling with HPO carboxylic acids, as
it is cheap and commercially available, while other amino sugars are not readily available
(in particular aminoglucose derivatives). The use of an O-protected amino sugar may be
advantageous for the formation of the amide bond, precluding side reactions leading to the
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Table 3.1: Optimisation of the Oxidation of 3-(Benzyloxy)maltol with SeO2.
Entry Reagent Eq. Solvent Temp. Time (h) Ratio 51/33a
1 SeO2 2 PhBr 20
◦C 22 no reaction
2 SeO2 2 PhBr 40
◦C 22 no reaction
3 SeO2 2 PhBr 80
◦C 22 1/625
4 SeO2 2 PhBr 120
◦C 22 1/72
5 SeO2 2 PhBr 160
◦C 22 1/1
Entry Reagent Eq. Solvent Temp. Time (h) Yield 51 Yield 33b
6 SeO2 1.5 PhBr 160
◦C 20 40% 20%
7 SeO2 2 PhBr 160
◦C 22 35% 21%
8 SeO2 2.5 PhBr 160
◦C 19 43% 36%
9 SeO2 4 PhBr 160
◦C 21 20% 51%
10 SeO2 2
c PhBr 160 ◦C 20 30% 30%
11 SeO2 2 AcOH/Ac2O 80
◦C 4 — 100%
12 SeO2 2 DMF 120
◦C 22 complex mixture
13d
CuBr·SMe2 0.15
DMSO 100 ◦C 29 — 100%
DABCO 1
a Determined by NMR. b Remainder to 100% isolated as mixture of 51 and 33. c Added in portions




































Scheme 3.8: Attempted Synthesis of 3-(Benzyloxy)-2-formylpyridin-4(1H )-one. Re-
agents and Conditions: i) Methylamine, NaOH, MeOH/H2O, reflux, 75% (53→54); ii)
trimethyl orthoformate, TsOH, dry MeOH, reflux, 89%.

















Scheme 3.9: Synthesis of 2-Carboxypyridin-4-one. Reagents and Conditions: i)
sulfamic acid, NaClO2, acetone/H2O, rt, 48%; ii) methylamine, H2O, 110
◦C, sealed
tube, 70%.
formation of esters with the carbohydrate hydroxyl groups. Therefore, glucosamine hydro-
chloride was selectively protected as its tetra-O-acetyl derivative 58 (see Scheme 3.10).
This reaction was ﬁrst described by Bergmann and Zervas in 1931,209 while this work is
using a modiﬁed procedure that was described by Myszka et al.210
Brieﬂy, glucosamine was reacted with anisaldehyde under neutral reaction conditions to
give imine 56 (yield: 84%). This was acetylated with acetic acid and pyridine to give fully
protected sugar 57 in very good yield, which was quantitatively deprotected by hydrolysis
































Scheme 3.10: Synthesis of 1,3,4,6-Tetra-O-acetyl-β-d-glucosamine hydrochloride.
Reagents and Conditions: i) NaOH, rt, 84%; ii) acetic anhydride, pyridine, 0 ◦C, then rt,
81%; iii) 5M HCl, acetone, reflux, quantitative.
3.1.4 Formation of Amides with Glucosamine Derivatives
Glycine derivative 39a (Scheme 3.11) was activated as its N -hydroxysuccinimide ester 61a
from the reaction of acid 39a with DCC and N -hydroxysuccinimide (NHS) in dry DMF
in 45% yield. The reaction proceeds via the O-acylisourea 62, which reacts quickly with
NHS to give the more stable NHS-ester 61a and N,N’ -dicylcohexylurea. The activated
ester can be separated from the formed urea by ﬁltration and unreacted acid may be






























Scheme 3.11: Synthesis of 1-(β-d-Glucopyranos-2-yl)-ω-(4-oxopyridin-1-yl)acyl-
amides.
removed by extraction if necessary. Ester 61a was reacted with protected glucosamine
58 in dry DMF in the presence of diisopropylethylamine to yield the desired amide 63a
in good yield (34% from 39a). For the synthesis of β-alanine derivative 63b, protected
glucosamine 58, acid 39b was reacted with 1-hydroxybenzotriazole and EDC (1-ethyl-3-
(3-dimethylaminopropyl)carbodiimide hydrochloride) in aqueous DMF at 80 ◦C to give the
desired amide 63b in 22% yield after prolonged reaction time.
The synthesised amides 59 were subjected to common deprotection conditions.211 Methan-
olic sodium methoxide or aqueous sodium hydroxide solutions were used to deprotect the
amides, but the desired products could not be isolated from the crude material, because
signiﬁcant quantities of decomposition products (i.e. fragments from the cleavage of the
amide bond) hampered the puriﬁcation. Side products co-eluted with the deprotected
products when puriﬁed by column chromatography, so that no deacetylated amides 60
could be obtained in suﬃcient purity for further use. The puriﬁcation of the synthesised
amides was ultimately abandoned in favour of diﬀerent amide conjugates described below.
3.2 Preparation of Glucuronamides
In addition to the amides described in the previous section, amide-linked conjugates were
investigated, where the amine- and acid-bearing moieties are reversed, i.e. a sugar bearing
a carboxylic acid being linked to an HPO with a free amino group (Scheme 3.12). The
necessary HPO may be readily obtained from the reaction of maltol and a diaminoalkane,
whereas various sugar acids could be used as starting material.





















Scheme 3.12: Retrosynthetic Analysis of Conjugates of Sugar Acids and HPOs.
3.2.1 Synthesis of Protected Glucurono-6,3-lactone
Glucuronic acid was selected as sugar acid, allowing ready access to conjugates that are
linked on position 6 of the sugar, thus expanding the diversity of the linked positions. The
glucuronic acid derivative glucurono-6,3-lactone (64) was chosen as starting point, because
the 5-membered lactone should activate the acid moiety suﬃciently to forego additional
activation steps. Fieser et al. demonstrated the viability of this idea by synthesising
glucuronamides from long chain alkylamines and glucurono-6,3-lactone.212 In order to
prevent side reactions of the amino group with the anomeric centre of the sugar, the sugar
hydroxyl groups in positions 1 and 2 had to be protected. 1,2-O-Protected glucurono-
6,3-lactones have been described previously and the most commonly used are acetonide
protected lactone 65 and the analogous benzylidene derivative 66 (see Scheme 3.13).212–215
The preparation of the acetonide derivative was ﬁrst described by Owen at al. in 1941,213
but herein the modiﬁcation by Fieser et al. was used.212 Glucurono-6,3-lactone (64) was
dissolved in acetone with addition of a catalytic amount of sulfuric acid to convert it into
its 1,2-O-acetonide 65 in excellent yield (Scheme 3.13).
Similarly, glucuronolactone was protected as its 1,2-O-benzylidene derivative 66, which
can be deprotected by hydrogenation.215 This should allow the deprotection of the con-
jugate in one step, rather than a two step procedure, which will be necessary for the
acetonide protected conjugates (deprotection of the sugar, followed by deprotection of the
HPO part). Reaction of glucurono-6,3-lactone with neat benzaldehyde in the presence
of zinc chloride gave 1,2-benzylidene protected sugar 66 in 59% yield. The product was
an epimeric mixture of S- and R-stereoisomers in a 4/1 ratio, as determined by NMR.
The assignment of the main constituent as the S-isomer was based on a recent paper
by Jenkinson et al., who puriﬁed the main reaction product and determined its absolute
conﬁguration by X-ray crystallographic analysis.216 The 13C-NMR spectrum reported by
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Csuk et al. for the S-isomer matches the spectrum of the mixture’s major component,214




















R = R' = CH3
R = Ph, R' = H64
65
66
Scheme 3.13: Preparation of 1,2-Protected Glucurono-6,3-lactones. Reagents and
Conditions: i) Acetone, H2SO4, rt, 93%; ii) Benzaldehyde, ZnCl2, rt, 59% (Ratio S/R:
41).
3.2.2 Preparation of 1-(ω-Aminoalkyl)-pyridin-4-ones
Following the general protocol described for the synthesis of N -substituted HPOs by
Dobbin et al.,199 benzylated maltol 33 was reacted with a slight excess of diaminoalkanes
of varying chain lengths (1.1 equivalents) to form the desired aminoalkyl-HPOs 67. The
reaction with ethylenediamine dihydrochloride gave pyridinone 67a in 38% yield, wheras
the butane derivative 67b and the previously undescribed hexane derivative 67c were
obtained in 62% and 64% yield, respectively. The novel octane derivative 67d was obtained


















n 67 Yield 68 Yield
2 a 38% a N/Ia
4 b 62% b 26%
6 c 64% c 36%
8 d 99% d N/Ia
a N/I – not isolated
Scheme 3.14: Synthesis of 1-(ω-Aminoalkyl)-pyridin-4-ones. Reagents and Condi-
tions: i) 1,2-Diaminoethane dihydrochloride or 1,4-diaminobutane or 1,6-diaminohexane
or 1,8-diaminooctane, NaOH, EtOH/water, reflux.
reactions where n=4 or n=6. This precipitate was the dimer 68b and 68c, which resulted
from the addition of a second molecule of protected maltol 33 to the desired product 67.
The dimer was identiﬁed by high resolution mass spectrometry and NMR spectroscopy,
showing the peaks and integration pattern which would be expected for a dimeric molecule.
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The formation of such dimers is facilitated by a high ratio of pyranone 33 to amine and
could have been avoided by addition of the diamine in larger excess.
Interestingly, an almost quantitative (combined) yield was observed for the longer chain
diaminoalkanes, while the shortest diaminoalkane (n=2) had a signiﬁcantly lower yield
of products. In contrast, the longest diaminoalkane (n=8) yielded no dimer, while the
shorter diamines did give signiﬁcant amounts of dimer. These diﬀerences could potentially
be due to the increased length and ﬂexibility of the side chain, allowing the formation of
an intramolecular hydrogen bond, which would not be possible in the shorter chained
analogues. Any dimer that had formed for n=2 was not isolated however, because it did
not precipitate during work up.
3.2.3 Preparation of N -(ω-(4-Oxopyridin-1-yl)alkyl)glucuronamides
The use of protected glucuronolactones for the synthesis of emulsiﬁers has been described
by Fieser et al., where the lactone was reacted directly with the respective amines, yielding
the desired long chained amides.212 In a ﬁrst set of trial experiments (Scheme 3.15),
protected glucuronolactone 65 was reacted with pentylamine or 5-amino-1-pentanol in
DMF at room temperature or 40 ◦C. The reaction mixtures were evaporated and analysis
of the crude material by 1H- and 13C-NMR spectroscopy showed full conversion to the
respective amides 69 and 70, as determined by the shift of the methylene protons adjacent






















Scheme 3.15: Reaction of Protected Glucuronolactone with Alkylamines. Reagents
and Conditions: i) Pentylamine or 5-amino-1-pentanol, DMF, rt or 40 ◦C, quantitative
by NMR.
Based on these results, lactones 65 and 66 were reacted with aminoalkyl HPOs 67b and
67c in dry DMF at room temperature. After extraction and column chromatography, the
desired protected amides 71b, 71c, 72b and 72c were obtained in fair yields (61–78%,
see Scheme 3.16).
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Scheme 3.16: Preparation of N -(ω-(4-Oxopyridin-1-yl)alkyl)glucuronamides.
Cmpd n R R’ Yield Cmpd n R R’ Yield
71a 2 CH3 CH3 —
a 72a 2 Ph H —a
71b 4 CH3 CH3 65% 72b 4 Ph H 78%
71c 6 CH3 CH3 61% 72c 6 Ph H 70%
71d 8 CH3 CH3 —
a 72d 8 Ph H —a
a Synthesis not attempted in this work.
According to Fieser et al., glucuronamides protected as 1,2-acetonide may be deprotec-
ted under acidic conditions.212 In a ﬁrst set of experiments, the deprotection of the
acetonide-protected lactone 65 was thus attempted with a range of acidic conditions
(Table 3.2). 1,2-O-Isopropylideneglucurono-6,3-lactone (65) was treated with 90% acetic
acid or triﬂuoroacetic acid at room temperature, but the reaction did not proceed, even
with prolonged reaction times. When heating the lactone in aqueous acetic acid solutions
to elevated temperatures, it was deprotected after few hours. Similarly, Amberlite (H+
form) did not deprotect the lactone at 40 ◦C, but did so when heating the reaction mixture
to 80 ◦C. Dilute hydrochloric acid was able to deprotect the lactone under reﬂux in less
than one hour. The deprotection of the sugar and thus the presence of a free anomeric
centre was tested with Fehling’s test. An aliquot of the reaction mixture was treated with
Fehling’s solution (copper(II)sulfate and sodium tartrate) and heated – the formation of a
reddish copper(I) oxide precipitate indicated the presence of an (reducing) aldehyde group,
which is only present in the unprotected sugar.
Reaction conditions that successfully deprotected glucuronolactone 65 (Table 3.2) were
then used for the deprotection of the full conjugates 71 and the reactions were monitored
in regular intervals by TLC. The reaction mixtures were evaporated and analysed by
NMR, to check the outcome of the reaction. The use of 60% acetic acid at 95 ◦C resulted
in extensive cleavage of the amide bond. When the temperature was reduced to 60 ◦C and
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reaction time to 6 hours, the main constituent of the crude product was the unreacted
amide, besides traces of the desired product. Increasing the acid concentration from 60%
to 70% however, signs of cleavage of the amide bond were observed, while substantial
amounts of starting material remained. A similar result was observed with Amberlite at
80 ◦C after 36 hours, while at shorter time points, no reaction could be observed. Dilute
hydrochloric acid (0.45M HCl) did not deprotect the glucuronamide after 30 minutes,
while the use of 1M hydrochloric acid for 45 minutes resulted in substantial cleavage of
the starting material and/or desired product.
These results suggest that a very narrow window exists for the deprotection of glucuron-
amides 71, where the 1,2-protecting group is hydrolysed before cleavage of the amide bond
occurs, which might make it impossible to isolate the ﬁnal product in substantial yield.
Eﬀorts were therefore focused on the hydrogenation of benzylidene protected amides 72.
Table 3.2: Acidic Deprotection of Glucuronolactones and Glucuronamides.
Cmpd Reagent Solvent Temp. Time (h) Result
65 90% AcOHa H2O 20
◦C 48 no reaction
65 90% TFAb H2O 20
◦C 48 no reaction
65 60% AcOH H2O 95
◦C 24 positivec
65 60% AcOH H2O 60
◦C 6 positive
65 70% AcOH H2O 60
◦C 6 positive
65 Amberlited MeOH/H2O 40
◦C 19 no reaction
65 Amberlite dioxane/H2O 80
◦C 24 positive
65 0.45M HCl H2O 90
◦C 30min positive
65 1M HCl MeOH/H2O 100
◦C 45min positive
71 60% AcOH H2O 95
◦C 24 cleavagee
71 60% AcOH H2O 60
◦C 6 partialf
71 70% AcOH H2O 60
◦C 6 partial, cleavage
71 Amberlite dioxane/H2O 80
◦C 36 partial, cleavage
71 0.45M HCl H2O 90
◦C 30min no reaction
71 1M HCl MeOH/H2O 100
◦C 45min cleavage
a Acetic acid. b Trifluoroacetic acid. c Positive Fehling’s test. d Amberlite Resin H+ form.
e Cleavage of amide bond observed. f Starting materials remaining.
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Like acetonides, benzylidene-protected diols may be deprotected under acidic conditions,
but they are also commonly deprotected by catalytic hydrogenation.211,215 Similar to
the acetonide protected molecules, various conditions were ﬁrst tried on benzylidene
glucuronolactone 66 (see Table 3.3) before applying them to the full conjugates (72).
1,2-O-Benzylidene glucuronolactone (66) was shaken with palladium on charcoal (Pd/C)
under hydrogen atmosphere. Hydrogenation under high pressure (9 bar, 3 days) was
previously shown by Weymouth-Wilson et al. to deprotect a modiﬁed glucuronic acid.215
The same conditions were used for lactone 66, but the reaction did not proceed and
only starting material was recovered, as was determined by NMR spectroscopy of the
recovered material. Based on previous reports that a mixture of palladium on charcoal
and palladium hydroxide on charcoal (Pd(OH)2/C) may serve as a better catalyst for
debenzylation,217 the eﬀect of the palladium mixture was investigated for the present
reaction. The mixture did successfully deprotect lactone 66 to lactone 64 when used in
methanol – hydrogenolysis in DMF did not proceed. This surprising diﬀerence between
Pd/C and the catalyst mixture was further investigated by using Pd(OH)2/C on its own,
which also deprotected the lactone. These results highlighted an interesting diﬀerence in
reactivity between Pd/C and Pd(OH)2/C in this particular case.
Having identiﬁed methods that are suitable for the removal of the benzylidene in sugar 66
by hydrogenolysis, these were then applied to the deprotection of conjugate 72 (Table 3.3).
As seen for the lactone, Pd/C is not suﬃcient for the removal of the benzylidene protecting
group, but the 1/1 mixture of palladium catalysts was also found to be inactive, when used
in methanol, THF or DMF. The use of rhodium catalyst also could not eﬀect deprotection
of the diol.
Unfortunately, catalysts that allowed the deprotection of glucuronamides 72 could not
be identiﬁed. Interestingly, the hydrogenolysis of the 3-benzyloxy group on pyridinones
usually proceeds readily under these conditions (Pd/C is commonly used as catalyst),199
but for pyridinones 72 this reaction was not detected in any of the hydrogenations. The
author therefore speculates that the lipophilic nature of the protected conjugates prevented
adsorption onto the catalyst surface, thus ultimately forestalling the reaction.
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Neither the deprotection of acetonide protected amides 71 nor benzylidene protected
amides 72 was successful. Thus, another method for the deprotection or an alternative
route for the synthesis need to be investigated. A possible route could be the coupling of
glucuronic acid to HPO amines 67 by conventional amidation protocols.
Table 3.3: Hydrogenation of Glucuronolactones and Glucuronamides.a
Cmpd Catalyst w/w H2 Pressure Time (d) Result
66 10% Pd/C 20% 2.5 bar 3.5 no reaction
66 10% Pd/C 20% 9 bar 3 no reaction
66 Pd mixtureb 30% 2.5 bar 3 full conversion
66 Pd mixture 30% 2.5 bar 4 no reactionc
66 20% Pd(OH)2/C 30% 2.5 bar 2 full conversion
72 10% Pd/C 20% 2.5 bar 3 no reaction
72 Pd mixture 30% 2.5 bar 3 no reaction
72 Pd mixture 30% 2.5 bar 3 no reactionc
72 Pd mixture 30% 2.5 bar 3 no reactiond
72 5% Rh/C 20% 2.5 bar 3 no reaction
a All reactions were suspensions in methanol. After hydrogenation, reactions were filtered
through celite and evaporated to dryness. b 1/1 Mixture of 10% Pd/C and 20% Pd(OH)2/C.
c Reaction was performed in DMF. d Reaction was performed in THF.
Chapter 4
Synthesis of Triazole-linked Conjugates
4.1 Formation of Triazoles by Click Chemistry
The use and synthetic application of 1,3-dipolar cycloadditions, which can be used for
the synthesis of various 5-membered heterocycles, was mainly developed by Huisgen from
the 1950s (for a review see ref. [218]). The reactions were not common, except for the
preparation of triazoles, and even for these, the reaction requires high temperatures and
forms mixtures of 1,4- and 1,5-substituted 1,2,3-triazoles.218
About 40 years later, Meldal219 and Sharpless220 independently developed a copper cata-
lysed variant, which proceeds under mild conditions and also in aqueous medium. This
copper catalysed azide-alkyne cycloaddition (CuAAC) gained considerable attention due
to its wide applicability, robustness and biocompatibility and its stereoselectivity for 1,4-
substituted triazoles, allowing even the labelling of molecules in vivo.∗
The CuAAC links azides and alkynes to form 1,4-substituted triazoles via a copper cata-
lysed reaction (Scheme 4.1). In the ﬁrst step, copper (or a copper-ligand complex) coordin-
ates with the acetylene pi-electrons, which lowers the pKa of the terminal proton. Then
the proton is abstracted and the acetylide is formed. Whether one copper atom or more
are directly involved in this acetylide complex remains unclear, but crystal structures of
alkyne-copper complexes suggest the involvement of two copper atoms, both at an angle to
the C-C bond.221 The acetylide-copper complex then coordinates the azide on the carbon-
bound oxygen, allowing attack of the terminal nitrogen on the non-terminal acetylene
carbon. This results in the formation of a 6-membered metallocycle, which could account
for the regioselectivity for the formation of 1,4-substituted triazoles. The triazole is formed
by further rearrangement, ﬁrst bound to the copper-complex, which is ﬁnally released by
∗For a review of CuAAC, see Meldal et al.221
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protonation, yielding the free copper-ligand complex and the 1,4-substituted triazole.
Sugars and other biomolecules are frequently used in CuAAC, but it also ﬁnds applications
in material sciences and other areas, demonstrating the wide range of possible substrates









































Scheme 4.1: Plausible Mechanism for the Cu(I) Catalysed Reaction between Organic
Azides and Terminal Alkynes. (Adapted from Meldal et al.221)
The application of azide-alkyne click chemistry has since been developed further, with
the advent of copper-free reactions.221 On the one hand, McNulty and co-workers de-
scribed the preparation of 1,4-substituted triazoles utilising silver(I) complexes instead
of copper,223,224 which has recently been expanded to the synthesis of pyrroles.225 The
Bertozzi group published a metal-free variant in 2007, which is based on the reaction of
cyclooctynes with azides.226 Here, the reaction proceeds due to the relief of steric strain
of the cyclic alkyne. Another variant of the CuAAC was developed by the Fokin group,
where ruthenium(II) complexes catalyse the formation of 1,4-substituted triazoles.227 In-
terestingly, 1,5-substituted triazoles are selectively formed, when the ruthenium catalyst
is complexed by cyclopentadienyl ligands.228,229
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4.2 Design of Triazole-linked Conjugates
In view of the instability of the amide-linked conjugates under deprotection conditions
discussed in the previous chapter, a strategy to obtain conjugates with a more stable
linkage had to be found. Triazoles are stable under most conditions and readily prepared
from an azide and an alkyne in an atom-eﬃcient and clean reaction and thus an attractive
alternative to amides. Triazole-tethered HPO-sugar conjugates were therefore designed.
For the synthesis of the triazole-linked HPO-sugar conjugates, HPO-azides and alkyne
bearing carbohydrates or alternatively, azidosugars and HPO-alkynes (Scheme 4.2) are re-
quired. The preparation of both alkyne- and azido-HPOs is straightforward, and azidosug-
ars are readily prepared either from commercial starting materials or in few steps.230,231
Contrarily, the synthesis of alkyne bearing carbohydrates takes several steps and often
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Scheme 4.2: Retrosynthetic Analysis of Triazole-linked HPO-sugar Conjugates.
4.3 Preparation of Azidosugars
Azidosugars have previously been used in click chemistry reactions.236 For the present

















Figure 4.1: Structures of Used Azidoglucose Derivatives.
For the synthesis of 1-azidoglucose, a rapid route had been described, where acetobromo
glucose 30 is reacted with sodium azide to give the desired azidosugar 73.237 Acetobromo
glucose is commercially available, or it may be synthesised from glucose in 2 steps. First,
glucose was per-O-acetylated with acetic anhydride in pyridine to yield pentaacetyl glucose
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76 (74%, Scheme 4.3), which was then brominated with hydrobromic acid in acetic acid.
This gave 2,3,4,6-tetra-O-acetyl-α-d-glucopyranosyl bromide (30) in almost quantitative
yield. Glucosyl bromide 30 was transformed to the azide in an exchange reaction with
sodium azide, tetrabutylammonium iodide and sodium bicarbonate in a biphasic reac-
tion mixture, yielding acetylated 1-azido-β-d-glucopyranoside 73 (69% yield). The β-
conformation was determined by NMR spectroscopy – as described in chapter 2 – in
particular by analysis of the coupling constant for the 3J coupling between the anomeric
proton and the proton in position 2 with 9.0Hz which is in agreement with published data
for this compound,238 and β-conﬁgured glucopyranoses in general.191
Goddard-Borger et al. described the facile synthesis of 2-azidoglucose from glucosamine.230
To this end, an eﬃcient diazotransfer reagent had been synthesised.230 Following this
synthetic strategy, imidazole was reacted with azidosulfonyl chloride, which was prepared
in situ from sulfuryl chloride and sodium azide (Scheme 4.4). The resulting diazotransfer
reagent 77 was not isolated due to its potentially explosive nature,239 but rather obtained
as the stable sulfate salt in 61% yield. The reagent 78 was then used to transfer a diazo
group onto the nitrogen of glucosamine (Scheme 4.5), a reaction which is catalysed by
copper(II) sulfate in the presence of potassium carbonate.230,239 This azide was directly
protected with acetic anhydride in pyridine for ease of handling and use. The desired
acetylated 2-azidoglucose 74 was obtained in 23% yield. This result is in stark contrast to
the published yield of 92%,230 and could be due to a low yielding acetylation reaction.
6-Azidoglucose was synthesised mainly following the route for the selective protection of
glucose by Amigues et al.231 Glucose was reacted with triphenylmethyl chloride in pyridine
to give 6-tritylglucose 79 in good yield (Scheme 4.6 The remaining hydroxy groups were
benzylated with benzyl bromide and sodium hydride as base in 76% yield. Aluminium
trichloride in DCM/Et2O achieved the selective deprotection of fully protected sugar 80,
yielding 6-hydroxy sugar 81 (72%).
The introduction of the azido group followed the general protocol reported by Tagamose et
al.240 In a one-pot reaction, the 6-hydroxy group was ﬁrst mesylated to give compound 82
with methanesulfonyl chloride and triethylamine, which was subsequently transformed to
the desired azide 75 with sodium azide in DMF containing trace water241 (66% yield over
both steps). The yield was improved however, when the mesylate 82 (89%) was isolated
and the azide introduced in a separate step (75 91%, 81% over both steps).

















Scheme 4.3: Synthesis of 2,3,4,6-Tetra-O-acetyl-α-d-glucopyranosyl azide. Reagents
and Conditions: i) Ac2O, pyridine, 0
◦C→rt, 74%; ii) HBr in AcOH, DCM, 0 ◦C→rt, 93%;



















Scheme 4.4: Synthesis of 3-(Azidosulfonyl)-3H -imidazol-1-ium hydrogen sulfate.
Reagents and Conditions: i) NaN3, SO2Cl2, dry ACN, 0
◦C→rt, then 0 ◦C, imidazole,


















Scheme 4.5: Synthesis of 2-Azido-2-deoxy-d-glucopyranose 1,3,4,6-tetra-O-acetate.
Reagents and Conditions: i) Imidazole-1-sulfonyl azide 78, K2CO3, CuSO4, MeOH, rt;



































Scheme 4.6: Synthesis of 6-Azido-1,2,3,4-tetra-O-benzyl-6-deoxy-d-glucopyranose.
Reagents and Conditions: i) Triphenylmethyl chloride, pyridine, 75 ◦C, 72%; ii) BnBr,
NaH, TBAI, dry DMF, N2 atmosphere, 0
◦C→rt, 76%; iii) AlCl3, dry DCM, dry Et2O,
rt, 72%; iv) mesyl chloride, TEA, dry DCM, N2 atmosphere, −10
◦C to 0 ◦C, 89%; v)
NaN3, DMF, 110
◦C, 91%.
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4.4 Preparation of Alkynes
The most convenient way to obtain an alkyne derivative of HPOs is the double Michael ad-
dition of propargylamine (Scheme 4.7) to a pyranone, following to the previously described
method (Chapter 3). Benzylated maltol 33 was reacted with propargylamine under basic
reaction conditions, but a very complicated reaction mixture was obtained, which could not
be puriﬁed by column chromatography. Alternatively, benzylated maltol was reacted with
ethanolamine to give pyridinone 83 (56% yield). The alkyne functionality was introduced
by alkylation of the hydroxyl group with propargyl bromide in DMF, obtaining the desired
alkyne 84 in 65% yield, easily identiﬁed because of the presence of a characteristic triplet


















Scheme 4.7: Synthesis of Alkyne-substituted HPOs. Reagents and Conditions: i)
Propargylamine, NaOH, MeOH/H2O, reflux; ii) ethanolamine, NaOH, MeOH/H2O,
reflux, 56%; iii) propargyl bromide, NaH, TBAI, dry DMF, N2 atm., −10
◦C→rt, 65%.
4.5 Formation of Triazole-Linker
The formation of triazoles from alkynes and azides via a copper-catalysed click reaction
has been well studied and numerous reaction conditions have been published (for a review
see ref. [221]).
A small set of diﬀerent conditions (see Table 4.1) was selected for trial reactions on
a small scale. HPO alkyne 84 and 1-azidosugar 73 were reacted in the presence of
copper(II) sulfate and ascorbic acid in DMF and water (Table 4.1, entry 1). Even after
prolonged reaction times and repeated addition of copper and reducing agent, no reaction
was observed and the starting material could be recovered. In the reaction in dry DMF,
catalysed by copper(I) iodide and triethylamine (entry 2), the quick appearance of multiple
weak spots on TLC was observed, but no further progress was observed after 5 days
reaction time and additional catalyst and base.
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Table 4.1: Reactions Conditions for Triazole-Formation.a
Entry Alkyne Azide Cu Species (eq.) Reductant (eq.) Solvent Time
1b 84 73 CuSO4 (0.75) Asc. (1.66) DMF/H2O 12 d
2b 84 73 CuI (0.7)c — dry DMF 5 d
3 84 73 CuSO4 (0.5) NaAsc (1+0.5)
d DCM/H2O 4 d
4 84 74 CuSO4 (0.5) NaAsc (1+0.5)
d DCM/H2O 4 d
5 86 NaN3 CuSO4 (0.75) Asc. (1.66) DCM/H2O 1 d
6 86 NaN3 CuSO4 (0.5) NaAsc (1) DCM/H2O 1 d
7 86 NaN3 CuI (0.5)
e — dry DMF 1 d
a All reactions were performed at room temperature. b Catalyst and reductant/base were added
in portions over the reaction time. c Triethylamine (4 eq.) was added to the reaction. d Second
portion added after 3 days. e Triethylamine (0.5 eq.) was added to the reaction.
Since many publications use sodium ascorbate, rather than ascorbic acid,221 further re-
actions (entries 3 and 4) were therefore performed with copper(II) sulfate and sodium
ascorbate (prepared from ascorbic acid and aqueous sodium hydroxide). Interestingly,
upon addition of the sodium ascorbate solution, the reaction mixtures changed to a
brownish colour and partly gelled. This gel dissolved over time, but no formation of
product could be observed.
In order to eliminate potential problems, phenyl propargyl ether 86 (Figure 4.2) and so-
dium azide were used as structurally simple starting materials (entries 5–7) and subjected
to all previously used reaction conditions. No reaction was observed for entries 5 and
6, but the reaction with copper(I) iodide as reagent did show the disappearance of the
starting material, a new spot on TLC. Upon work-up, NMR of the crude material only
showed unchanged starting material 86, however.
While similar to the previously used methods, a protocol published by Sharpless et al.242 in
2005, applied light heat (60 ◦C) and aqueous tert-butanol as solvent. A model reaction with
phenyl propargyl ether (86) and benzyl azide (87, see Table 4.2, entry 1) gave 1-benzyl-4-
(phenoxymethyl)-1H -1,2,3-triazole (88) in 84% yield. Reaction of phenyl propargyl ether
with 1-azidoglucose 73 gave the appropriate triazole 89 in excellent yield (93%), but
required longer reaction times for completion.
Applying these reaction conditions to couple HPO alkyne 84 with benzyl azide gave 1-{2-
[(1-benzyl-1H -1,2,3-triazol-4-yl)methoxy]ethyl}-3-(benzyloxy)-2-methylpyridin-4(1H )-one

































Figure 4.2: Structures of Alkynes, Azides and Products.
(90) in good yield (87%). HPO alkyne 84 was linked with 1-azidoglucose 73 in good yield
under the described reaction conditions, despite some partially insoluble starting materials
at the beginning of the reaction. In a separate experiment (entry 5), chloroform was added
to the reaction mixture until the starting materials were fully dissolved. Surprisingly, this
reaction did not proceed as smoothly as entry 4. After 18 hours, the reaction showed only
partial turnover of alkyne 84, while the reaction without added chloroform (entry 4) had
gone to completion. The reactions linking HPO alkyne 84 with the prepared azidosugars
74 and 75 (Figure 4.2 and Table 4.2, entries 6 and 7) – performed without additional
chloroform – furnished the desired triazoles 92 and 93 in 84 and 66% yield, respectively.
Table 4.2: Synthesis of Triazoles.a
Entry Alkyne Azide Time (h) Product Yield
1 86 87 1 88 84
2 86 73 22 89 93
3 84 87 20 90 87
4 84 73 18 91 85
5b 84 73 18 91 inc.c
6 84 74 23 92 84
7 84 75 20 93 66
a Alkyne (1 eq.), azide (1 eq.), ascorbic acid (0.1 eq.), 1M NaOH
(0.1 eq.), 1M CuSO4 (0.05 eq.), tBuOH/H2O 1/1, sealed tube.
b CHCl3 added for solubility.
c Incomplete turnover.













































(a) Structures and Numbering. (b) Possible HMBC Correlations between
Substituent Protons and the Unsubstituted
Triazole Carbon.
Figure 4.3: Possible 1,4- and 1,5-substituted Triazole Isomers.
In order to conﬁrm that the desired 1,4-substituted triazoles were synthesised and not the
1,5-substituted isomers, the 1D and 2D NMR studies, which were performed, are described
here. 1H-NMR, decoupled 13C-NMR, DEPT135, HSQC and HMBC spectra were recorded
for all compounds (except 88), 1H,1H-COSY spectra were recorded where necessary. With
these spectra, all 1H- and 13C-NMR signals – including 1H,1H-coupling constants – were
assigned in full and unambiguously.
DEPT135, HSQC and HMBC spectra were recorded in order to determine which struc-
tural isomer was produced by the click reactions. The carbon signals at ∼145 ppm and
∼122 ppm were analysed (for exact shifts, see Table 4.3). DEPT135 and HSQC allowed
the assignment of the CH and the quaternary carbon of the triazole ring as the signals
at ∼122 ppm and ∼145 ppm, respectively. The carbon shift of the triazole-CH signal
lies around 120 ppm in 1,4-substituted triazoles, while in 1,5-substituted triazoles the
signal is around 133 ppm.243–245 This suggests, that the isolated compounds are indeed the
1,4-substituted isomers, as would be expected from the reported stereoselectivity of the
CuAAC. HMBC data conﬁrms this assignment, because correlation peaks from H-6 and
H-7 with the triazole-CH carbon were observed. The latter correlation (H-7 to triazole-CH)
would not be expected in the 1,5-substituted isomer 94 (Figure 4.3). Additionally, NOESY
experiments could have shown the close spatial proximity of the protons in position 6 and
7 in the 1,5-substituted, but not in the 1,4-substituted triazoles.246
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Table 4.3: NMR Chemical Shift Data of Triazoles (δ ppm in CDCl3).
Compound H-5 C-5 C-4
89 7.86 121.03 145.11
90 7.22 122.48 144.55
91 7.58 121.000 144.93
92 7.56/7.44a 122.15/122.09a 144.93
93 7.43 124.62/124.34a 143.88
a β isomer/α isomer
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4.6 Deprotection of Triazole-linked Conjugates
Conjugates 91, 92 and 93 were then deprotected to obtain their diﬀerentially protected
derivatives. The 1-linked conjugate 91 was debenzylated by hydrogenolysis over Pd/C
to give 3-hydroxy pyridinone 96 in 71% yield (Scheme 4.8), while selective deacetylation
was achieved with sodium methoxide in methanol, quantitatively yielding the desired 97.
The fully deprotected pyridinone 98 was obtained in quantitative yield as its HCl salt by







































Scheme 4.8: Deprotection of 1-(2-{[1-(β-d-Glucopyranosyl)-1,2,3-triazol-4-yl]meth-
oxy}ethyl)pyridinones. Reagents and Conditions: i) Pd/C (10%), 2 bar H2, MeOH, rt,
71%; ii) NaOMe, dry MeOH, rt, quant.; iii) Pd/C (10%), HCl, 2 bar H2, MeOH, rt, quant.
as HCl salt.
Similarly, 2-linked conjugate 92 was debenzylated by hydrogenolysis over Pd/C to give its
respective 3-hydroxy pyridinone 99 (quantitative). Deacetylation of 92 with sodium meth-
oxide in dry methanol yielded pyridinone 100 in surprisingly poor yield (27%). Finally,
fully deprotected pyridinone 101 could be obtained by hydrogenation of fully protected

































Scheme 4.9: Deprotection of 1-(2-{[1-(2-Deoxy-d-glucopyranos-2-yl)-1,2,3-triazol-4-
yl]methoxy}ethyl)pyridinones. Reagents and Conditions: i) Pd/C (10%), 2 bar H2,
MeOH, rt, quant.; ii) NaOMe, dry MeOH, rt, 27%; iii) Pd/C (10%), HCl, 2 bar H2,
MeOH, rt, 92%.
Chapter 4 – Synthesis of Triazole-linked Conjugates 84
Selective deprotection the 6-linked conjugate 93 (Scheme 4.10) – as it was achieved for
the other triazole-linked HPO conjugates – is impossible, because the compound is fully
benzylated, rather than protected with multiple diﬀerent protecting groups. Benzyl pro-
tecting groups are usually removed by hydrogenolysis,211 but after hydrogenation of the
conjugate 93 with Pd/C, only unreacted starting material was recovered.
Boron tribromide has previously been used to debenzylate HPOs in excellent yields in
the presence of amide bonds,247 which indicates a selectivity for benzyl groups over other
functionalities.
Conjugate 93 was reacted with boron tribromide in dry DCM. Full consumption of the
starting material was observed, but puriﬁcation of the reaction mixture by reverse phase
chromatography did not give the desired product 102. The only products that could be
isolated were N -(hydroxyethyl)pyridinone 83 and its 3-hydroxy derivative, indicating that





















Scheme 4.10: Deprotection of 1-(2-{[1-(6-Deoxy–d-glucopyranos-6-yl)-1,2,3-triazol-
4-yl]methoxy}ethyl)pyridinones. Reagents and Conditions: i) Pd/C (10%), 2 bar H2,
MeOH/CHCl3, rt; ii) BBr3, dry DCM, N2 atmosphere, 0
◦C→rt.
In summary, the desired triazoles derived from 1- and 2-azidoglucose in diversely protected
forms were successfully prepared, as well as the triazole derived from 6-azidoglucose in its
protected form. The purity of 98 and 101 was determined by HPLC to be above 98% and
therefore pure enough to be used in the uptake and permeability assays.
It may be necessary to ﬁnd another route to obtain fully deprotected 6-linked conjugates.
This may be achieved by the use of diﬀerent protecting groups, or by avoiding the ether
bond in the tether. A potential route could be the reaction of N -unsubstituted pyridinone
44 with propargyl bromide to give 85, which could then be clicked to azidoglucose 75.
Chapter 5
Interaction of Glycoconjugates with GLUT1
Studies that discussed glycosylated compounds usually did not report biological data
relating to their brain permeability, while only a number of them measured the interaction
of the glycosylated compounds with GLUT1. This was generally done by inhibition
studies of GLUT1 transportable substrates in erythrocytes. The transport of glycosylated
compounds was only measured directly in select studies, either based on the accumulation
of compounds into erythrocytes, or by in vivo/in situ brain perfusion, as has been discussed
in Section 1.2.3. Due to these shortcomings in experimental design, incorrect conclusions
have been drawn, regarding the eﬀect of glycosylation on molecules’ brain permeability. It
is therefore necessary to measure the movement and distribution of compounds directly,
rather than making assumptions about a molecule’s behaviour based on indirect meas-
urements (e.g. pharmacological eﬀect or inhibition of another molecules’ transport). A
number of in vitro models of the BBB have been developed previously, based on primary
or immortalised cell lines from various species.248–254
In this work, the permeability of glucosylated compounds (Figure 5.1) and their interaction
with GLUT1 were studied in assays based on primary porcine brain endothelial cells
(PBECs).255 The model was chosen, because primary cells are the closest representation
of the properties the BBB has in vivo and are expected to express the relevant range
of transport systems. The PBEC system used has previously been characterised and
expresses tight junction proteins, both uptake and eﬄux transport systems and has a high
transendothelial electrical resistance, which indicates the formation of a tight barrier.256,257
For the determination of uptake and interaction with GLUT1, the previously synthesised
compounds (described in the preceding chapters) were complemented by compounds kindly
supplied by Shen Liu and Yongping Yu from Zheijang University, China. These additional
compounds are amides of glucosamine or methyl 6-amino-6-deoxy-α-d-mannoside. All
85













































































































Figure 5.1: Structures of Tested Compounds.
The synthesis of compounds 26a, 29a, 98 and 101 is described in the preceding chapters;
Gly, Val, Phe and M5–10 were procured from collaborators.
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tested compounds were quantiﬁed directly by HPLC (see Experimental Chapter), as
opposed to indirect measurements.
5.1 Uptake of Compounds into a PBEC Monolayer
In a ﬁrst set of experiments, PBECs were cultured as a conﬂuent monolayer in micro-
plates (96-, 24-, or 12-well) and used to (a) determine the uptake of the test compounds
(Figure 5.2) into the cells, or (b) determine the inhibitory eﬀect of the test compounds on
the uptake of GLUT1 transported non-metabolised sugar [3H]3-O-methylglucose (3OMG).































Figure 5.2: Structures of Compounds Used in Experiments Performed on Microplates.
Uptake of Hydroxypyridinones. PBECs were incubated with 500 µm CP20 or 500 µm
Phe in the presence or absence of 5mm glucose in a 96-well plate format (200 µl) for 1, 4
or 24 hours. At the end of the incubation time, the washed cells were lysed (200µl water
or 100 µl Triton X-100 solution) and the lysate analysed by HPLC. CP20 and Phe could
be detected in the incubation medium, but not in the cell lysate for any test condition.
Inhibition of [3H]3-O-Methylglucose Uptake by Hydroxypyridinones. Glycosylated
and non-glycosylated HPOs (CP20, CP40, Val, Phe; Figure 5.2) were tested at a range
of concentrations (0–500µm) for their inhibition of 3OMG uptake in a 96-well plate setup.
The cells were co-incubated with 3OMG (0.3µCi per well) and a compound for either 10 or
20 minutes, then washed and lysed. The result of the experiments could not be interpreted
due to very low and variable counts from the scintillation counter (Data not shown).
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Further optimisation steps were then carried out. CP20 and Phe at 500 µm were tested
for their inhibition of 3OMG (1.5µCi/ml) uptake in 24-well plates for 15 and 60 minutes.
Glucose (5mm) was tested for its eﬀect on 3OMG (1.5 µCi/ml) uptake in 24- and 12-
well plates for 15 seconds. In order to deplete any intracellular glucose, which could
aﬀect the transport of 3OMG, the cells were pre-incubated with (glucose free) assay
buﬀer for 30 minutes. At the end of the experiment, the cells were washed with an
equal volume stopping buﬀer containing mercuric chloride (1µm) and phloretin (100 µm)
to inhibit potential eﬄux of 3OMG by GLUT1 before lysis. When corrected for the
extracellular component using [14C]sucrose (0.15 µCi/ml), the intracellular radioactivity
counts were below zero, indicating no uptake of 3OMG, even under control conditions
(Data not shown).
These results may be explained by the extremely small cellular volume of brain endothelial
cells. The thickness of brain endothelial cells is less than 0.5 µm.258 The surface area of
a single well on a 96-, 24- and 12-well microplate is 0.32, 1.9 and 3.8 cm2, respectively. A
conﬂuent monolayer of PBECs would therefore have an approximate total cell volume of
16, 95 and 190 nl. The concentration of the compounds that might have been taken up
by the cells falls below the level of detection and/or quantiﬁcation of the HPLC after the
lysis of the cells and the consequent dilution, this limitation should have been accounted
for, when the experiment was designed.∗
The shortfall of this experimental setup might be overcome by the use of cells with a
larger cellular volume (e.g. erythrocytes), or by using a diﬀerent assay setup, in which the
compounds can accumulate in a larger volume. In this work, a Transwell assay was chosen,
where the compounds can cross the monolayer and accumulate in basolateral compartment.
5.2 Transport of Compounds across a PBEC Monolayer
Transwells are microporous ﬁlter membranes, on which cells are grown. The membranes
can be inserted into multiwell plates, which allows access for the independent manipulation
of the apical and basolateral compartments.
Patabendige et al. recently reported the use of PBECs in a Transwell setup and showed
its applicability for permeability studies. The group tested molecules that cross a PBEC
∗For a compound that reaches a 500 µm concentration within the cells of a 24-well plate, the lysis and
dilution into 100 µl would result in a 0.5 µm concentration in the lysate. The level of quantification for the
tested compounds lies around 1–2 µm.
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monolayer by passive diﬀusion, LAT-1 transport or are subject to active eﬄux.257 The
BBB permeability of glycosylated drugs has not been determined in an in vitro assay based
on brain endothelial cells before (1.2.3.2), making this a novel method, which is closer to
the natural processes at the BBB than the erythrocyte based assays that have been used
by other groups.
PBECs in a Transwell-based assay closely model the in vivo properties of the BBB, which
has been demonstrated by Abbott and co-workers.257 The cells were shown to grow in a
monolayer and retain their morphology, also forming tight junctions – resulting in relatively
high TEER (transendothelial electrical resistance). PBECs express eﬄux transporters,
which are found at the BBB,256,257 and also express GLUT1 express high levels256
5.2.1 Transendothelial Electrical Resistance.
The transendothelial electrical resistance is a good indicator for the tightness of the cell
monolayer,259 and has been determined to be around 1800Ω cm2 in vivo.260
In this work, the TEER values were very dependent on the particular isolation batch
(Figure 5.3). The values for inserts after 3 days of growth and 2 days of treatment with
induction medium ranged from 84 to 1537Ω cm2. Within a batch, values were generally
consistent, while the batch to batch variation was large. Batch 25 had signiﬁcantly higher
TEER values, than all other batches, with a mean of 948± 35 Ω cm2. Batches 23 and 26
had lower TEER values than batch 25 – 700± 36 Ω cm2 and 698± 46 Ω cm2, respectively
– and their TEER values did not diﬀer signiﬁcantly. The remaining batches 4, 22, 24 and
24 SF had much low TEER values (192, 218, 198 and 134 Ω cm2, respectively; Table 5.1).
The supplementation with (batch 24) or without serum (batch 24 SF) did not have a
signiﬁcant impact on the cells (see B24 vs B24 SF in Table 5.1), but in cells with higher
TEERs, serum supplementation on the apical side may have a measurable eﬀect.
The TEER on day one of supplementation is a good indication of the insert’s ﬁnal TEER
value. Inserts with low values (<150 Ω cm2) showed no signiﬁcant improvement the next
day (Table 5.2), medium TEER inserts (150–350 Ω cm2) showed an increase of up to
100 Ω cm2, while inserts with a high TEER (>350 Ω cm2, e.g. batches 23, 25 and 26)
improved signiﬁcantly on the second day (increase by 200–300 Ω cm2).
Sodium ﬂuorescein is a small ﬂuorescent molecule, which has previously been used as a
marker for paracellular permeability.261,262 PBECs with a low TEER (<150 Ω cm2) are

































Figure 5.3: Comparison of Transendothelial Electrical Resistance (TEER) for Batches
Isolated on Different Days. All batches were measured after one and two days of treatment
with supplements (left and right bar, respectively). (SF = serum free induction medium
on both sides; Error bars = SEM)
lacking barrier tightness and thus were found to be much more permeable for sodium
ﬂuorescein than cells with TEERs above 300 Ω cm2 (Figure 5.4). The permeability of cells
with a very low TEER is similar to ﬁlter inserts without cells.
Table 5.1: Statistical Results of Batch-to-Batch
Comparison of TEERs (2-Way ANOVA).
Batch n B4 B22 B23 B25 B26 B24 B24 SF
B4 8 X nsa **** **** **** ns ns
B22 38 X **** **** **** ns ns
B23 46 X **** ns **** ****
B25 68 X *** **** ****
B26 14 X **** ****
B24 36 X ns
B24 SF 12 X
a ns = not significant, * = p < 0.05, *** = p < 0.001, **** = p < 0.0001.
Table 5.2: Comparison of TEERs
after 1 or 2 days of Supplementation.







B24 SF 6 ns
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Figure 5.4: Correlation of Sodium Fluorescein Permeability with TEER. (◦, 60 min;
•, 30 min; ⋄, blank insert; NaF, sodium fluorescein; each point represents one well)
5.2.2 Inhibition of 3OMG Transport by Glycosylated Compounds
An assay based on the Transwell format allows the collection of two sets of data at the
same time. On the one hand, the permeability of compounds can be determined by HPLC
and on the other hand one can measure the inhibitory eﬀect the compound has on the
transport of 3OMG by liquid scintillation. The large volume of the receiver compartment
allows suﬃcient test compound for quantiﬁcation by HPLC (see Experimental Chapter).
In the setup that was used, [14C]sucrose was used as marker for paracellular permeability.
Compounds 26a, CP20, Val, Phe (all 500 µm, Figure 5.5) and glucose (5mm) were tested
for their inhibitory eﬀect on the transport of [3H]3-O-methylglucose by GLUT1 when (a)
present on both sides or (b) on the apical side only. The incubation time was 30, 60 or
120 minutes.
All samples contained both radioisotopes ([14C]sucrose and 3OMG), which posed problems
for the scintillation reading. The emission energies of tritium and carbon-14 overlap
(Figure 5.6), the program thus takes a correction factor into account using stored standard
curves. But because the ratio of tritium to carbon-14 shifts over time in these experiments,
any single correction factor would only be correct for a small subset of analysed samples.
Therefore, the scintillator could not calculate the correct quantities of both isotopes and
no information about the inhibition of 3OMG transport could be extracted from these
experiments. In addition, the donor and receiver compartments were analysed by HPLC.
The measured permeability could not be corrected for paracellular permeability, due to the































































































Figure 5.5: Structures of Compounds Used in Transwell Experiments.
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(a) [3H]3-O-Methyl-d-glucose (b) d-[14C]Sucrose (c) 1:1 Mixture of both
Figure 5.6: Overlapping Energy Emission Profiles of [3H]3OMG and [14C]sucrose.
x-Axis is the Energy of the Detected Photons and the y-Axis the Number of Counts.
same problems with [14C]sucrose quantiﬁcation. A diﬀerent, non-radioactive paracellular
marker was therefore required to avoid these problems.
Another set of experiments was performed with sodium ﬂuorescein as paracellular marker,
instead of [14C]sucrose. [3H]3OMG transport over 30 minutes was tested in the pres-
ence of 5mm glucose, 250 µm phloretin (a GLUT1 inhibitor), CP20, 26a, Phe, M6
or M10 (all 500 µm). The apparent permeability (Papp) of 3OMG was calculated ac-
cording to the equation given by Youdim et al.263 It was found that the Papp of 3OMG
(3.72±0.35 ×10−5cm s−1, Figure 5.7) was not aﬀected by any of the compounds. Glucose
and the GLUT1 inhibitor phloretin also had no eﬀect, while M10 appeared to increase the

























































−5 cm s−1 ± SEM
3OMG 3.72 0.35
+ Glc 5mM 3.19 0.48
+ Glc 10mM 3.41 0.49
+ Phloretin 250uM 2.95 0.60
+ CP20 3.70 0.91
+ 26a 4.08 1.37
+ Phe 4.95 0.46
+ M6 4.08 0.28
+ M10 7.66 0.94
Figure 5.7: Competitive Inhibition of [3H]3OMG. Papp after 30 min Incubation in
Transwells. (All data points shown)
The penetration of the test compounds across the monolayer was determined by HPLC
(Figure 5.8). The Papp of CP20 was about 1.00±0.05 ×10−5cm s−1, while permeability
of all the glycosylated compounds was lower (0.53–0.72 ×10−5cm s−1) and phloretin was
comparable with 1.01±0.05 ×10−5cm s−1.

















































































Figure 5.8: Permeability Assay, 30 min Incubation Time. A) Papp of Tested
Compounds. B) Permeability of Tested Compounds, Normalised to CP20. (All data
points shown)
The tested compounds have a much lower permeability than the known GLUT1 sub-
strate 3OMG, which indicates, that the other substances are either not transported by
GLUT1, or much worse substrates for the transport protein than 3OMG. Both, the Papp
of radiolabelled sugar 3OMG in the presence of compounds (Figure 5.7) and the HPLC-
determined permeability of compounds (Figure 5.8), exhibited a relatively high variability,
which makes deﬁnitive statements about the brain permeability of the compounds or
interactions with GLUT1 impossible. A large portion of inserts had TEER values between
150–200 Ω cm2. The permeability in low TEER cells tends to be higher, even after
correction for paracellular permeability, which could explain the high variability.
5.2.3 Transport of Glycosylated Compounds by GLUT1
Ten hydroxypyridinones (Figure 5.5: CP20, 26a, 29a, 98, 101, Gly, Val, Phe, M5
and M9) were selected to investigate their BBB permeability in the Transwell setup.
Only cells with a TEER value >400 Ω cm2 were used, in order to reduce variability.
Incubation time was prolonged to 60 minutes to achieve higher concentrations in the
receiver compartment. The permeability of compounds was determined by HPLC analysis
of both compartments. Since the experiment was performed over a longer timescale
without removal of accumulated compound, the possibility of non-linear uptake existed
due to a reduced concentration gradient across the monolayer. The permeability of the
compounds was low enough, however, that this did not have a marked eﬀect on the results
of these experiments.

























































































Figure 5.9: Permeability Assay, 60 min Incubation Time. (n = 2–11, Error bars =
SEM) A) Papp of Tested Compounds. B) Permeability of Tested Compounds, Normalised
to CP20.
The apparent permeability (Papp) of CP20 was 1.99±0.31 ×10−5cm s−1 (Figure 5.9.A and
Table 5.3), about twice as high as the Papp in the previous experiments (Figure 5.8). While
there was a signiﬁcant diﬀerence between the Papp of CP20 and 3OMG, Gly, Val, Phe,
M5, M9 or 101, no signiﬁcant diﬀerence was observed between CP20 and 26a, 29a or
98 (1.36±0.19, 2.76±0.32 and 1.00±0.13 ×10−5cm s−1, respectively; see Table 5.3).
The results from each experiment were normalised to CP20 as 100%, in order to account
for day-to-day variability (Figure 5.9.B). A highly signiﬁcant diﬀerence (p < 0.001) was
found between the permeability of CP20 and all other compounds except sodium ﬂuores-
cein (NaF): 29a showed the highest permeability (147%±5), followed by NaF (103%±11),
CP20 (100%), 26a (56%±3) and 98 (53%±1). The other compounds had a permeability



























Figure 5.10: Papp of Tested Compounds Plotted Against their milogP. (Error bars
= SEM)
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Glucosylation did not enhance the BBB permeability, but rather had the opposite eﬀect
of a drastic reduction in permeability (147% vs 56% for the non-glycosylated 29a vs the
glycosylated derivative 26a). Interestingly, the permeability of the compounds appears
to correlate linearly with the compounds’ lipohilicity (Figure 5.10, Table 5.3, R2 = 0.79).
Compound 29a had the highest BBB permeability and is also the most lipophilic com-
pound with a milogP† of 0.996. CP20 is less lipophilic (milogP -0.601) and 26a is even less
than CP20 (milogP -1.052). The iodinated derivative 26c has a higher milogP than 26a,
and thus would be expected to permeate the BBB at a higher rate, possibly close to, or even
higher than CP20. A milogP around -1.2 appears to be the threshold for permeability,
because all compounds with a lower logP value barely penetrated the BBB. This ﬁnding
indicates that the tested HPOs do not cross the BBB by GLUT1 mediated transport, but
rather by passive diﬀusion. In view of the information on substrate speciﬁcity of GLUT1
(Section 1.2.3.1) that exists, it is not too surprising that the glycosylated HPOs were not
transported by the transporter. All conjugates were linked in position 1 or 2 of the sugar,
or – in the case of the 6-linked mannosides – had a modiﬁcation in position 1. These
positions in particular had been identiﬁed to be critical for substrate recognition for the
outward facing conformation.
While the author was aware of GLUT1 selectivity, the preparation of more suitable
substrates for the transport protein, namely 6-linked glucoconjugates, was unfortunately
unsuccessful despite several methodological trials (see Chapter 4).
†milogP are a predicted clogP values, calculated using the physicochemical property calculator provided
online by Molinspiration.264
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Table 5.3: Physicochemical Properties of Tested Compounds.a
Cpd MW milogP HBD HBA PSA Papp c ± SEM
CP20 139 −0.601 1 3 42.2 1.99 0.31
29a 201 0.996 1 3 42.2 2.76 0.32
26a 363 −1.052 4 8 121.4 1.36 0.19
26cb 489 0.031 4 8 121.4 – –
98 412 −3.19 5 12 172.3 1.00 0.13
101 412 −3.19 5 12 172.3 0.55 0.09
Gly 344 −4.036 6 10 161.5 0.36 0.21
Val 386 −2.927 6 10 161.5 0.56 0.02
Phe 434 −2.245 6 10 161.5 0.27 0.15
M5 443 −2.72 7 11 176.5 0.00 0.00
M6 372 −2.931 5 10 150.5 – –
M9 358 −3.202 5 10 150.5 0.34 0.00
M10 448 −1.411 5 10 150.5 – –
a MW = Molecular Weight, milogP = clogP calculated by Molinspiration
(http://www.molinspiration.com/), HBD = Hydrogen Bond Donors, HBA =
Hydrogen Bond Acceptors, PSA = Polar Surface Area.
b Compound not tested.
c Papp in ×10
−5 cm s−1 after 60 min.
Chapter 6
Conclusions and Future Work
The aim of this work was to investigate the BBB permeability of 3-hydroxypyridin-4-
one iron chelators and whether glycosylation can improve the molecules’ permeability by
utilising the glucose transporter GLUT1 for facilitated transport across the BBB.
6.1 Synthetic Chemistry
Glucosides of N -phenyl and N -4-bromophenyl substituted HPOs (26a,b, Figure 6.1) were
synthesised from maltol, the respective aniline and a glycosyl donor. The 4-iodophenyl ana-
logue (26c) could not be synthesised, however. The published procedure (Scheme 2.2),186
and other routes described in this work (Scheme 2.3 and Scheme 2.5) did not yield the



























Figure 6.1: Structures of N -Phenyl hydroxypyridinones.
hydroxy-2-methylpyridin-4-one 29b did not proceed, while masking of the 3-hydroxy group
allowed the successful transformation of 34a into the 4-iodophenyl derivative 34b. This
indicates that the copper catalyst was chelated by the hydroxypyridinone part of the
molecule, which is known as an iron and copper chelator, thus preventing the trans-
halogenation of the 3-hydroxy derivative. While the 3-hydroxy group in glucoside 31b
is also masked, the reaction mainly furnished unreacted starting material and some side
98
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products. Attempts to directly obtain iodinated pyridinones by using 4-iodoaniline did
not yield any products due to extensive polymerisation. It is the opinion of the author
that the relatively high reactivity of aromatic iodine atoms, compared to bromine, is
the cause of these side reactions. The author believes that further optimisations of the
transhalogenation protocol will aﬀord the 4-iodophenyl derivative 26c.
Pyridinones bearing carboxylic acid substituents on the ring nitrogen were readily prepared
from maltol and amino acids in good yields. Pyridinone 48 (Figure 6.2), with a carboxyl
group in position 2 of the ring, was obtained from a much shorter synthesis than previ-
ously published routes (4 steps instead of 8), additionally foregoing any chromatographic
puriﬁcations. Amide-linked conjugates were prepared from the HPOs derived from amino
acids, which were coupled with protected glucosamine after optimisation of the coupling
protocol. The ﬁnal products could not be isolated, however. Decomposition occurred
during treatment with base when attempting to deacetylate the compounds. Glucuro-
namides of N -alkylamine HPOs (Figure 6.2) were prepared from 1,2-acetonide or 1,2-
benzylidene protected glucuronolactones and the respective HPOs. The resultant amides
were subjected to varying deprotection conditions. Acidic conditions led to decomposition
of the amide bond, while hydrogenation of the benzylidene protected compounds did not
proceed at all, even at very high pressures. While the deprotection under acidic conditions
might be improved, the author believes that the coupling with unprotected glucuronic
acid or glucuronolactone is a better alternative to obtain the desired HPO-glucuronamide
conjugates.
Conjugation using a triazole-tether (Figure 6.2) was achieved by reaction of an alkyne-



































Figure 6.2: Structures of Amide and Triazole-linked Conjugates.
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were prepared from glucose or glucosamine and linked to an alkyne-HPO after optimisation
of the coupling protocol. The resultant acetylated triazole-conjugates were deprotected by
the action of sodium methoxide, followed by hydrogenation. The 6-linked conjugate was
fully benzylated, and subjecting it to the same conditions gave only starting materials,
while the use of boron tribromide resulted in decomposition. The deprotection of the 6-
linked conjugate could not be investigated further due to time constraints, but should be
pursued in future work, because the literature suggests that 6-linked glycoconjugates are
most likely to be transported by GLUT1.
Overall, the deprotection of various conjugates posed the biggest problems in this work.
Hydrogenation of the benzyl protected triazole derivatives, or the benzylidene protected
glucuronamides did not proceed, while other derivatives were readily hydrogenated. The
author believes, that the compounds may have been too lipophilic and thus could not be
adsorbed onto the catalyst, preventing hydrogenation. It may therefore be necessary to
substitute overly lipophilic protecting groups for smaller and/or more polar groups.
In conclusion, the synthesis of some novel sugar conjugates of 3-hydroxypyridin-4-ones
has been successful, while others could not be obtained due to problematic syntheses and
time constraints. Unfortunately, 6-linked glucoconjugates, which were expected to have
the highest chance to be transported by GLUT1, could not be synthesised, limiting the
study to 1- and 2-linked gluconjugates.
6.2 Biological Data
The conjugates that had been synthesised, and additional conjugates that were supplied
by Shen Liu and Yongping Yu from Zheijang University, China, were tested for their
behaviour in blood-brain barrier models based on PBECs. Multiple call based assays
were evaluated for their use to determine the uptake into or permeability across a PBEC
monolayer. The models were further used to investigate the compounds’ interaction with
the BBB glucose transporter GLUT1.
The uptake experiments did not give interpretable results, because the cell monolayer was
found to be too thin to accumulate measurable quantities of the tested compounds. The
same problem persisted for the inhibition assay in a multiwell plate setup. This problem
could have been circumvented by using higher compound concentrations, however. The
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interpretation of results generated in the Transwell format was complicated by problems
with the scintillation counter. This was due to the overlapping emission energy proﬁles of
the used radioisotopes.
The permeability assay was performed using cells grown on a permeable Transwell ﬁlter
membrane. Due to the high density of GLUT1 found in the BBB, a substrate of GLUT1
would be expected to have a higher permeability than its non-glycosylated analogue, which
can permeate merely by passive diﬀusion. When tested directly and quantiﬁed by HPLC,
rather than through indirect measurements as in previous studies, none of the tested HPO-
sugar conjugates had a higher permeability than the tested non-glycosylated parent HPOs.
The compounds with the highest lipophilicity were able to cross the BBB the most, while
the permeability of compounds with a milogP lower -1 was very limited. There is therefore
no evidence that the tested molecules were transported by GLUT1, as the permeability
of the molecules was not inﬂuenced by the absence or presence of a sugar moiety, except
for the sugar’s eﬀect on lipophilicity. The sugar moiety hindered – rather than enhanced
– permeability due to its high hydrophilicity and multiple hydrogen bond donors and
acceptors. It thus appears imperative to design transportable glucose conjugates in order
to facilitate their brain penetration, compared to their parent molecules. However, the
study did identify a non-conjugated molecule, 29b, with superior permeability compared
to CP20. This molecules is not fully characterised in terms of its iron-chelating and
neuroprotection capabilities, but warrants further studies.
6.3 Ideas for Future Work
Future areas for development of this work would include the synthesis and testing of
additional HPO-sugar conjugates, in particular those that are linked in position 6 of the
sugar moiety. The only conjugates that have previously been shown by Gynther et al. to
utilise GLUT1 transporter to enter the brain, have been linked in position 6.163
A potential route towards the synthesis of 6-linked triazole derivatives could proceed
via 1,2,3,4-tetraacetylated glucose 105 (Scheme 6.1), which could be prepared from com-
pound 79 via acetylation and selective deprotection of position 6 by catalytic hydrogen-
ation. Alternatively, the primary alcohol of glucose could be selectively silylated with
tert-butyldimethylsilyl chloride (TBDMSCl).211 Acetylation, followed by the removal of
the silyl group with tetrabutylammonium ﬂuoride, would furnish 6-hydroxysugar 105.
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Scheme 6.1: Possible Reaction Pathway towards 6-linked Triazole Conjugates.
Introduction of the azido group on the sugar and triazole formation, following the syntheses
described in chapter 4, gives protected sugar conjugate 106. This could be deprotected
similarly to 1- and 2-linked triazoles by hydrogenation and deacetylation, giving the
desired 6-linked triazole 102. Amides linked in position 6 could be obtained directly
from carboxylic acids and this 6-azido sugar via Staudinger ligation, or by classic amide
formation, following the reduction of the azide.
In order to eﬃciently investigate the permeability of glucose conjugates, the author sug-
gests two diﬀerent screening methods. The preliminary screening of the membrane per-
meability could be achieved in an assay investigating the uptake into erythrocytes, which
are readily available, uncomplicated to handle and express GLUT1 on their cell membrane.
A facile assay determining the uptake into erythrocytes in the presence and absence of
GLUT1 inhibitor would serve as primary screening method. Promising candidates should
then be evaluated further in the PBEC-based BBB assay that was used in the present
work. This assay allows the reliable detection and quantiﬁcation of a compounds BBB
permeability by common methods such as HPLC, and it closely reﬂects the barrier and
transport properties of the blood-brain barrier (Section 1.2.3.1, Chapter 5 and references
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therein). Modiﬁcations and optimisations are possible, such as studying the eﬀect of
glucose (substrate inhibition), a GLUT1 inhibitor (e.g. phloretin or cytochalasin B) and
reduced temperature on the permeability of the candidate. These experiments would
indicate if, and to what extent, GLUT1 is involved in the compound’s transport across the
BBB. It could be worthwhile to study the levels of GLUT1 expression in diﬀerent batches
of PBECs, as this could also shed some light on the variability of 3OMG transport that
was seen in some experiments.
For a better understanding of the interactions of GLUT1 with its natural and non-natural
substrates, the author recommends that potential candidates molecules should be screened
in silico, before testing them in vitro. Studying molecules by docking them into the recently
published crystal structures of GLUT1124 and its bacterial homologue XylE122,123 should
provide a better understanding of the exact interactions of GLUT1 with its substrates,
and may highlight where modiﬁcations are tolerated by the protein, thus allowing a more
focused approach to the design of novel glycoconjugates.
The identiﬁcation of a successful candidate could allow the expansion of the glycosylation
strategy to other substance classes, such as anti-retroviral or chemotherapeutic drugs, as
discussed in Chapter 1, in order to allow a more targeted therapy reducing global side-
eﬀects or to gain access the brain with drugs which had previously not been able to
penetrate the BBB. This is of particular importance in diseases such as HIV or parasite
infections, where the brain serves as a reservoir for the pathogens which cannot be reached
with conventional drugs.157,265,266
Further avenues include the design of cleavable linkers, so that the drug is released in
the brain, otherwise the formed iron complex may not be able to cross the blood-brain
barrier back into the blood, eﬀectively trapping the complexed iron within the brain. A
ﬁrst approach could be the use of ester-linked molecules, which may even turn out to be
too labile to reach the blood-brain barrier intact.
Much more work remains to be done in order to develop successful glycoconjugation
strategies for the delivery of drugs via GLUT1 and the author hopes that the present





Melting points were determined on an Electrothermal apparatus and are uncorrected.
IR spectra were recorded on a Perkin Elmer Spectrum Two FT-IR spectrophotometer.
1H- and 13C-NMR spectra were recorded on a Bruker Avance 400 spectrometer at 298K
(400.13MHz for 1H, 100.62MHz for 13C). The spectra were referenced against TMS where
present, or the centre of the solvent signal was used as an internal standard, which was
related to TMS according to Gottlieb et al.267 The digital resolution was 0.13Hz/data
point in the 1H- spectra and 0.37Hz/data point in the 13C-NMR spectra. Chemical
shifts (δ) are given as parts per million (ppm), coupling constants as Hertz (Hz). The
EPSRC National Mass Spectrometry Facility Swansea kindly recorded all mass spectra on
a Thermoﬁsher LTQ Orbitrap XL.
All reagents were obtained from major suppliers (Sigma-Aldrich, Alfa Aesar, VWR In-
ternational, Thermo Fisher Scientiﬁc) and were used as received and without further
puriﬁcation, unless stated otherwise. For chromatographic separations, silica gel 60 (pore
size 60Å, 230-400 mesh, Sigma-Aldrich) was used. For thin layer chromatography, silica
coated aluminium plates (silica gel 60, UV indicator 254 nm, Merck KGaA) were used.
Room temperature indicates a temperature in the range 16 ◦C to 22 ◦C.
Where possible, systematic names were generated by ChemDraw (PerkinElmer, Inc., Walt-
ham, MA, USA) The numbering within chemical structures is used to aid the unambiguous
assignment of NMR signals and is unrelated to the systematic names of substances.
Purity determination by HPLC. The purity of all compounds tested in cell assays
was determined on a Waters HPLC system (600 controller, 626 pump, 996 PDA detector,
717 autosampler; Waters Corp, Milford, MA, USA) and found to be 98% or higher. A
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reverse-phase polymer column (PLRP-S 150 x 4.6mm, pore size 300Å, particle size 8 µm)
with a ﬂow rate of 1ml/min was used for separation with gradient elution. Acetonitrile,
water and 1-heptanesulfonic acid (all HPLC grade) were obtained from Thermo Fisher
Scientiﬁc. The mobile phase was composed of a buﬀer (5mmol 1-heptanesulfonic acid in
water, adjusted to pH 2 with HCl) and acetonitrile.
A gradient of 2-35% acetonitrile was run for 20 min, followed by 5 min at 35% acetonitrile
and a 5 min post-run period at 2% acetonitrile. The total time per sample was 31 min,
samples were injected twice or thrice (100µl per injection). Sample components were











Glucose (9.0 g, 50mmol) was added to an ice-cooled solution of acetic anhydride (25ml)
in pyridine (75ml). The reaction mixture was allowed to warm to room temperature
and stirred over night, then poured onto ice-water and stirred for 2 hours. The formed
precipitate was collected by vacuum ﬁltration to give fully acetylated sugar 76 as a white
powder (14.4 g, 36.9mmol, 74%, ratio α/β: >10).
All analytical data is in good agreement with published data for the α isomer.268
1H-NMR (CDCl3, 400MHz): δ 6.33 (d,
3J (H1,H2) = 3.8Hz, 1H, H-1), 5.47 (‘t’, 3J =
9.9Hz, 1H, H-3), 5.14 (‘t’, 3J = 10.1Hz, 1H, H-4), 5.10 (dd, 3J (H2,H3) = 10.4Hz, H2J (H1,
,) = 3.8Hz 1H, H-2), 4.27 (dd, 2J (H6a,H6b) = 12.7Hz, 3J (H6a,H5) = 4.5Hz, 1H, H-6a),
4.14–4.11 (m, 1H, H-5), 4.09 (dd, 2J (H6b,H6a) = 12.7Hz, 3J (H6b,H5) = 2.4Hz, 1H, H-
6b), 2.18 (s, 3H, CH3), 2.09 (s, 3H, CH3), 2.04 (s, 3H, CH3), 2.03 (s, 3H, CH3), 2.02 (s,
3H, CH3).
13C-NMR (CDCl3, 100MHz): δ 170.65 (C=O), 170.24 (C=O), 169.67 (C=O), 169.40
(C=O), 168.77 (C=O), 89.07 (C-1), 69.83 (C-3,C-5), 69.19 (C-2), 67.87 (C-4), 61.45 (C-6),
20.91 (CH3), 20.72 (CH3), 20.69 (CH3), 20.59 (CH3), 20.48 (CH3).









Peracetyl glucose 76 (2.0 g, 5.1mmol) was dissolved in DCM (10ml) and cooled to 0 ◦C,
then hydrobromic acid (45% w/v in acetic acid, 3ml) was added and the reaction mixture
stirred on ice for 1 hour and at room temperature for 4 hours. The reaction mixture was
diluted with DCM (20ml) and poured onto ice water. The organic phase was washed
with saturated NaHCO3 solution and brine, then dried and evaporated. The residue was
recrystallised from ethanol and the precipitate collected on a ﬁlter and washed with cold
ethanol to yield 2,3,4,6-tetra-O-acetyl-α-d-glucopyranosyl bromide (30) as white crystals
(1.95 g, 4.74mmol, 93%).
All analytical data is in good agreement with published data.269
1H-NMR (CDCl3, 400MHz): δ 6.61 (d,
3J (H1,H2) = 4.0Hz, 1H, H-1), 5.56 (‘t’, 3J (H3,
H2) = 10.0Hz, 3J (H3,H4) = 9.5Hz, 1H, H-3), 5.17 (‘t’, 3J (H4,H5) = 10.1Hz, 3J (H4,H3)
= 9.5Hz, 1H, H-4), 4.84 (dd, 3J (H2,H3) = 10.0Hz, 3J (H2,H1) = 4.0Hz, 1H, H-2), 4.33
(dd, 2J (H6a,H6b) = 12.3Hz, 3J (H6a,H5) = 3.7Hz, 1H, H-6a), 4.30 (ddd, 3J (H5,H4) =
10.0Hz, 3J (H5,H6a) = 3.7Hz, 3J (H5,H6b) = 1.9Hz, 1H, H-5), 4.13 (dd, 2J (H6b,H6a) =
12.3Hz, 3J (H6b,H5) = 1.9Hz, 1H, H-6b), 2.11 (s, 3H, CH3), 2.10 (s, 3H, CH3), 2.06 (s,
3H, CH3), 2.04 (s, 3H, CH3).
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Maltol (12.6 g, 100mmol) and aniline (18.2ml, 200mmol) were suspended in 0.5M HCl
(250ml). The reaction mixture was heated to reﬂux for 72 hours, then cooled and kept at
4 ◦C over night. The formed precipitated was collected by vacuum ﬁltration and washed
with cooled water to give 3-hydroxy-2-methyl-1-phenylpyridin-4(1H )-one (29a) as yellow
needles (12.0 g, 59.6mmol, 60%).
Analytical data is in agreement with published data.270,271
Melting point: m.p. 212−213 ◦C (lit. m.p. 222 ◦C).272
1H-NMR (CD3OD, 400MHz): δ 7.61–7.57 (m, 4H, H-6,3’,4’,5’), 7.42–7.39 (m, 2H, H-
2’,6’), 6.48 (d, 3J (H5,H6) = 7.2Hz, 1H, H-5), 2.11 (s, 3H, CH3).
13C-NMR (CD3OD, 100MHz): δ 171.54 (C-4), 146.85 (C-2), 143.20 (C-1’), 139.31 (C-6),
















Maltol (5.04 g, 40mmol) and 4-bromoaniline (13.76 g, 80mmol, 2 eq.) were dissolved in
methanol (40ml) and 0.5M HCl (100ml) and heated to reﬂux for 48 hours. The reaction
mixture was kept at 4 ◦C for 3 days, the formed precipitate was then collected by vacuum
ﬁltration and washed with cold water and cold methanol to give 1-(4-bromophenyl)-
3-hydroxy-2-methylpyridin-4(1H )-one (29b) as pale brown crystals (3.72 g, 13.3mmol,
33%).
Analytical data is in agreement with published data.186
1H-NMR (CD3OD, 400MHz): δ 7.76 (d,
3J = 8.7Hz, 2H, H-3’,5’), 7.59 (d, 3J = 7.3Hz,
1H, H-6), 7.36 (d, 3J = 8.7Hz, 2H, H-2’,6’), 6.47 (d, 3J = 7.3Hz, 1H, H-5), 2.13 (s, 3H,
CH3).
















Maltol (1.0 g, 8mmol) and 4-iodoaniline (3.5 g, 16mmol, 2 eq.) were dissolved in methanol
(8ml) and water (20ml). Concentrated HCl (37%, 0.5ml) was added and the reaction mix-
ture heated to reﬂux for 49 hours. The reaction mixture was neutralised with 1M NaOH,
then extracted with ethyl acetate. The organic phase was washed with brine, then dried
over Na2SO4 before evaporation. The residue was puriﬁed by column chromatography











A solution of NaOH (3.5 g, 88mmol) in water (10ml) was added to a solution of maltol
(10.1 g, 80mmol) in methanol (10ml). The resulting solution was heated to reﬂux while
benzyl bromide (10.5ml, 88mmol) was added via a dropping funnel. The reaction mixture
was heated to reﬂux for 18 hours, then concentrated in vacuo, diluted with water (50ml)
and extracted with ethyl acetate (2×). The combined organic phases were washed with
1M NaOH and brine twice, then dried over Na2SO4 and evaporated to give the crude
product as brown oil. The crude residue crystallised upon addition of a seed crystal and
was recrystallised from Et2O to give 3-(benzyloxy)-2-methyl-4H -pyran-4-one (33) as pale
pink needles (15.9 g, 74mmol, 92%).
All analytical data is in good agreement with published data.273
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Melting point: m.p. 51−52 ◦C (lit. m.p. 53−55 ◦C).199
IR (neat) cm-1: 1641, 1425, 1250, 1181.
1H-NMR (CDCl3, 400MHz): δ 7.59 (d,
3J (H6,H5) = 5.6Hz, 1H, H-6), 7.40 (dd, 3J =
7.7Hz, 3J = 1.8Hz, 2H, Ph H-3,5), 7.37–7.32 (m, 3H, Ph H-2,4,6), 6.36 (d, 3J (H5,H6) =
5.6Hz, 1H, H-5), 5.16 (s, 2H, O−CH2−Ph), 2.08 (s, 3H, CH3).
13C-NMR (CDCl3, 100MHz): δ 175.10 (C-4), 159.74 (C-2), 153.42 (C-6), 143.77 (C-3),
136.86 (Ph C-1), 129.04 (Ph C-3,5), 128.43 (Ph C-2,6), 128.32 (Ph C-4), 117.18 (C-5),
73.54 (O−CH2−Ph), 14.79 (CH3).
NSI-MS m/z (%): 455 (29, [2M+Na+]), 433 (22, [2M+H+]), 239 (14, [M+Na+]), 217
(100, [M+H+]).
HRMS-NSI m/z : Calc. for C13H13O3 [M+H














3-(Benzyloxy)-2-methyl-4H -pyran-4-one (33) (1.08 g, 5mmol) and 4-bromoaniline (1.72 g,
10mmol, 2 eq.) were dissolved in methanol (10ml) and 0.5M HCl (10ml). The resulting
mixture was heated to reﬂux for 60 hours and then concentrated in vacuo and extracted
with DCM (3×). The combined organic phases were washed with 1M NaOH and water,
then dried over Na2SO4. Evaporation gave the crude product as a brown oil (2.1 g), which
was puriﬁed by column chromatography (chloroform/methanol: 50/1 → 20/1 → 9/1).
3-(Benzyloxy)-1-(4-bromophenyl)-2-methylpyridin-4(1H )-one was isolated as pale yellow
crystals (1.46 g, 3.9mmol, 79%).
Melting point: m.p. 144−145 ◦C.
IR (neat) cm-1: 3017, 2966, 1622, 1576, 1488, 1356, 1280, 1169, 961.
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1H-NMR (CD3OD, 400MHz): δ 7.73 (d,
3J (H3’,5’,H2’,6’) = 8.6Hz, 2H, H-3’,5’), 7.67
(d, 3J (H6,H5) = 7.4Hz, 1H, H-6), 7.44–7.41 (m, 2H, Ph H-3,5), 7.38–7.32 (m, 3H, Ph
H-2,4,6), 7.28 (d, 3J (H2’,6’,H3’,5’) = 8.6Hz, 2H, H-2’,6’), 6.54 (d, 3J (H5,H6) = 7.4Hz,
1H, H-5), 5.13 (s, 2H, O−CH2−Ph), 1.89 (s, 3H, CH3).
13C-NMR (CD3OD, 100MHz): δ 175.67 (C-4), 146.78 (C-1’), 144.84 (C-2), 142.05 (C-
3), 141.31 (C-6), 138.46 (Ph C-1), 134.31 (C-3’,5’), 130.25 (Ph C-3,5), 129.89 (Ph C-2,6),
129.43 (C-2’,6’), 129.40 (Ph C-4), 124.83 (C-4’), 117.21 (C-5), 74.58 (O−CH2−Ph), 14.79
(CH3).
NSI-MS m/z (%): 743 (10, [2M+H+]), 741 (21, [2M+H+]), 739 (10, [2M+H+]), 372 (98,
[M+H+]), 370 (100, [M+H+]).
HRMS-NSIm/z : Calc. for C19H17BrNO2 [M+H















A pressure tube was charged with 3-(benzyloxy)-1-(4-bromophenyl)-2-methylpyridin-4(1H )-
one (34a) (741mg, 2.0mmol), sodium iodide (604mg, 4.0mmol, 2 eq.) and copper(I) iodide
(24.0mg, 125 µmol, 6.25%mol) and ﬂushed with nitrogen. N,N’ -Dimethylethylenediamine
(21.6 µl, 200 µmol, 10%mol) and dry dioxane (2ml) were added and the tube sealed before
heating to 110 ◦C for 24 hours. The reaction mixture was diluted with aqueous ammonia
(20ml), then poured onto water (40ml) before extraction with DCM (3× 25ml). The
combined organic phases were dried over Na2SO4 and evaporated to aﬀord a pale olive
green oil (640mg) which solidiﬁed on cooling. The crude product was found to be a
mixture of the desired 3-(benzyloxy)-1-(4-iodophenyl)-2-methylpyridin-4(1H )-one (34b)
and starting material 34a in a 5:1 ratio (determined by NMR), and was not puriﬁed
further (Product: 534mg, 1.28mmol, 64%).
Chapter 7 – Experimental 111
Melting point: m.p. 129−132 ◦C.
IR (neat) cm-1: 2967 (w), 2949 (w), 2783 (br), 1622, 1568, 1484, 1453, 1391, 1350, 1283,
1160, 1010, 947.
1H-NMR (CDCl3, 400MHz): δ 7.83 (d,
3J (H3’,5’,H2’,6’) = 8.6Hz, 2H, H-3’,5’), 7.44
(dd, 3J (Ph H2,6,Ph H3,5) = 7.7Hz,4J (Ph H2,6,Ph H4) = 1.7Hz, 2H, Ph H-2,6), 7.36–7.29
(m, 3H, Ph H-3,4,5), 7.20 (d, 3J (H6,H5) = 7.5Hz, 1H, H-6), 6.93 (d, 3J (H2’,6’,H3’,5’) =
8.6Hz, 2H, H-2’,6’) 6.47 (d, 3J (H5,H6) = 7.5Hz, 1H, H-5), 5.27 (s, 2H, O−CH2−Ph), 1.81
(s, 3H, CH3).
NSI-MSm/z (%): 835 (8, [2M+H+]), 418 (100, [M+H+), 372/370 (9, [C19H16BrNO2+H
+]).
HRMS-NSI m/z : Calc. for C19H17INO2 [M+H



















Maltol (3.79 g, 30mmol), glucopyranosyl bromide 30 (4.11 g, 10mmol) and tetrabutyl-
ammonium bromide (3.19 g, 9.9mmol) were dissolved in DCM (40ml) and 1M NaOH
(40ml). The resulting solution was stirred vigorously and heated to 35 ◦C for 4.5 hours,
before extraction with ethyl acetate (300ml). The organic phase was washed twice with
1M NaOH, water and brine, before drying over Na2SO4. Evaporation gave a slowly
crystallising orange oil (2.45 g) which was puriﬁed by column chromatography (ethyl
acetate/hexane: 2/1) to give an oﬀ-white solid. Recrystallisation from water gave 3-
(2,3,4,6-tetra-O-acetyl-β-d-glucopyranosyloxy)-2-methylpyran-(4H )-one (32) as colourless
needles (1.35 g, 2.96mmol, 30%).
All analytical data is in good agreement with published data.51,274
1H-NMR (CDCl3, 400MHz): δ 7.63 (d,
3J (H6,H5) = 5.7Hz, 1H, H-6), 6.34 (d, 3J (H5,
H6) = 5.7Hz, 1H, H- H-5), 5.35 (d, 3J (H1’,H2’) = 7.9Hz, 1H, H-1’), 5.29 (‘t’, 3J (H3’,
H2’) = 9.6Hz, 3J (H3’,H4’) = 9.2Hz, 1H, H-3’), 5.18 (dd, 3J (H2’,H3’) = 9.6Hz, 3J (H2’,
H1’) = 7.9Hz, 1H, H-2’), 5.11 (‘t’, 3J (H4’,H5’) = 10.1Hz, 3J (H4’,H3) = 9.2Hz, 1H, H-4’),
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4.20 (dd, 2J (H6a’,H6b’) = 12.3Hz, 3J (H6a’,H5’) = 4.5Hz, 1H, H-6a’), 4.12 (dd, 2J (H6b’,
H6a’) = 12.3Hz, 3J (H6b’,H5’) = 2.6Hz, 1H, H-6b’), 3.65 (ddd, 3J (H5’,H4’) = 10.1Hz,
3J (H5’,H6a’) = 4.5Hz, 3J (H5’,H6b’) = 2.6Hz, 1H, H-5), 2.31 (s, 3H, 2-CH3), 2.13 (s, 3H,
2’-CH3), 2.04 (s, 3H, 6’-CH3), 2.02 (s, 3H, 4’-CH3), 2.02 (s, 3H, 3’-CH3).
13C-NMR (CDCl3, 100MHz): δ 173.81 (C-4), 170.62 (6’-C=O), 170.26 (2’-C=O), 170.19
(3’-C=O), 169.68 (4’-C=O), 161.45 (C-2), 153.86 (C-6), 141.38 (C-3), 117.47 (C-5), 99.53
(C-1’), 72.65 (C-3’), 71.93 (C-5’), 71.46 (C-2’), 68.58 (C-4’), 61.68 (C-6’), 21.01 (2’-CH3),
20.80 (6’-CH3), 20.76 (3’-CH3, 4’-CH3), 15.38 (2-CH3).
NSI-MS m/z (%): 935 (22, [2M+Na+]), 930 (16, [2M+NH4
+]), 479 (14, [M+Na+]), 457
(100, [M+H+]), 331 (9, [M-pyranone]+).
HRMS-NSI m/z : Calc. for C20H25O12 [M+H





















2,3,4,6-Tetra-O-acetyl-α-d-glucopyranosyl bromide 30 (616mg, 1.5mmol), pyridinone 29a
(608mg, 3mmol, 2 eq.), and tetrabutylammonium hydrogensulfate (517mg, 1.52mmol)
were taken up in DCM (5ml) and 1M NaOH (5ml). Stirring vigorously, the biphasic
reaction mixture was heated to 35 ◦C over night, then diluted with ethyl acetate (50ml)
and washed with 1M NaOH (3×), water and brine before drying over Na2SO4. Evaporation
gave the crude product as dark brown solid (605mg), which was puriﬁed by column
chromatography (ethyl acetate/methanol: 9/1) to yield glucoside 31a as pale beige plates
(317mg, 0.60mmol, 40%).
Melting point: m.p. 173−175 ◦C.
IR (neat) cm-1: 1746, 1634, 1580, 1367, 1219, 1180, 1036.
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1H-NMR (CDCl3, 400MHz): δ 7.55–7.50 (m, 3H, H-3’,4’,5’), 7.35–7.26 (m, 1H, H-2’/6’),
7.28 (d, 3J (H6,H5) = 7.6Hz, 1H, H-6), 7.25–7.17 (m, 1H, H6’/2’), 6.43 (d, 3J (H5,H6) =
7.6Hz, 1H, H-5), 5.70 (d, 3J (H1”,H2”) = 7.9Hz, 1H, H-1”), 5.34 (‘t’, 3J (H3”,H2”) = 9.7Hz,
3J (H3”,H4”) = 9.5Hz, 1H, H-3”), 5.22 (dd, 3J (H2”,H3”) = 9.7Hz, 3J (H2”,H1”) = 7.9Hz,
1H, H-2”), 5.13 (‘t’, 3J (H4”,H5”) = 9.9Hz, 3J (H4”,H3”) = 9.5Hz, 1H, H-4”), 4.22 (dd,
2J (H6a”,H6b”) = 12.3Hz, 3J (H6a”,H5”) = 4.5Hz, 1H, H-6a”), 4.13 (dd, 2J (H6b”,H6a”) =
12.3Hz, 3J (H6b”,H5”) = 2.5Hz, 1H, H-6b”), 3.68 (ddd, 3J (H5”,H4”) = 10.0Hz, 3J (H5”,
H6a”) = 4.4Hz, 3J (H5”,H6b”) = 2.6Hz, 1H, H-5”), 2.16 (s, 3H, CH3), 2.05 (s, 3H, 2-CH3),
2.03 (s, 3H, CH3), 2.02 (s, 3H, CH3), 2.01 (s, 3H, CH3).
13C-NMR (CDCl3, 100MHz): δ 172.75 (C-4), 171.05 (C=O), 170.48 (C=O), 170.40 (2
C=O), 143.01 (C-2), 142.63 (C-1’), 139.02 (C-3), 138.96 (C-6), 130.00 (C-3’,5’), 129.61
(C-4’), 126.82 (C-2’,6’), 117.32 (C-5), 98.83 (C-1”), 72.77 (C-3”), 71.69 (C-5”), 71.61 (C-
2”), 68.54 (C-4”), 61.57 (C-6”), 20.95 (CH3), 20.78 (CH3), 20.58 (CH3), 20.38 (CH3), 14.79
(2-CH3).
NSI-MS m/z (%): 532 (100, [M+H+]), 202 (36, [C12H11NO2+H
+]).
HRMS-NSI m/z : Calc. for C26H30NO11 [M+H






















Pyridinone 29b (2.80 g, 10mmol) was reacted with sugar 30 (1.84 g, 4.5mmol) and tetra-
butylammonium bromide (1.77 g, 5.5mmol) in DCM (10ml) and 1M NaOH (15ml) as
described for the synthesis of 31a. Column chromatography (ethyl acetate/methanol:
9/1) gave the glycoside 31b as oﬀ-white solid (1.20 g, 1.97mmol, 44%).
1H-NMR data is in agreement with published data.186
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IR (neat) cm-1: 1749, 1631, 1576, 1488, 1366, 1295, 1215, 1035.
1H-NMR (CDCl3, 400MHz): δ 7.67 (d,
3J (H2’,6’,H3’,5’) = 8.5Hz, 2H, H-2’,6’), 7.24
(d, 3J (H6,H5) = 7.6Hz, 1H, H-6), 7.11 (br, 2H, H-3’,5’), 6.42 (d, 3J (H5,H6) = 7.6Hz, 1H,
H-5), 5.69 (d, 3J (H1”,H2”) = 7.9Hz, 1H, H-1”), 5.33 (‘t’, 3J (H3”,H2”) = 9.7Hz, 3J (H3”,
H4”) = 9.3Hz, 1H, H-3”), 5.21 (dd, 3J (H2”,H3”) = 9.7Hz, 3J (H2”,H1”) = 7.9Hz, 1H, H-
2”), 5.13 (‘t’, 3J (H4”,H5”) = 10.0Hz, 3J (H4”,H3”) = 9.4Hz, 1H, H-4”), 4.21 (dd, 2J (H6a”,
H6b”) = 12.2Hz, 3J (H6a”,H5”) = 4.3Hz, 1H, H-6a”), 4.14 (dd, 2J (H6b”,H6a”) = 12.2Hz,
3J (H6b”,H5”) = 2.6Hz, 1H, H-6b”), 3.67 (ddd, 3J (H5”,H4”) = 10.1Hz, 3J (H5”,H6a”) =
4.1Hz, 3J (H5”,H6b”) = 2.7Hz, 1H, H-5”), 2.15 (s, 3H, CH3), 2.04 (s, 3H, 2-CH3), 2.03 (s,
3H, CH3), 2.02 (s, 3H, CH3), 2.01 (s, 3H, CH3).
13C-NMR (CDCl3, 100MHz): δ 172.96 (C-4), 170.80 (C=O), 170.58 (C=O), 170.45
(C=O), 170.22 (C=O), 143.21 (C-3), 142.62 (C-2), 140.37 (C-1’), 138.95 (C-6), 133.48
(C-2’,6’), 128.70 (C-3’,5’), 117.63 (C-5), 116.72 (C-4’), 98.77 (C-1”), 72.81 (C-3”), 71.97
(C-5”), 71.69 (C-2”), 68.75 (C-4”), 61.60 (C-6”), 21.14 (CH3), 21.13 (CH3), 20.88 (CH3),
20.80 (CH3), 15.02 (2-CH3).
NSI-MS m/z (%): 634/632 (14, [M+Na+]), 612/610 (100, [M+H+]), 282/280 (27,
[C12H10BrNO2+H
+]).
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Method A: From maltol glucoside – acidic reaction conditions Glucoside 32
(92mg, 200 µmol) and 4-iodoaniline (88mg, 400 µmol) were dissolved in methanol (1.5ml)
and 0.2M HCl (1ml) and heated to reﬂux for 24 hours, then neutralised with NaHCO3.
The reaction mixture was diluted with water and extracetd with ethyl acetate. The
organic phase was washed with brine, dried over Na2SO4 and evaporated. Only starting
material and decomposed materials could be isolated after column chromatography (ethyl
acetate/hexane: 2/1).
Method B: From maltol glucoside – sealed tube Glucoside 32 (92mg, 200 µmol)
and 4-iodoaniline (89mg, 400 µmol) were dissolved in methanol (2ml) and water (2ml)
and heated to 150 ◦C in a sealed tube for 24 hours. Work up as described for method A
yielded only unreacted starting material.
Method C: Transhalogenation 4-Bromo glucoside 31b (1.22 g, 2mmol), copper(I)
iodide (40mg, 0.2mmol, 10%mol) and sodium iodide (600mg, 4mmol, 2 eq.) were added
to dry dioxane (3ml) under nitrogen atmosphere. N,N’ -dimethylethylenediamine (43 µl,
0.4mmol, 20%mol) was added to the solution and the tube sealed tightly before heating
to 110 ◦C for 18 hours. The reaction mixture was diluted with water (20ml) and dilute
ammonia (10ml) and extracted with DCM. The organic phase was dried over Na2SO4,
then evaporated to give a dark brown residue (2 g). Column chromatography (ethyl
acetate/methanol: 9/1) gave multiple fractions, which did not contain the desired product.
Method D: Via Stannane 4-Bromo glucoside 31b (550mg, 0.9mmol) and tetrakis(tri-
phenylphosphine)palladium(0) (110mg, 95 µmol, 10.5%mol) were added to a ﬂask under
nitrogen atmosphere. Dry toluene (15ml) and bis(tributyltin) (2.27ml, 4.5mmol, 5 eq.)
were added to the ﬂask and the reaction mixture heated to reﬂux under nitrogen for 20
hours. The reaction mixture was ﬁltered through celite, washed thoroughly with DCM and
evaporated in vacuo. The residue was dissolved in acetonitrile (15ml) and washed with
hexane (3× 30ml). The acetonitrile layer was evaporated and and puriﬁed by column chro-
matography (ethyl acetate/methanol: 20/1) to give 3-(2,3,4,6-tetra-O-acetyl-β-d-gluco-
pyranosyloxy)-2-methyl-1-(4-(tributylstannyl)phenyl)pyridin-4(1H )-one (31c) as a pale yel-
low glass (94mg, 115 µmol, 13%).
Stannane 31c (16mg, 20 µmol), sodium iodide (15mg, 100 µmol, 5 eq.) and dilute phos-
phoric acid (0.05N, 100 µl) were dissolved in ethanol (3ml). A fresh aqueous solution
of chloramine T (50mg, 180 µmol, 9 eq. in 2ml) was added and the reaction mixture
stirred at room temperature for 1 hour. The reaction was monitored by TLC (ethyl
acetate/methanol: 20/1), which showed consumption of the starting materials, but after
work-up, no product could be isolated.
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3-(2,3,4,6-tetra-O-acetyl-β-d-glucopyranosyloxy)-2-methyl-1-(4-(tributylstannyl)
phenyl)pyridin-4(1H )-one (31c)
1H-NMR data is in agreement with published data, the corrected assignment for the
stannylbutyl substituents is reported below.
Melting point: m.p. 46−48 ◦C.
IR (neat) cm-1: 2956 (w), 2926 (w), 1748, 1633, 1578, 1367, 1287, 1215, 1036.
1H-NMR (CDCl3, 400MHz): δ 7.57 (d,
3J (H3’,5’,H2’,6’) = 7.9Hz, 2H, H-3’,5’), 7.28 (d,
3J (H6,H5) = 7.6Hz, 1H, H-6), 7.23–7.07 (br d, 2H, H-2’,6’), 6.41 (d, 3J (H5,H6) = 7.6Hz,
1H, H-5), 5.66 (d, 3J (H1”,H2”) = 8.0Hz, 1H, H-1”), 5.32 (‘t’, 3J (H3”,H2”) = 9.7Hz, 3J (H3”,
H4”) = 9.3Hz, 1H, H-3”), 5.20 (dd, 3J (H2”,H3”) = 9.7Hz, 3J (H2”,H1”) = 8.0Hz, 1H, H-
2”), 5.10 (‘t’, 3J (H4”,H5”) = 10.1Hz, 3J (H4”,H3”) = 9.3Hz, 1H, H-4”), 4.20 (dd, 2J (H6a”,
H6b”) = 12.1Hz, 3J (H6a”,H5”) = 4.4Hz, 1H, H-6a”), 4.10 (dd, 2J (H6b”,H6a”) = 12.1Hz,
3J (H6b”,H5”) = 2.4Hz, 1H, H-6a”), 3.67 (ddd, 3J (H5”,H4”) = 10.1Hz, 3J (H5”,H6a”) =
4.3Hz, 3J (H5”,H6b”) = 2.5Hz, 1H, H-5”), 2.14 (s, 3H, CH3), 2.04 (s, 3H, 2-CH3), 2.01 (s,
3H, CH3), 2.00 (s, 3H, CH3), 1.99 (s, 3H, CH3), 1.63–1.43 (m, 6H, SnCH2CH2C2H5), 1.32
(‘sex’, 3J = 7.3Hz, 6H, SnC2H4CH2CH3), 1.09 (‘t’,
3J = 8.1Hz, 6H, SnCH2C3H7), 0.88
(t, 3J (CH3,CH2) = 7.3Hz, 9H, SnC3H6CH3).
13C-NMR (CDCl3, 100MHz): δ 172.56 (C-4), 170.57 (C=O), 170.47 (C=O), 170.13
(C=O), 169.72 (C=O), 145.14 (C-4’), 142.91 (C-3), 142.67 (C-2), 141.46 (C-1’), 139.18 (C-
6), 137.84 (C-3’,5’), 125.93 (C-2’,6’), 117.23 (C-5), 98.95 (C-1”), 72.82 (C-3”), 71.74 (C-5”),
71.67 (C-2”), 68.76 (C-4”), 61.70 (C-6”), 29.10 (SnCH2CH2C2H5), 27.41 (SnC2H4CH2CH3),
21.08 (CH3), 20.80 (CH3), 20.74 (2 CH3), 15.00 (2-CH3), 13.76 (SnC3H6CH3), 9.85 (SnCH2
C3H7).
NSI-MS m/z (%): 822 (100, [M+H+]), 820 (78, [M+H+]), 818 (40, [M+H+]), 279 (20,
[P(O)Ph3+H+]).
HRMS-NSI m/z : Calc. for C39H56NO11Sn [M+H
+]: 822.2878; found: 822.2868.




















Glucoside 31a (714mg, 1.34mmol) was dissolved in dry methanol (7.5ml), then 1M
sodium methoxide (1.0ml, 1mmol) was added and the reaction mixture was stirred at room
temperature for 1 hour. The solution was neutralised with 2M HCl and evaporated to dry-
ness. The residue was puriﬁed by column chromatography (chloroform/methanol: 20/1→
6/1) to yield 3-(β-d-glucopyranosyloxy)-2-methyl-1-phenylpyridin-4(1H )-one (26a) as a
pale tan solid (360mg, 0.99mmol, 74%).
NMR data is in good agreement with published data.188 Melting point data does not
match the published data.275
Melting point: Decomposition at 198 ◦C (lit. m.p. 230−231 ◦C).275
IR (neat) cm-1: 3318 (w), 3187 (br), 1622, 1545, 1492, 1274, 1083, 1059, 1028.
1H-NMR (CD3OD, 400MHz): δ 7.75 (d,
3J (H6,H5) = 7.4Hz, 1H, H-6), 7.63–7.57 (m,
3H, H-3’,4’,5’), 7.47–7.41 (m, 2H, H-2’,6’), 6.57 (d, 3J (H5,H6) = 7.4Hz, 1H, H-5), 4.73
(d, 3J (H1”,H2”) = 7.4Hz, 1H, H-1”), 3.84 (dd, 2J (H6a”,H6b”) = 11.9Hz, 3J (H6a”,H5”) =
2.1Hz, 1H, H-6a”), 3.66 (dd, 2J (H6b”,H6a”) = 11.9Hz, 3J (H6b”,H5”) = 5.5Hz, 1H, H6b”),
3.47–3.40 (m, 2H, H-2”,3”), 3.34 (‘t’, 3J = 9.1Hz, 1H, H-4”), 3.27 (ddd, 3J (H5”,H4”) =
9.4Hz, 3J (H5”,H6b”) = 5.4Hz, 3J (H5”,H6a”) = 2.1Hz, 1H, H-5”), 2.25 (s, 3H, 2-CH3).
13C-NMR (CD3OD, 100MHz): δ 174.86 (C-4), 146.76 (C-2), 145.91 (C-3), 143.05 (C-1’),
142.30 (C-6), 131.23 (C-3’,5’), 131.16 (C-4’), 127.99 (C-2’,6’), 116.89 (C-5), 107.06 (C-1”),
78.72 (C-5”), 78.48 (C-3”), 75.58 (C-2”), 71.11 (C-4”), 62.63 (C-6”), 15.74 (2-CH3).
NSI-MS m/z (%): 761 (32, [2M+Cl–]), 400 (34, [M+Cl–]), 398 (100, [M+Cl–]).
HRMS-NSIm/z : Calc. for C18H21NO7Cl [M+Cl
–]: 398.1012/400.0983; found: 398.1007/
400.0973.





















Glucoside 31b (220mg, 360 µmol) was dissolved in dry methanol (5ml), then 1M sodium
methoxide (150µl, 150 µmol) was added and the solution was allowed to stir for 8 hours,
then further sodium methoxide (300 µl) was added. The reaction mixture was stirred for
further 20 hours (28 hours total) before neutralisation with 2M HCl and evaporation to dry-
ness. The residue was puriﬁed by column chromatography (chloroform/methanol: 6/1) to
give 1-(4-bromophenyl)-3-(β-d-glucopyranosyloxy)-2-methylpyridin-4(1H )-one (26b) as a
pale brown solid (108mg, 242 µmol, 67%).
Melting point: Decomposition at 174 ◦C.
IR (neat) cm-1: 3265 (br), 1623, 1552, 1485, 1282,1195, 1066, 1011.
1H-NMR (CD3OD, 400MHz): δ 7.76 (d,
3J (H2’,6’,H3’,5’) = 8.2Hz, 2H, H-2’,6’), 7.75
(d, 3J (H6,H5) = 7.4Hz, 1H, H-6), 7.40 (d, 3J (H3’,5’,H2’,6’) = 8.2Hz,2H, H-3’,5’), 6.56
(d, 3J (H5,H6) = 7.4Hz, 1H, H-5), 4.73 (d, 3J (H1”,H2”) = 7.4Hz, 1H, H-1”), 3.84 (dd,
2J (H6a”,H6b”) = 11.9Hz, 3J (H6a”,H5”) = 1.8Hz, 1H, H-6a”), 3.66 (dd, 2J (H6b”,H6a”) =
11.9Hz, 3J (H6b”,H5”) = 5.5Hz, 1H, H6b”), 3.47–3.38 (m, 2H, H-2”,3”), 3.34 (‘t’, 3J =
8.9Hz, 1H, H-4”), 3.27 (ddd, 3J (H5”,H4”) = 9.4Hz, 3J (H5”,H6b”) = 5.5Hz, 3J (H5”,H6a”)
= 2.0Hz, 1H, H-5”), 2.25 (s, 3H, 2-CH3).
13C-NMR (CD3OD, 100MHz): δ 174.94 (C-4), 146.51 (C-3), 145.84 (C-2), 143.05 (C-1’),
142.30 (C-6), 134.32 (C-2’,6’), 130.01 (C-3’,5’), 124.95 (C-4’), 117.01 (C-5), 106.86 (C-1”),
78.65 (C-5”), 78.35 (C-3”), 75.44 (C-2”), 71.03 (C-4”), 62.51 (C-6”), 15.71 (2-CH3).
NSI-MS m/z (%): 502/500 (14), 488/486/484 (23/29/30), 478/476 (100/73, [M+Cl–]),
442/440 (18, [M-H+]).
HRMS-NSIm/z : Calc. for C18H19BrNO7 [M−H
+]−: 440.0350/442.0330; found: 440.0354/
442.0332.
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amino acid g mmol product g Yield
g mmol
5.4 25.0 glycine 4.7 62.6 39a 6.43 94%
10.0 46.2 β-alanine 5.0 56.1 39b 9.36 71%
15.0 69.4 GABA 8.3 80.5 39c 20.55 98%
Benzyl maltol 33 (5.4 g, 25mmol) and glycine (4.7 g, 62.6mmol, 2.5 eq.) were dissolved in
methanol (50ml) and 1M NaOH (60ml). The resulting solution was heated to reﬂux for
22 hours, then concentrated in vacuo and diluted with water. The solution was extracted
with ethyl acetate, the organic phase discarded and the aqueous phase acidiﬁed with HCl
to pH 4, then cooled to 4 ◦C over night. The formed precipitate was collected by vacuum
ﬁltration to give 2-(3-(benzyloxy)-2-methyl-4-oxopyridin-1-(4H )-yl)propanoic acid (39a)
as a pale tan powder (6.43 g, 23.5mmol, 94%).
An analogous procedure using β-alanine and γ-aminobutyric acid (GABA) gave 3-(3-
(benzyloxy)-2-methyl-4-oxopyridin-1-(4H )-yl)propanoic acid (39b) and 4-(3-(benzyloxy)-
2-methyl-4-oxopyridin-1-(4H )-yl)butanoic acid (39c) respectively.
2-(3-(Benzyloxy)-2-methyl-4-oxopyridin-1-(4H )-yl)acetic acid (39a)
Melting point: m.p. 191−194 ◦C.
IR (neat) cm-1: 3050 (br), 2348 (br), 1893 (br), 1616, 1497, 1375, 1360, 1299, 1271, 1250,
968.
1H-NMR (CD3OD, 400MHz): δ 7.77 (d,
3J (H6,H5) = 7.4Hz, 1H, H-6), 7.42–7.39 (m,
2H, Ph H-3,5), 7.37–7.31 (m, 3H, Ph H-2,4,6), 6.62 (d, 3J (H5,H6) = 7.4Hz, 1H, H-5), 5.09
(s, 2H, O−CH2−Ph), 4.84 (s, 2H, H-2’), 2.16 (s, 3H, CH3).
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13C-NMR (CD3OD, 100MHz): δ 173.36 (C-4), 170.44 (C-1’), 147.08 (C-2), 146.42 (C-
3), 142.70 (C-6), 138.19 (Ph C-1), 130.17 (Ph C-3,5), 129.51 (Ph C-2,6), 129.42 (Ph C-4),
116.37 (C-5), 75.05 (O−CH2−Ph), 56.66 (C-2’), 13.02 (CH3).
NSI-MS m/z (%): 545 (49, [2M-H+]), 272 (100, [M-H+]).
HRMS-NSI m/z : Calc. for C15H14NO4 [M−H
+]−: 272.0928; found: 272.0928.
3-(3-(Benzyloxy)-2-methyl-4-oxopyridin-1-(4H )-yl)propanoic acid (39b)
NMR data is in good agreement with published data.273
Melting point: m.p. 160−161 ◦C (lit. m.p. 170−171 ◦C).199).
IR (neat) cm-1: 2454 (w), 1913 (w), 1699, 1621, 1534, 1496, 1259, 1224, 1056, 1006.
1H-NMR (CD3OD, 400MHz): δ 7.77 (d,
3J (H5,H6) = 7.5Hz, 1H, H-6), 7.40–7.32 (m,
5H, Ph H-2–6), 6.47 (d, 3J (H5,H6) = 7.5Hz, 1H, H-5), 5.07 (s, 2H, O−CH2−Ph), 4.25
(t, 3J (H3’,H2’) = 6.9Hz, 2H, H-3’), 2.70 (t, 3J (H2’,H3’) = 6.9Hz, 2H, H-2’), 2.20 (s, 3H,
2-CH3).
13C-NMR (CD3OD, 100MHz): δ 174.68 (C-4), 173.49 (C-1’), 147.00 (C-2), 145.32 (C-
3), 141.60 (C-6), 138.38 (Ph C-1), 130.27 (Ph C-3,5), 129.43 (Ph C-2,6), 129.37 (Ph C-4),
117.15 (C-5), 74.58 (O−CH2−Ph), 50.87 (C-3’), 35.40 (C-2’), 12.77 (2-CH3).
4-(3-(Benzyloxy)-2-methyl-4-oxopyridin-1-(4H )-yl)butanoic acid (39c)
NMR data is in good agreement with published data.276
Melting point: m.p. 154−156 ◦C (lit. m.p. 169−170 ◦C).199
IR (neat) cm-1: 3395 (br), 2498 (br), 1892 (br), 1688 (w), 1615, 1531, 1497, 1453, 1324,
1219, 1155, 1038 (w).
1H-NMR (CD3OD, 400MHz): δ 7.69 (d,
3J (H6,H5) = 7.4Hz, 1H, H-6), 7.40–7.31 (m,
5H, Ph H-2–6), 6.48 (d, 3J (H5,H6) = 7.4Hz, 1H, H-5), 5.08 (s, 2H, O−CH2−Ph), 4.00
(tt, 3J (H4’,H3’) = 7.6Hz, 4J (H4’,H2’) = 1.7Hz, 2H, H-4’), 2.33 (t, 3J (H2’,H3’) = 6.9Hz,
2H, H-2’), 2.19 (s, 3H, 2-CH3), 1.91 (tt,
3J (H4’,H3’) = 7.6Hz, 3J (H4’,H3’) = 6.9Hz, 2H,
H-3’).
13C-NMR (CD3OD, 100MHz): δ 176.20 (C-4), 174.79 (C-1’), 146.98 (C-2), 145.30 (C-
3), 141.19 (C-6), 138.38 (Ph C-1), 130.36 (Ph C-3,5), 129.41 (Ph C-2,6), 129.39 (Ph C-4),
117.39 (C-5), 74.48 (O−CH2−Ph), 54.46 (C-4’), 31.23 (C-2’), 26.83 (C-3’), 12.75 (2-CH3).











Benzyl maltol 33 (540mg, 2.5mmol) and aqueous methylamine (40% w/v, 344 µl, 4.0mmol)
were dissolved in methanol (4ml) and 1M NaOH (0.5ml). The solution was heated to reﬂux
for 2 hours, then evaporated to near dryness and resuspended in methanol. 1M HCl was
added dropwise until no more precipitate formed. The suspension was heated to reﬂux,
Et2O was added until the solution turned slightly cloudy. The precipitate, which had
formed after refrigeration, was collected by vacuum ﬁltration and washed with Et2O to give
3-(benzyloxy)-1,2-dimethylpyridin-4(1H )-one (49) as oﬀ-white ﬂakes (542mg, 2.0mmol,
82%).
1H-NMR (CD3OD, 400MHz): δ 8.25 (d,
3J (H6,H5) = 7.1Hz, 1H, H-6), 7.46–7.43 (m,
2H, Ph H-3,5), 7.40–7.36 (m, 3H, Ph H-2,4,6), 7.17 (d, 3J (H5,H6) = 7.1Hz, 1H, H-5), 5.17
(s, 2H, O−CH2−Ph), 4.00 (s, 3H, 1-CH3), 2.48 (s, 3H, 2-CH3).
13C-NMR (CD3OD, 100MHz): δ 165.66 (C-4), 151.75 (C-2), 144.62 (C-3), 143.62 (C-6),
137.18 (Ph C-1), 130.03 (Ph C-3,5), 129.88 (Ph C-4), 129.67 (Ph C-2,6), 113.59 (C-5),
76.18 (O−CH2−Ph), 45.00 (2-CH3), 13.96 (1-CH3).
NSI-MS m/z (%): 459 (32, [2M+H+]), 230 (100, [M+H+]).
HRMS-NSI m/z : Calc. for C14H16NO2 [M+H
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Benzyl maltol 33 (1085mg, 5mmol) and selenium dioxide (117mg, 10mmol, 2 eq.) were
suspended in bromobenzene (20ml) and heated to reﬂux for 20 hours. The reaction
mixture was ﬁltered through a pad of celite and washed with water and DCM. The ﬁltrate
was extracted with DCM, the organic phase dried over Na2SO4 and evaporate to give
the crude product as brown oil. Puriﬁcation by column chromatography (hexane/ethyl
acetate: 2/1) yielded unreacted starting material 33 (224mg, 1mmol) and 3-(benzyloxy)-
2-formyl-4H -pyran-4-one (51) as a pale orange oil (400mg, 1.7mmol, 35%).
All analytical data is in good agreement with published data.277
1H-NMR (CDCl3, 400MHz): δ 9.82 (s, 1H, 2-CHO), 7.69 (d,
3J (H6,H5) = 5.7Hz, 1H,
H-6), 7.36–7.26 (m, 5H, Ph H-2–6), 6.45 (d, 3J (H6,H5) = 5.7Hz, 1H, H-5), 5.46 (s, 2H,
O−CH2−Ph).
13C-NMR (CDCl3, 100MHz): δ 182.63 (2-CHO), 176.96 (C-4), 154.26 (C-6), 151.84 (C-
3), 149.31 (C-2), 135.02 (Ph C-1), 129.22 (Ph C-3,5), 129.18 (Ph C-4), 128.90 (Ph C-2,6),
118.37 (C-5), 74.98 (O−CH2−Ph).
NSI-MS m/z (%): 547 (47, [2M+2MeOH+Na+]), 525 (12, [2M+2MeOH+H+]), 285 (23,
[M+MeOH+Na+]), 263 (100, [M+MeOH+H+]), 231 (8, [M+H+]).
HRMS-NSI m/z : Calc. for C13H11O4 [M+H
+]: 231.0652, found: 231.0654; calc. for
C14H15O5 [M+MeOH+H













Aldehyde 51 (345mg, 1.5mmol) and tosylic acid (5mg, catalytic) were dissolved in dry
methanol (7.5ml), trimethyl orthoformate (250 µl, 2.3mmol) was added and the reaction
mixture heated to reﬂux for 3 hours under anhydrous conditions. The reaction mixture was
evaporated to dryness, diluted with water and extracted with ethyl acetate. The organic
phase was washed with brine, dried over Na2SO4 and evaporated to give 3-(benzyloxy)-2-
(dimethoxymethyl)-4H -pyran-4-one (53) as a brown oil (367mg, 1.33mmol, 89%).
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1H-NMR (CDCl3, 400MHz): δ 7.72 (d,
3J (H6,H5) = 5.6Hz, 1H, H-6), 7.41–7.33 (m,
5H, Ph H-2–6), 6.43 (d, 3J (H5,H6) = 5.6Hz, 1H, H-5), 5.24 (s, 1H, 2-CH(OCH3)2), 5.22
(s, 2H, O−CH2−Ph), 3.29 (s, 6H, O−CH3).
13C-NMR (CDCl3, 100MHz): δ 175.64 (C-4), 154.96 (C-2), 154.15 (C-6), 144.41 (C-
3), 136.39 (Ph C-1), 129.32 (Ph C-3,5), 128.71 (Ph C-2,4,6), 117.56 (C-5), 97.28 (2-













Pyranone 53 (135mg, 490 µmol) and aqueous methylamine (40% w/v, 70 µl, 810 µmol)
were dissolved in methanol (2ml). 1M NaOH (200 µl) was added and the reaction mixture
heated to reﬂux for 4 hours. The reaction mixture was diluted with water and extraced
with ethyl acetate and the organic phase was washed with brine. Evaporation and drying
in vacuo gave 3-(benzyloxy)-2-(dimethoxymethyl)-1-methylpyridin-4(1H )-one (54) as a
brown oil (106mg, 366 µmol, 75%).
The product was subjected to a range of deprotection conditions, but none of these could
successfully reconstitute the aldehyde.
IR (neat) cm-1: 2932 (w, br), 1623, 1566, 1454 (w), 1250, 1207, 1100, 1065, 952.
1H-NMR (CDCl3, 400MHz): δ 7.33–7.31 (m, 2H, Ph H-3,5), 7.29–7.22 (m, 3H, Ph
H-2,4,6), 7.09 (d, 3J (H6,H5) = 7.5Hz, 1H, H-6), 6.33 (d, 3J (H5,H6) = 7.5Hz, 1H, H-5),
5.44 (s, 1H, 2-CH(OCH3)2), 5.18 (s, 2H, O−CH2−Ph), 3.65 (s, 3H, 1-CH3), 3.14 (s, 6H,
O−CH3).
13C-NMR (CDCl3, 100MHz): δ 173.65 (C-4), 146.96 (C-3), 141.12 (C-6), 138.03 (C-2),
137.12 (Ph C-1), 129.07 (Ph C-3,5), 128.41 (Ph C-2,6), 128.13 (Ph C-4), 117.26 (C-5),
100.10 (2-CH(OCH3)2), 73.64 (O−CH2−Ph), 55.99 (O−CH3), 42.18 (1-CH3).
NSI-MS m/z (%): 601 (22, [2M+Na+]), 290 (100, [M+H+]), 230 (23).
HRMS-NSI m/z : Calc. for C16H20NO4 [M+H
+]: 290.1387; found: 290.1389.













Aldehyde 51 (230mg, 1mmol), sulfamic acid (107mg, 1.1mmol) and sodium chlorite (80%
w/w, 124mg, 1.1mmol) were suspended in acetone/water (5ml). The reaction mixture
was stirred over night at room temperature, then ﬁltered and the residue was washed with
water and a small quantity of acetone to give carboxylic acid 50 as a white powder. More
product could be isolated by concentrating the ﬁltrate (117mg, 475 µmol, 48%).
NMR data is in good agreement with published data.278
Melting point: m.p. 138−140 ◦C (lit. m.p. 150−152 ◦C).278
IR (neat) cm-1: 2414 (br), 1896 (br), 1712, 1620, 1583, 1286, 1199, 1050, 973.
1H-NMR (DMSO−d6, 400MHz): δ 8.21 (d,
3J (H6,H5) = 5.6Hz, 1H, H-6), 7.48–7.31
(m, 5H, Ph H-2–6), 6.55 (d, 3J (H6,H5) = 5.6Hz, 1H, H-5), 5.11 (s, 2H, O−CH2−Ph).
NSI-MS m/z (%): 419 (29, [2M-H+]), 245 (100, [M-H+]).
HRMS-NSI m/z : Calc. for C13H9NO5 [M-H













Pyranone 50 (82mg, 333 µmol) was added to a solution of aqueous methylamine (40%
w/v, 200 µl, 2.3mmol) in water (3ml). The reaction mixture was heated to 110 ◦C in a
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sealed tube for 20 hours, then diluted with water (10ml) and acidiﬁed to pH 2 with HCl
and stirred for 10min. The formed precipitate was collected by vacuum ﬁltration and
washed with water and acetone to give 3-(benzyloxy)-2-carboxy-4H -pyran-4-one (48) as
oﬀ-white powder (60.5mg, 233 µmol. 70%).
Melting point: m.p. 120−122 ◦C.
IR (neat) cm-1: 3065 (br, w), 1678, 1633, 1544 (w), 1454, 1435, 1360, 1260, 1182 (w), 972.
1H-NMR (CD3OD, 400MHz): δ 8.01 (d,
3J (H6,H5) = 7.1Hz, 1H, H-6), 7.52–7.49 (m,
2H, Ph H-2,6), 7.37–7.28 (m, 3H, Ph H-3,4,5), 6.96 (d, 3J (H5,H6) = 7.1Hz, 1H, H-5), 5.14
(s, 2H, O−CH2−Ph), 3.97 (s, 3H, 1-CH3).
13C-NMR (CD3OD, 100MHz): δ 173.85 (C-4), 169.53 (2-CO2H), 149.92 (C-3), 142.23
(C-6), 137.84 (Ph C-1), 136.42 (C-2), 129.80 (Ph C-2,6), 129.34 (Ph C-3–5), 115.37 (C-5),
76.53 (O−CH2−Ph), 44.01 (1-CH3).
NSI-MS m/z (%): 519 (33, [2M+H+]), 260 (100, [M+H+]).
HRMS-NSI m/z : Calc. for C14H14NO4 [M+H













Anisaldehyde (8.5ml, 70mmol, 1.2 eq.) was added to a solution of glucosamine hydrochlor-
ide (12.5 g, 58mmol) in 1M NaOH (60ml). The mixture was stirred vigorously for 10min
and a large amount of precipitate formed after a few minutes. The reaction mixture was
cooled to 4 ◦C over night, and the solid collected by vacuum ﬁltration, washed with cold
water, then Et2O/ethanol (2/1 v/v) to give N -(4-methoxybenzylidene)-d-glucosamine (56)
as a white powder. Concentrating the mother liquor yielded additional product. (14.2 g,
48mmol, 84%).
All analytical data is in good agreement with published data.279
1H-NMR (DMSO−d6, 400MHz): δ 8.11 (s, 1H, N=CH), 7.68 (d,
3J (H2’,6’,H3’,5’) =
8.8Hz, 2H, H-2’,6’), 6.98 (d, 3J (H3’,5’,H2’,6’) = 8.8Hz, 2H, H-3’,5’), 6.53 (d, 3J (OH,H1)
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= 6.8Hz, 1H, 1-OH), 4.94 (d, 3J (OH,H4) = 5.3Hz, 1H, 4-OH), 4.82 (d, 3J (OH,H3) =
5.6Hz, 1H, 3-OH), 4.69 (‘t’, 3J (H1,H2) = 7.9Hz, 3J (H1,OH) = 6.8Hz, 1H, H-1), 4.56
(t, 3J (OH,H6) = 5.7Hz, 1H, 6-OH), 3.80 (s, 3H, 4’-OCH3), 3.72 (ddd,
2J (H6a,H6b) =
11.5Hz, 3J (H6a,OH) = 5.7Hz, 3J (H6a,H5) = 1.9Hz, 1H, H-6a), 3.50 (dd, 2J (H6b,H6a) =
11.5Hz, 3J (H6b,OH) = 5.7Hz, 1H, H-6b), 3.46–3.40 (m, 3J (H3,H2) = 9.0Hz, 3J (H3,OH)
= 5.6Hz, 1H, H-3), 3.26–3.21 (m, 1H, H-5), 3.17–3.12 (m, 3J (H4,OH) = 5.3Hz, 1H, H-4),
2.78 (dd, 3J (H2,H3) = 9.0Hz, 3J (H2,H1) = 7.9Hz, 1H, H-2).
13C-NMR (DMSO−d6, 100MHz): δ 161.23 (N=CH), 161.06 (C-4’), 129.64 (C-2’,6’),
129.12 (C-1’), 113.91 (C-3’,5’), 95.64 (C-1), 78.20 (C-2), 76.88 (C-5), 74.60 (C-3), 70.36
(C-4), 61.27 (C-6), 55.29 (4’-OCH3).
NSI-MS m/z (%): 671 (7, [2M+Na+]), 320 (9, [M+Na+]), 298 (100, [M+H+]).
HRMS-NSI m/z : Calc. for C14H20NO6 [M+H













Benzylidene 56 (10.0 , 33.6mmol) was added to an ice-cooled mixture of pyridine (55ml)
and acetic anhydride (30ml). The reaction mixture was allowed to warm to room temperat-
ure and stirred over night, then poured onto ice-water (250ml) and stirred for 30min. The
formed precipitate was collected by vacuum ﬁltration and washed liberally with cold water
and dried over P2O5, giving N -(4-methoxybenzylidene)-β-d-glucosamine 1,3,4,6-tetra-O-
acetate (57) as a white to cream coloured powder (12.5 g, 27.3mmol, 81%).
All analytical data is in good agreement with published data.279
1H-NMR (CDCl3, 400MHz): δ 8.15 (s, 1H, N=CH), 7.67 (d,
3J (H2’,6’,H3’,5’) = 8.6Hz,
2H, H-2’,6’), 6.92 (d, 3J (H3’,5’,H2’,6’) = 8.8Hz, 2H, H-3’,5’), 5.95 (d, 3J (H1,H2) = 8.3Hz,
1H, H-1), 5.43 (t, 3J (H3,H2) = 9.7Hz, 3J (H3,H4) = 9.5Hz, 1H, H-3), 5.14 (‘t’, 3J (H4,H5)
= 10.1Hz, 3J (H4,H3) = 9.5Hz, 1H, H-4), 4.38 (dd, 2J (H6a,H6b) = 12.4Hz, 3J (H6a,H5)
= 4.5Hz, 1H, H-6a), 4.13 (dd, 2J (H6b,H6a) = 12.4Hz, 3J (H6b,H5) = 2.0Hz, 1H, H-6b),
3.97 (ddd, 3J (H5,H4) = 10.1Hz 3J (H5,H6a) = 4.5Hz, 3J (H5,H6b) = 2.0Hz, 1H, H-5),
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3.84 (s, 3H, 4’-OCH3), 3.46 (dd,
3J (H2,H3) = 9.7Hz, 3J (H2,H1) = 8.3Hz, 1H, H-2), 2.10
(s, 3H, COCH3), 2.03 (s, 3H, COCH3), 2.02 (s, 3H, COCH3), 1.88 (s, 3H, COCH3).
13C-NMR (CDCl3, 100MHz): δ 170.85 (C=O), 170.05 (C=O), 169.70 (C=O), 168.89
(C=O), 164.51 (N=CH), 162.46 (C-4’), 130.43 (C-2’,6’), 128.25 (C-1’), 114.26 (C-3’,5’),
93.26 (C-1), 73.38 (C-3), 73.13 (C-2), 72.91 (C-5), 68.17 (C-4), 61.96 (C-6), 55.58 (OCH3),
20.97 (COCH3), 20.92 (COCH3), 20.84 (COCH3), 20.67 (COCH3).
NSI-MS m/z (%): 953 (8, [2M+Na+]), 931 (17, [2M+H+]), 488 (7, [M+Na+]), 466 (100,
[M+H+]).
HRMS-NSI m/z : Calc. for C22H28NO10 [M+H











Fully protected sugar 57 (11.6 g, 25.4mmol) was dissolved in warm acetone (80ml) and the
solution heated to reﬂux. To the reﬂuxing solution, 5M HCl (6ml, 30mmol) was added,
immediately turning the reaction mixture solid. The solid was broken up mechanically
and stirred for 2 hours after addition of Et2O, then cooled to 4
◦C over night. The solid
was collected by vacuum ﬁltration and washed with Et2O to give the selectively protected
sugar 1,3,4,6-tetra-O-acetyl-β-d-glucosamine hydrochloride (58) as a white solid (10 g,
quantitative).
All analytical data is in agreement with published data.279
1H-NMR (D2O, 400MHz): δ 5.89 (d,
3J (H1,H2) = 8.8Hz, 1H, H-1), 5.41 (dd, 3J (H3,
H2) = 10.5Hz, 3J (H3,H4) = 9.1Hz, 1H, H-3), 5.13 (‘t’, 3J (H4,H5) = 10.0Hz, 3J (H4,H3)
= 9.1Hz, 1H, H-4), 4.40 (dd, 2J (H6a,H6b) = 12.9Hz, 3J (H6a,H5) = 4.1Hz, 1H, H-6a),
4.24–4.18 (m, 2H, H-5,6b), 3.61 (dd, 3J (H2,H3) = 10.5Hz, 3J (H2,H1) = 8.8Hz, 1H, H-2),
2.23 (s, 3H, CH3), 2.15 (s, 3H, CH3), 2.111 (s, 3H, CH3), 2.105 (s, 3H, CH3).
13C-NMR (D2O, 100MHz): δ 176.54 (C=O), 176.11 (C=O), 175.73 (C=O), 174.41
(C=O), 94.39 (C-1), 75.01 (C-5), 74.82 (C-3), 71.08 (C-4), 64.42 (C-6), 55.65 (C-2), 23.12
(2× CH3), 22.99 (CH3), 22.96 (CH3).
Chapter 7 – Experimental 128
NSI-MS m/z (%): 835 (29, [M+Starting material+Na+), 717 (68, [2M+Na+]), 695 (12,
[2M+H+]), 488 (31, [Starting material+Na+]), 466 (17, [Starting material+H+]), 370 (100,
[M+Na+]), 348 (33, [M+H+]).
HRMS-NSI m/z : Calc. for C14H22NO9 [M+H







































Pyridinone 39a (957mg, 3.5mmol) was dissolved in dry DMF (20ml) under nitrogen at-
mosphere and combined with solutions of N,N’ -dicyclohexylcarbodiimide (825mg, 4mmol,
1.14 eq.) and N -hydroxysuccinimide (407mg, 3.5mmol) in dry DMF (5ml). The resulting
solution was stirred under nitrogen for 21 h, then ﬁltered and the ﬁltrate evaporated
to give a pale orange residue. The residue was dissolved in DCM and few drops of
Et2O and ﬁltered. The ﬁltrate was diluted with Et2O and the formed precipitate was
collected by vacuum ﬁltration and washed with diethyl ether and little DCM to give 2,5-
dioxopyrrolidin-1-yl 2-(3-(benzyloxy)-2-methyl-4-oxopyridin-1(4H )-yl)acetate (61a) as a
white powder (720mg, 3:1 mixture with unreacted acid 39a). The crude intermediate
product (592mg, 1.56mmol, 45%) was used directly and without further puriﬁcation.
1,3,4,6-Tetra-O-acetyl-β-d-glucosamine hydrochloride (58) (385mg, 1.0mmol) and N,N’ -
diisopropylethylamine (350 µl, 2mmol) were added to a solution of activated acid 61a
(1.1mmol, 700mg crude intermediate) in dry DMF (15ml). The resulting solution was
stirred for 21 hours at room temperature, then evaporated to dryness and the residue
dissolved in DCM (25ml) and washed with dilute HCl (pH 5). The formed precipitate
was removed by ﬁltration. The aqueous layer was exctracted with DCM, and the combined
organic layers washed with HCl (pH 5), water and aqueous NaHCO3 (pH 8.5). Drying over
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Na2SO4 and evaporation gave 1-(1,3,4,6-tetra-O-acetyl-2-deoxy-β-d-glucopyranos-2-yl)-2-
(3-(benzyloxy)-2-methyl-4-oxopyridin-1(4H )-yl)acetamide (59a) as a yellow gum (458mg,
0.76mmol, 76%, 34% over both steps).
2,5-Dioxopyrrolidin-1-yl 2-(3-(benzyloxy)-2-methyl-4-oxopyridin-1(4H )-yl)
acetate (61a)
1H-NMR (DMSO−d6, 400MHz): δ 7.69 (d,
3J (H6,H5) = 7.6Hz, 1H, H-6), 7.42–7.39 (m,
2H, Ph H-3,5), 7.37–7.30 (m, 3H, Ph H-2,4,6), 6.21 (d, 3J (H5,H6) = 7.6Hz, 1H, H-5), 5.48
(s, 2H, H-2’), 5.01 (s, 2H, O−CH2−Ph), 2.83 (s, 4H, H-4’,5’), 2.15 (s, 3H, 2-CH3).
13C-NMR (DMSO−d6, 100MHz): δ 172.47 (C-4), 169.87 (C-3’,6’), 165.20 (C-1’), 145.30
(q), 140.86 (q), 140.37 (q), 137.58 (q, Ar), 128.41 (Ph C-2,6), 128.25 (Ph C-3,5), 127.88
(Ph C-4), 116.36 (C-5), 71.98 (O−CH2−Ph), 51.56 (C-2’), 25.51 (C-4’,5’), 11.72 (2-CH3).
1-(1,3,4,6-Tetra-O-acetyl-2-deoxy-β-d-glucopyranos-2-yl)-2-(3-(benzyloxy)-2-
methyl-4-oxo-pyridin-1(4H )-yl)acetamide (59a)
1H-NMR (CD3OD, 400MHz): δ 7.55 (d,
3J (H6,H5) = 7.5Hz, 1H, H-6), 7.42–7.38 (m,
2H, Ph H-3,5), 7.37–7.29 (m, 3H, Ph H-2,4,6), 6.46 (d, 3J (H5,H6) = 7.4Hz, 1H, H-5),
5.84 (d, 3J (H1”,H2”) = 8.8Hz, 1H, H-1”), 5.32 (dd, 3J (H3”,H2”) = 10.4Hz, 3J (H3”,H4”)
= 9.3Hz, 1H, H-3”), 5.06 (s, 2H, O−CH2−Ph), 5.05 (dd, 3J (H4”,H5”) = 10.1Hz, 3J (H4”,
H3”) = 9.3Hz, 1H, H-4”), 4.63 (s, 2H, H-2’), 4.27 (dd, 2J (H6a”,H6b”) = 12.5Hz, 3J (H6a”,
H5”) = 4.5Hz, 1H, H-6a”), 4.09 (dd, 2J (H6b”,H6a”) = 12.5Hz, 3J (H6a”,H5”) = 2.1Hz,
1H, H-6b”), 4.05 (dd, 3J (H2”,H3”) = 10.4Hz, 3J (H2”,H1”) = 8.8Hz, 1H, H-2”), 3.92 (ddd,
3J (H5”,H4”) = 10.1Hz, 3J (H5”,H6a”) = 4.5Hz, 3J (H5”,H6b”) = 2.2Hz, 1H, H-5”), 2.05 (s,
6H, CH3, 2-CH3), 2.04 (s, 3H, CH3), 2.01 (s, 3H, CH3), 1.96 (s, 3H, CH3).
13C-NMR (CD3OD, 100MHz): δ 175.14 (C-4), 172.13 (C=O), 171.69 (C=O), 171.05
(C=O), 170.45 (C=O), 168.53 (C-1’), 146.88 (C-3), 145.00 (C-2), 142.32 (C-6), 138.35 (Ph
C-1), 129.94 (Ph C-2,6), 129.40 (Ph C-3,5), 129.23 (Ph C-4), 117.11 (C-5), 92.93 (C-1”),
74.56 (O−CH2−Ph), 73.54 (C-3”), 73.48 (C-5”), 69.41 (C-4”), 62.76 (C-6”), 56.66 (C-2’),
54.46 (C-2”), 20.78 (CH3), 20.73 (CH3), 20.66 (CH3), 20.62 (CH3), 12.88 (2-CH3).
NSI-MS m/z (%): 1227 (6, [2M+Na+]), 625 (27, [M+Na+]), 603 (100, [M+H+]).
HRMS-NSI m/z : Calc. for C29H35N2O12 [M+H
+]: 603.2185; found: 603.2179.






















Pyridinone 39b (570mg, 2mmol), 1-hydroxybenzotriazole hydrate (100mg, 0.6mmol) and
1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride (EDC, 422mg, 2.2mmol)
were dissolved in DMF (15ml) and water (5ml) and stirred for 5min. Selectively protected
glucosamine 58 (763mg, 2mmol) and N,N’ -diisopropylethylamine (380 µl, 4mmol) were
added, and the reaction mixture heated to 80 ◦C for 40 hours. The reaction mixture was
concentrated, then diluted with water and extracted with chloroform (3×). The combined
organic phases were washed with sodium acetate buﬀer (pH 4) and 1M NaOH, then
dried over Na2SO4. Evaporation gave 1-(1,3,4,6-tetra-O-acetyl-2-deoxy-β-d-glucopyranos-
2-yl)-3-(3-(benzyloxy)-2-methyl-4-oxopyridin-1(4H )-yl)propanamide (59b) as a tan foam
(274mg, 0.44mmol, 22%).
Melting point: m.p. 74−87 ◦C.
IR (neat) cm-1: 2925 (br, w), 1744, 1679 (w), 1625, 1554, 1366, 1213, 1033.
1H-NMR (CDCl3, 400MHz): δ 8.16 (d,
3J (NH,H2”) = 8.9Hz, 1H, NH), 7.39–7.31 (m,
5H, Ph H-2–6), 7.26 (d, 3J (H6,H5) = 7.4Hz, 1H, H-6), 6.23 (d, 3J (H5,H6) = 7.4Hz, 1H,
H-5), 5.89 (d, 3J (H1”,H2”) = 8.8Hz, 1H, H-1”), 5.33 (‘t’, 3J (H3”,H2”) = 10.2Hz, 3J (H3”,
H4”) = 9.2Hz, 1H, H-3”), 5.10 (s, 2H, O−CH2−Ph), 5.08 (‘t’, 3J (H4”,H5”) = 10.2Hz,
3J (H4”,H3”) = 9.2Hz, 1H, H-4”), 4.25 (dd, 2J (H6a”,H6b”) = 12.5Hz, 3J (H6a”,H5”) =
4.4Hz, 1H, H-6a”), 4.11 (ddd, 3J (H2”,H3”) = 10.1Hz, 3J (H2”,NH) = 9.0Hz, 3J (H2”,H1”)
= 8.8Hz, 1H, H-2”), 4.06 (‘t’, 3J (H3’,H2’) = 7.0Hz, 2H, H-3’), 4.03 (dd, 2J (H6b”,H6a”)
= 12.5Hz, 3J (H6b”,H5”) = 2.2Hz, 1H, H-6b”), 3.74 (ddd, 3J (H5”,H4”) = 10.3Hz, 3J (H5”,
H6a”) = 4.3Hz, 3J (H5”,H6b”) = 2.2Hz, 1H, H-5”), 2.50–2.44 (m, 2H, H-2’), 2.12 (s, 3H,
2-CH3), 2.07 (s, 3H, CH3), 2.02 (s, 3H, CH3), 2.01 (s, 3H, CH3), 1.96 (s, 3H, CH3).
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13C-NMR (CDCl3, 100MHz): δ 173.02 (C-4), 170.67 (C=O), 169.58 (C=O), 169.40
(C=O), 169.09 (C=O), 168.03 (C-1’), 145.92 (C-3), 141.69 (C-2), 138.80 (C-6), 137.06 (Ph
C-1), 129.02 (Ph C-3,5), 128.43 (Ph C-2,6), 128.27 (Ph C-4), 116.80 (C-5), 92.07 (C-1”),
73.11 (O−CH2−Ph), 72.69 (C-3”), 72.26 (C-5”), 68.07 (C-4”), 61.53 (C-6”), 53.32 (C-2”),















Concentrated H2SO4 (2ml) was added to a solution of glucuronolactone 64 (10 g, 57mmol)
in acetone (250ml) and the reaction mixture stirred for 24 hours at room temperature.
The yellow solution was neutralised with 6M NaOH and the formed precipitate removed
by ﬁltration. Evaporation of the ﬁltrate gave 1,2-O-isopropylidene-d-glucofuranurono-6,3-
lactone (65) as oﬀ-white solid (11.5 g, 53mmol, 93%).
All analytical data is in good agreement with published data.214,280
Melting point: m.p. 114−116 ◦C (lit. m.p. 118−119 ◦C).280
IR (neat) cm-1: 3436, 2974 (w), 1172, 1377, 1230, 1158, 1126, 1090, 1019, 948, 900.
1H-NMR (DMSO−d6, 400MHz): δ 6.13 (d,
3J (OH,H5) = 7.5Hz, 1H, OH), 5.96 (d,
3J (H1,H2) = 3.8Hz, 1H, H-1), 4.82 (d, 3J (H3,H4) = 2.8Hz, 1H, H-3), 4.80 (d, 3J (H2,H1)
= 3.8Hz, 1H, H-2), 4.77 (dd, 3J (H4,H5) = 4.3Hz, 3J (H4,H3) = 2.9Hz, 1H, H-4), 4.62
(dd, 3J (H5,OH) = 7.5Hz, 3J (H5,H4) = 4.3Hz, 1H, H-5), 1.43 (s, 3H, CH3), 1.27 (s, 3H,
CH3).
13C-NMR (DMSO−d6, 100MHz): δ 174.74 (C-6), 111.97 (C (CH3)2), 106.21 (C-1),
82.06 (C-2), 80.99 (C-3), 79.00 (C-4), 69.56 (C-5), 26.62 (CH3), 26.39 (CH3).















Glucuronolactone 64 (1.0 g, 5.7mmol) and zinc chloride (970mg, 7.15mmol, 1.25 eq.)
were added to benzaldehyde (5ml, 49mmol) and stirred at room temperature for 48
hours. The reaction mixture was diluted with Et2O (30ml) and washed twice with water
(30ml). The organic phase was dried over Na2SO4 and evaporated, the residue taken up
in methanol (30ml) and washed twice with hexane. The methanolic phase was evaporated
and the residue taken up hexane/ethyl acetate (4/1, 5ml) and stirred vigorously. The
pale yellow precipitate was collected by vacuum ﬁltration to give 1,2-O-benzylidene-α-
d-glucofuranurono-6,3-lactone (66) as mixture of stereoisomers (894mg, 3.4mmol, 59%,
Ratio S/R:216 4/1).
All analytical data is in agreement with published data for the S isomer.214
Melting point: m.p. 135−138 ◦C (lit. m.p. 168−169 ◦C (S isomer)).281
IR (neat) cm-1: 3475 (br), 3321 (br), 1780, 1463 (w), 1395 (w), 1308 (w), 1218 (w), 1170,
1137, 1112, 1098, 1022, 956.
1H-NMR (CDCl3, 400MHz): δ 7.50–7.37 (m, 25H, S/R, Ph H-2–6), 6.16 (d,
3J (H1,H2)
= 3.5Hz, 4H, S, H-1), 6.15 (d, 3J (H1,H2) = 3.7Hz, 1H, R, H-1), 6.07 (s, 1H, R, CH -Ph),
6.05 (s, 4H, S, CH -Ph), 5.04–4.96 (m, 12H, S, H-2,3,4), 4.93 (d, 3J (H2,H1) = 3.8Hz, 1H,
R, H-2), 4.85 (d, 3J (H3,H4) = 2.6Hz, 1H, R, H-3), 4.70 (dd, 3J (H4,H5) = 4.1Hz, 3J (H4,
H3) = 2.6Hz, 1H, R, H-4), 4.57 (d, 3J (H5,H4) = 3.7Hz, 4H, S, H-5), 4.46 (d, 3J (H5,H4)
= 4.3Hz, 1H, R, H-5).
13C-NMR (CDCl3, 100MHz): δ 173.48 (S/R, C-6), 135.74 (R, Ph C-1), 135.40 (S, Ph
C-1), 130.32 (S, Ph C-4), 130.05 (R, Ph C-4), 128.76 (R, Ph C-3,5), 128.73 (S, Ph C-3,5),
126.63 (S, Ph C-2,6), 126.25 (R, Ph C-2,6), 106.78 (R, C-1), 106.34 (S, C-1), 106.03 (R,
CH -Ph), 106.00 (S, CH -Ph), 83.73 (R, C-2), 83.36 (S, C-2), 81.29 (R, C-3), 81.17 (S,
C-3), 80.04 (S, C-4), 78.64 (R, C-4), 71.06 (S, C-5), 70.60 (R, C-5).








































cpd 33 cpd 109
product mg Yield dimer mg Yield
g mmol mg mmol
2 2.0 9.2 1330 10 67a 780 38% 68a — —
4 1.0 4.6 441 5 67b 814 62% 68b 289 26%
6 1.0 4.6 581 5 67c 870 64% 68c 420 36%
8 1.0 4.6 721 5 67d 1553 99% 68d — —
Benzyl maltol 33 and diamine 109 (1.1 eq., n=2 as dihydrochloride) were dissolved in
ethanol (2ml/mmol) and water (2ml/mmol, n=2: 1ml), then 1M NaOH (0.2ml/mmol,
n=2: 2ml/mmol) was added and the reaction mixture heated to reﬂux over night. The
solution was acidiﬁed to pH 1 with HCl and concentrated in vacuo. Any formed precipitate
(for n = 3 and 5) was collected by ﬁltration to yield the dimers 68b and 68c, respectively,
as pale tan powder. The ﬁltrate was extracted with Et2O, the organic phase discarded and
the aqueous phase adjusted to pH 12 with 10M NaOH before extraction with DCM (3×).
The combined organic phases were washed with water, dried over Na2SO4 and evaporated.
The desired N-aminoalkyl pyridinone 67 was obtained as orange syrup.
1-(2-Aminoethyl)-3-(benzyloxy)-2-methylpyridin-4(1H )-one (67a)
NMR data is in good agreement with published data.282
1H-NMR (CDCl3, 400MHz): δ 7.41–7.28 (m, 5H, Ph H-2–6), 7.29 (d,
3J (H6,H5) =
7.7Hz, 1H, H-6), 6.40 (d, 3J (H5,H6) = 7.5Hz, 1H, H-5), 5.20 (s, 2H, O−CH2−Ph), 3.83
(t, 3J (H1’,H2’) = 6.2Hz, 2H, H-1’), 2.95 (t, 3J (H2’,H1’) = 6.2Hz, 2H, H-2’), 2.10 (s, 3H,
2-CH3).
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13C-NMR (CDCl3, 100MHz): δ 173.36 (C-4), 146.00 (C-3), 140.78 (C-2), 138.77 (C-6),
137.48 (Ph C-1), 129.13 (Ph C-3,5), 128.21 (Ph C-2,6), 127.98 (Ph C-4), 117.04 (C-5),
72.93 (O−CH2−Ph), 55.90 (C-1’), 41.85 (C-2’), 12.57 (2-CH3).
NSI-MS m/z (%): 539 (56, [2M+Na+]) 517 (17, [2M+H+]) 457 (19, [Dimer+H+]), 281
(37, [M+Na+]), 259 (100, [M+H+]).
HRMS-NSI m/z : Calc. for C15H19N2O2 [M+H
+]: 259.1441; found: 259.1444.
1-(4-Aminobutyl)-3-(benzyloxy)-2-methylpyridin-4(1H )-one (67b)
NMR data is in general agreement with published data.283
1H-NMR (CDCl3, 400MHz): δ 7.42–7.28 (m, 5H, Ph H-2–6), 7.21 (d,
3J (H6,H5) =
7.5Hz, 1H, H-6), 6.41 (d, 3J (H5,H6) = 7.5Hz, 1H, H-5), 5.21 (s, 2H, O−CH2−Ph), 3.76
(t, 3J (H1’,H2’) = 7.5Hz, 2H, H-1’), 2.95 (t, 3J (H4’,H3’) = 6.9Hz, 2H, H-4’), 2.10 (s, 3H,
2-CH3) 1.68 (tt,
3J (H2’,H3’) = 7.9Hz, 3J (H2’,H1’) = 7.5Hz, 2H, H-2’), 1.44 (tt, 3J (H3’,
H2’) = 7.9Hz, 3J (H3’,H4’) = 6.9Hz, 2H, H-3’).
13C-NMR (CDCl3, 100MHz): δ 173.26 (C-4), 146.03 (C-3), 140.61 (C-2), 138.77 (C-6),
137.54 (Ph C-1), 129.11 (Ph C-3,5), 128.20 (Ph C-2,6), 127.93 (Ph C-4), 117.25 (C-5),
72.90 (O−CH2−Ph), 53.59 (C-1’), 41.29 (C-4’), 29.62 (C-3’), 28.14 (C-2’), 12.38 (2-CH3).
NSI-MS m/z (%): 595 (18, [2M+Na+]) 573 (27, [2M+H+]) 485 (32, [Dimer+H+]), 329
(13), 309 (22, [M+Na+]), 287 (100, [M+H+]).
HRMS-NSI m/z : Calc. for C17H23N2O2 [M+H
+]: 287.1754; found: 287.1759.
1-(6-Aminohexyl)-3-(benzyloxy)-2-methylpyridin-4(1H )-one (67c)
IR (neat) cm-1: 3279 (br), 2931, 2858 (w), 1623, 1556, 1498, 1247, 1217, 1037.
1H-NMR (CDCl3, 400MHz): δ 7.43–7.28 (m, 5H, Ph H-2–6), 7.18 (d,
3J (H6,H5) =
7.5Hz, 1H, H-6), 6.42 (d, 3J (H5,H6) = 7.5Hz, 1H, H-5), 5.22 (s, 2H, O−CH2−Ph), 3.73
(t, 3J (H1’,H2’) = 7.5Hz, 2H, H-1’), 2.70 (t, 3J (H4’,H3’) = 6.9Hz, 2H, H-6’), 2.07 (s, 3H,
2-CH3) 1.63 (tt,
3J (H2’,H1’) = 7.5Hz, 3J (H2’,H3’) = 7.4Hz,2H, H-2’), 1.45 (tt, 3J (H5’,
H4’) = 7.4Hz, 3J (H5’,H6’) = 6.9Hz, 2H, H-5’). 1.39–1.24 (m, 4H, H-3’,4’).
13C-NMR (CDCl3, 100MHz): δ 173.32 (C-4), 146.08 (C-3), 140.59 (C-2), 138.13 (C-6),
137.62 (Ph C-1), 129.17 (Ph C-3,5), 128.23 (Ph C-2,6), 127.96 (Ph C-4), 117.30 (C-5),
72.94 (O−CH2−Ph), 53.74 (C-1’), 41.83 (C-6’), 33.11 (C-5’) 30.71 (C-2’), 26.42 (C-3’ or
4’), 26.19 (C-3’ or 4’), 12.41 (2-CH3).
NSI-MS m/z (%): 513 (12, [Dimer+H+]), 315 (100, [M+H+]).
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HRMS-NSI m/z : Calc. for C19H27N2O2 [M+H
+]: 315.2067; found: 315.2073.
1-(8-Aminooctyl)-3-(benzyloxy)-2-methylpyridin-4(1H )-one (67d)
IR (neat) cm-1: 3302 (br), 2931, 2857 (w), 1623, 1548, 1506, 1248, 1218, 1030.
1H-NMR (CDCl3, 400MHz): δ 7.42–7.29 (m, 5H, Ph H-2–6), 7.17 (d,
3J (H6,H5) =
7.5Hz, 1H, H-6), 6.41 (d, 3J (H5,H6) = 7.5Hz, 1H, H-5), 5.23 (s, 2H, O−CH2−Ph), 3.72
(t, 3J (H1’,H2’) = 7.5Hz, 2H, H-1’), 2.68 (t, 3J (H8’,H7’) = 7.0Hz, 2H, H-8’), 2.07 (s, 3H,
2-CH3) 1.61 (tt,
3J (H2’,H1’) = 7.5Hz, 3J (H2’,H3’) = 6.9Hz,2H, H-2’), 1.43 (tt, 3J (H7’,
H6’) = 7.2Hz, 3J (H7’,H8’) = 6.9Hz, 2H, H-7’). 1.35–1.21 (m, 8H, H-3’–6’).
13C-NMR (CDCl3, 100MHz): δ 173.34 (C-4), 146.16 (C-3), 140.54 (C-2), 138.06 (C-6),
137.64 (Ph C-1), 129.18 (Ph C-3,5), 128.22 (Ph C-2,6), 127.94 (Ph C-4), 117.32 (C-5),
72.94 (O−CH2−Ph), 53.80 (C-1’), 42.15 (C-8’), 33.63 (C-7’) 30.75 (C-2’), 29.27 (C-3’ or
4’), 29.12 (C-3’ or 4’), 26.75 (C-5’ or 6’), 26.29 (C-5’ or 6’), 12.40 (2-CH3).
NSI-MS m/z (%): 541 (76, [Dimer+H+]), 343 (100, [M+H+]).
HRMS-NSI m/z : Calc. for C21H31N2O2 [M+H
+]: 343.2380; found: 343.2383.
1,1’-(Butane-1,4-diyl)bis[3-(benzyloxy)-2-methylpyridin-4(1H )-one] (68b)
NMR data is in agreement with published data.284
1H-NMR (CD3OD, 400MHz): δ 8.36 (d,
3J (H6,H5) = 7.2Hz, 1H, H-6), 7.45–7.36 (m,
5H, Ph H-2–6), 7.21 (d, 3J (H5,H6) = 7.1Hz, 1H, H-5), 5.20 (s, 2H, O−CH2−Ph), 4.37
(‘t’, 3J (H1’,H2’) = 6.5Hz, 2H, H-1’), 2.52 (s, 3H, 2-CH3), 1.90–1.85 (m, 2H, H-2’).
13C-NMR (CD3OD, 100MHz): δ 165.74 (C-4), 151.35 (C-2), 144.97 (C-3), 143.09 (C-6),
137.27 (Ph C-1), 130.16 (Ph C-3,5), 129.95 (Ph C-4), 129.72 (Ph C-2,6), 114.14 (C-5),
76.27 (O−CH2−Ph), 57.01 (C-1’), 27.81 (C-2’), 13.69 (2-CH3).
NSI-MS m/z (%): 991 (26, [2M+Na+]), 969 (14, [2M+H+]), 507 (100, [M+Na+]), 485
(70, [M+H+]).
HRMS-NSI m/z : Calc. for C30H33N2O4 [M+H
+]: 485.2435; found: 485.2426.
1,1’-(Hexane-1,6-diyl)bis[3-(benzyloxy)-2-methylpyridin-4(1H )-one] (68c)
1H-NMR (CD3OD, 400MHz): δ 8.33 (d,
3J (H6,H5) = 7.2Hz, 1H, H-6), 7.45–7.35 (m,
5H, Ph H-2–6), 7.18 (d, 3J (H5,H6) = 7.1Hz, 1H, H-5), 5.19 (s, 2H, O−CH2−Ph), 4.37 (‘t’,
3J (H1’,H2’) = 7.7Hz, 2H, H-1’), 2.47 (s, 3H, 2-CH3), 1.84–1.75 (m, 2H, H-2’), 1.45–1.38
(m, 2H, H-3’).
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13C-NMR (CD3OD, 100MHz): δ 165.84 (C-4), 150.75 (C-2), 144.65 (C-3), 143.06 (C-6),
137.27 (Ph C-1), 130.26 (Ph C-3,5), 129.95 (Ph C-4), 129.72 (Ph C-2,6), 114.11 (C-5),
76.21 (O−CH2−Ph), 57.68 (C-1’), 30.99 (C-’), 26.70(C-’), 13.64 (2-CH3).
NSI-MS m/z (%): 535 (100, [M+Na+]), 513 (37, [M+H+]).
HRMS-NSI m/z : Calc. for C32H37N2O4 [M+H






























The lactone 65 (973mg, 4.5mmol) and pyridinone 67b (859mg, 3mmol) were dissolved
in dry DMF (30ml) and stirred at room temperature for 3 days. The reaction mixture
was evaporated and the residue taken up in DCM. The solution was washed twice with
water, then dried over Na2SO4 and evaporated. The resulting dark brown syrup was then
puriﬁed by column chromatography (DCM/methanol: 6/1) to give the desired product N -
{4-[3-(benzyloxy)-2-methyl-4-oxopyridin-1(4H )-yl ]butyl}-1,2-O-isopropylidene-α-d-gluco-
furanuronamide (71b) as a pale yellow glass (982mg, 1.95mmol, 65%).
An analogous procedure reacting pyridinone 67c (943mg, 3mmol) with lactone 65 gave N -
{6-[3-(benzyloxy)-2-methyl-4-oxopyridin-1(4H )-yl ]hexyl}-1,2-O-isopropylidene-α-d-gluco-
furanuronamide (71c) as a light brown glass (971mg, 1.83mmol, 61%).
N -{4-[3-(Benzyloxy)-2-methyl-4-oxopyridin-1(4H )-yl ]butyl}-1,2-O-isopropylidene-
α-d-glucofuranuronamide (71b)
IR (neat) cm-1: 3317 (br), 2934, 1797 (w), 1623, 1542, 1509, 1455, 1374, 1249, 1216, 1163,
1069, 1010.
1H-NMR (CD3OD, 400MHz): δ 7.66 (d,
3J (H6,H5) = 7.4Hz, 1H, H-6), 7.45–7.35 (m,
5H, Ph H-2–6), 6.46 (d, 3J (H5,H6) = 7.4Hz, 1H, H-5), 5.83 (d, 3J (H1”,H2”) = 3.6Hz,
1H, H-1”), 5.04 (s, 2H, O−CH2−Ph), 4.46 (d, 3J (H2”,H1”) = 3.6Hz, 1H, H-2”), 4.33 (d,
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3J (H5”,H4”) = 6.4Hz, 1H, H-5”), 4.22 (dd, 3J (H4”,H5”) = 6.4Hz, 3J (H4”,H3”) = 2.7Hz,
1H, H-4”), 4.19 (d, 3J (H3”,H4”) = 2.7Hz, 1H, H-3”), 3.93 (t, 3J (H1’,H2’) = 7.7Hz, 2H,
H-1’), 3.26 (t, 3J (H4’,H3’) = 6.4Hz, 2H, H-4’), 2.16 (s, 3H, 2-CH3), 1.66 (‘quint’,
3J (H2’,
H1’) = 7.7Hz, 3J (H2’,H3’) = 7.5Hz, 2H, H-2’), 1.51 (tt, 3J (H3’,H2’) = 7.5Hz, 3J (H3’,
H4’) = 6.4Hz, 2H, H-3’), 1.38 (s, 3H, CH3), 1.25 (s, 3H, CH3).
13C-NMR (CD3OD, 100MHz): δ 174.77 (C-6”), 174.51 (C-4), 146.87 (C-3), 145.00 (C-
2), 141.16 (C-6), 138.35 (Ph C-1), 130.17 (Ph C-3,5), 129.37 (Ph C-2,6), 129.29 (Ph C-4),
117.32 (C-5), 112.75 (C (CH3)2), 106.31 (C-1”), 86.42 (C-2”), 82.48 (C-4”), 75.65 (C-3”),
74.37 (O−CH2−Ph), 70.73 (C-5”), 54.76 (C-1’), 39.01 (C-4’), 28.50 (C-2’), 27.13 (CH3),
27.05 (C-3’), 26.44 (CH3), 12.83 (2-CH3).
NSI-MS m/z (%): 1003 (19, [2M-H+]), 547 (23), 501 (100, [M-H+]).
HRMS-NSI m/z : Calc. for C26H33N2O8 [M-H
+]: 501.2242; found: 501.2238.
N -{6-[3-(Benzyloxy)-2-methyl-4-oxopyridin-1(4H )-yl ]hexyl}-1,2-O-isopropyl-
idene-α-d-glucofuranuronamide (71c)
Melting point: m.p. 67−72 ◦C.
IR (neat) cm-1: 3251 (br), 2933, 2860 (w), 1622, 1546, 1510, 1455, 1373, 1248, 1217, 1163,
1069, 1010.
1H-NMR (CDCl3, 400MHz): δ 7.39–7.27 (m, 5H, Ph H-2–6), 7.22 (d,
3J (H6,H5) =
7.5Hz, 1H, H-6), 7.06 (d, 3J (NH,H6’) = 5.8Hz, 1H, NH), 6.41 (d, 3J (H5,H6) = 7.4Hz,
1H, H-5), 5.93 (d, 3J (H1”,H2”) = 3.6Hz, 1H, H-1”), 5.14 (s, 2H, O−CH2−Ph), 4.52 (d,
3J (H2”,H1”) = 3.6Hz, 1H, H-2”), 4.48 (d, 3J (H5”,H4”) = 4.6Hz, 1H, H-5”), 4.39 (dd,
3J (H4”,H5”) = 4.7Hz, 3J (H4”,H3”) = 3.0Hz, 1H, H-4”), 4.33 (d, 3J (H3”,H4”) = 3.0Hz,
1H, H-3”), 3.74 (t, 3J (H1’,H2’) = 7.4Hz, 2H, H-1’), 3.36–3.19 (m, 3J (H6’,NH) = 5.8Hz,
2H, H-6’), 2.08 (s, 3H, 2-CH3), 1.60 (‘quint’,
3J (H2’,H1’) = 7.4Hz, 3J (H2’,H3’) = 6.8Hz,
2H, H-2’), 1.52–1.45 (m, 2H, H-5’), 1.44 (s, 3H, CH3), 1.34–1.22 (m, 7H, CH3, H-3’,4’).
13C-NMR (CDCl3, 100MHz): δ 173.18 (C-4), 172.28 (C-6”), 145.98 (C-3), 141.52 (C-2),
138.53 (C-6), 137.22 (Ph C-1), 129.05 (Ph C-3,5), 128.28 (Ph C-2,6), 128.11 (Ph C-4),
116.92 (C-5), 111.79 (C (CH3)2), 105.16 (C-1”), 85.41 (C-2”), 81.47 (C-4”), 75.36 (C-3”),
73.07 (O−CH2−Ph), 70.18 (C-5”), 54.00 (C-1’), 38.82 (C-6’), 30.28 (C-2’), 29.05 (C-5’),
26.92 (CH3), 26.30 (CH3), 26.04 (C-3’ or 4’), 25.78 (C-3’ or 4’), 12.42 (2-CH3).
NSI-MS m/z (%): 1083 (8, [2M+Na+]), 1062 (6, [2M+H+]), 553 (13, [M+Na+]), 531
(100, [M+H+]).
HRMS-NSI m/z : Calc. for C28H39N2O8 [M+H
+]: 531.2701; found: 531.2688.






























The lactone 66 (119mg, 0.45mmol) and pyridinone 67b (86mg, 0.3mmol) were dissolved
in dry DMF (5ml) and stirred at room temperature for 3 days. The reaction mixture
was evaporated and the residue taken up in DCM. The solution was washed twice with
water, then dried over Na2SO4 and evaporated. The resulting dark brown oil was puri-
ﬁed by column chromatography (DCM/methanol: 6/1) to give 1,2-O-benzylidene-N -{4-
[3-(benzyloxy)-2-methyl-4-oxopyridin-1(4H )-yl]butyl}-α-d-glucofuranuronamide (72b) as
pale yellow glass (128mg, 233 µmol, 78%).
An analogous procedure using pyridinone 67c (943mg, 3mmol) gave 1,2-O-benzylidene-N -
{6-[3-(benzyloxy)-2-methyl-4-oxopyridin-1(4H )-yl]hexyl}-α-d-glucofuranuronamide (72c) as
pale tan solid (121mg, 209 µmol, 70%).
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2,3,4,6-Tetra-O-acetyl-α-d-glucopyranosyl bromide (30) (1.4 g, 3.3mmol) was dissolved
in DCM (20ml), then sodium azide (1.3 g, 20mmol, 6 eq.), tetrabutylammonium iodide
(370mg, 1.0mmol, 0.3 eq.) and saturated NaHCO3 solution (20ml) were added to the
solution. The resulting bi-phasic mixture was stirred vigorously at room temperature
over night, before extraction with DCM (2×). The combined organic phases were washed
with NaHCO3, water and brine before drying over Na2SO4. Evaporation gave a yellow
crystalline solid (1.2 g) which was puriﬁed by column chromatography (hexane/ethyl acet-
ate: 3/1 → 1/1) to yield 2,3,4,6-tetra-O-acetyl-α-d-glucopyranosyl azide (73) as white
crystalline powder (870mg, 2.3mmol, 69%).
Analytical data is in agreement with published data.238
Melting point: m.p. 120−121.5 ◦C (lit. m.p. 129−130 ◦C).238
IR (neat) cm-1: 2117, 1750, 1731, 1368, 1233, 1210, 1057, 1037, 908.
1H-NMR (CD3OD, 400MHz): δ 5.29 (‘t’,
3J (H3,H4) = 9.5Hz, 3J (H3,H2) = 9.1Hz, 1H,
H-3), 5.06 (‘t’, 3J (H4,H5) = 10.1Hz, 3J (H4,H3) = 9.5Hz, 1H, H-4), 1H, H-4), 4.91–4.84
(m, 3H, H-1,2), 4.30 (dd, 2J (H6a,H6b) = 12.5Hz, 3J (H6a,H5) = 4.7Hz, 1H, H-6a), 4.17
(dd, 2J (H6b,H6a) = 12.5Hz, 3J (H6b,H5) = 2.3Hz, 1H, H-6b), 3.99 (ddd, 3J (H5,H4) =
10.1Hz, 3J (H6a,H5) = 4.7Hz, 3J (H6b,H5) = 2.3Hz, 1H, H-5), 2.07 (s, 3H, CH3), 2.05 (s,
3H, CH3), 2.01 (s, 3H, CH3), 1.97 (s, 3H, CH3).
13C-NMR (CD3OD, 100MHz): δ 168.34 (C=O), 168.08 (C=O), 167.67 (C=O), 167.53
(C=O), 88.89 (C-1), 75.08 (C-5), 74.14 (C-3), 72.20 (C-2), 69.46 (C-4), 62.99 (C-6), 20.66
(CH3), 20.60 (CH3), 20.57 (CH3), 20.53 (CH3).
NSI-MS m/z (%): 769 (12, [2M+Na+]), 391 (100, [M+NH4
+]).
HRMS-NSI m/z : Calc. for C14H23N4O9 [M+H
+]: 391.1460; found: 391.1462.
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Sodium azide (1.3 g, 20mmol) was taken up in dry acetonitrile (20ml) under nitrogen
atmosphere and cooled to 0 ◦C on an ice-bath. Sulfuryl chloride (1.6ml, 20mmol) was
added dropwise to the solution, which was then stirred at room temperature (16 ◦C) for 16
hours. The solution was cooled to 0 ◦C, before the addition of imidazole (2.62 g, 38.2mmol)
in 5 portions. Then reaction mixture was allowed to warm and stirred at room temperature
for 4 hours, before dilution with ethyl acetate (40ml). The solution was washed twice
each with water, saturated NaHCO3 solution and brine, then dried over Na2SO4. The
solution was concentrated to 10ml and cooled to 0 ◦C. Concentrated sulfuric acid (1.07ml,
20mmol) in ethyl acetate (20ml) was added slowly, the reaction mixture stirred at room
temperature for 2 hours. The formed precipitate was collected by vacuum ﬁltration and
dried over P2O5 in vacuo to give 3-(azidosulfonyl)-3H -imidazol-1-ium hydrogen sulfate
(78) as a white powder (3.32 g, 12.2mmol, 61%).
Caution! Imidazole-1-sulfonyl azide and its salts are energetic materials with sensitivities
toward shock and friction. Speciﬁcally, neat imidazole-1-sulfonyl azide is very sensitive and
has to be handled with great care.230,239,285
All analytical data is in agreement with published data.239
1H-NMR (DMSO−d6, 400MHz): δ 14.27 (br s, 1H), 9.09 (‘s’, 1H), 8.57 (‘s’, 1H), 7.97
(t, ,J = 1.5Hz 1H), 7.70 (d, ,J = 0.8Hz 1H), 7.32 (d, ,J = 0.8Hz 1H), 6.16 (br s, 11H).
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Glucosamine hydrochloride (1.14 g, 5.3mmol), imidazole-1-sulfonyl azide 78 (1.725 g, 6.36
mmol, 1.2 eq.) and K2CO3 (2.93 g, 21.2mmol, 4 eq.) were suspended in methanol (25ml).
CuSO4 · 5H2O (15mg, 60 µmol, 11%mol) was added to the solution and the resulting
mixture was stirred for 4 days. The solvent was evaporated and residual methanol removed
by co-evaporation with toluene (4× 10ml). The residue was taken up in pyridine (25ml)
and acetic anhydride (10ml) and stirred for 2 days. The reaction mixture was evaporated
and dissolved in water. The solution was extracted with ethyl acetate (3×) and the
combined organic phases were washed with brine, then dried over Na2SO4 and evaporated
to give a brown residue (1.13 g). The crude azide was puriﬁed by column chromatography
(hexane/ethyl acetate: 10/1→3/1) to give 2-azido-2-deoxy-d-glucopyranose 1,3,4,6-tetra-
O-acetate (74) as a colourless wax (458mg, 1.23mmol, 23%, α:β 1:2.1).
All analytical data and the assignment of α/β isomers is in good agreement with published
data.286,287
Melting point: m.p. 70−72 ◦C (lit. m.p. 80 ◦C (β anomer)).287
IR (neat) cm-1: 2112 (s), 1743, 1367, 1205, 1032.
1H-NMR (CDCl3, 400MHz): δ 6.30 (d,
3J (H1,H2) = 3.7Hz, 1H, α, H-1), 5.56 (d, 3J (H1,
H2) = 8.6Hz, 2H, β, H-1), 5.46 (dd, 3J (H3,H2) = 10.6Hz, 3J (H3,H4) = 9.4Hz, 1H, α,
H-3), 5.12 (dd, 3J (H4,H3) = 10.6Hz, 3J (H4,H5) = 9.5Hz, 1H, α, H-4, overlapping with β
H-3), 5.09 (dd, 3J (H3,H2) = 9.9Hz, 3J (H3,H4) = 9.3Hz, 2H, β, H-3, overlapping with α
H-4), 5.05 (dd, 3J (H4,H5) = 9.7Hz, 3J (H4,H3) = 9.3Hz, 2H, β, H-4), 4.31 (dd, 2J (H6a,
H6b) = 12.7Hz, 3J (H6a,H5) = 4.4Hz, 2H, β, H-6a, overlapping with α), 4.29 (dd, 2J (H6a,
H6b) = 12.7Hz, 3J (H6a,H5) = 4.2Hz, 1H, α, H-6a, overlapping with β), 4.11–4.04 (m,
4H, α H-5,6b, β H-6b), 3.81 (ddd, 3J (H5,H4) = 9.7Hz, 3J (H5,H6a) = 4.3Hz, 3J (H6b,,)
= 2.1Hz 2H, β, H-5), 3.68 (dd, 3J (H2,H3) = 10.1Hz, 3J (H2,H3) = 8.6Hz, 2H, β, H-2,
overlapping with α), 3.67 (dd, 3J (H2,H3) = 10.6Hz, 3J (H2,H3) = 3.7Hz, 1H, α, H-2,
overlapping with β), 2.20 (s, 9H, β/α, CH3), 2.11 (s, 3H, α, CH3), 2.10 (s, 6H, β, CH3),
2.08 (s, 9H, β/α, CH3), 2.05 (s, 3H, α, CH3), 2.03 (s, 6H, β, CH3).
13C-NMR (CDCl3, 100MHz): δ 170.71 (β/α, C=O), 170.22 (α, C=O), 169.95 (β, C=O),
169.77 (β/α, C=O), 168.72 (β, C=O), 168.67 (α, C=O), 92.70 (β, C-1), 90.08 (α, C-1),
72.86 (β, C-5), 72.81 (β, C-3), 70.87 (α, C-3), 69.88 (α, C-5), 67.96 (α, C-4), 67.86 (β,
C-4), 62.67 (β, C-2), 61.52 (α, C-6), 61.50 (β, C-6), 60.40 (α, C-2), 21.09 (α, CH3), 21.04
(β, CH3), 20.85 (α, CH3), 20.83 (β, CH3), 20.78 (β, CH3), 20.71 (β/α, CH3).
NSI-MS m/z (%): 769 (12, [2M+Na+]), 396 (23, [M+Na+]), 391 (100, [M+NH4
+]).
HRMS-NSI m/z : Calc. for C14H23N4O9 [M+NH4
+]: 391.1460; found: 391.1462.









Triphenylmethyl chloride (8.5 g, 30.5mmol, 1.1 eq.) was added to a solution of glucose
(5.0 g, 27.8mmol) in pyridine (60ml), which was subsequently heated to 75 ◦C for 14 hours.
Volatiles were removed by evaporation and the orange residue dissolved in DCM (75ml).
The solution was washed twice with saturated NH4Cl and NaHCO3 solutions and brine,
before drying over Na2SO4. Evaporation gave a yellow foam, which was puriﬁed by
column chromatography (chloroform/methanol: 100/0→9/1) aﬀording 6-O-trityl-d-gluco-
pyranose (79) as a yellow foam. (8.4 g, 19.9mmol, 72%, α:β 1.3:1).
All analytical data is in good agreement with published data.231
IR (neat) cm-1: 3337 (br), 2924 (w), 1490, 1448, 1033.
1H-NMR (CD3OD, 400MHz): δ 7.39–7.36 (m, 14H, Ar), 7.20–7.16 (m, 14H, Ar), 7.14–
7.09 (m, 7H, Ar), 5.07 (d, 3J (H1,H2) = 3.7Hz, 1.3H, α, H-1), 4.42 (d, 3J (H1,H2) = 7.7Hz,
1H, β, H-1), 3.88 (ddd, 3J (H5,H4) = 10.1Hz, 3J (H5,H6a) = 5.5Hz, 3J (H5,H6b) = 2.0Hz,
1.4H, α, H-5), 3.56 (dd, 3J (H3,H2) = 9.6Hz, 3J (H3,H4) = 8.9Hz, α, H-3), 3.37 (ddd, 5.8,
3.3, J = 1.7Hz, 1H, β, H-5), 3.35–3.22 (m, 7.5H, α, H-2, H-4, H-6a; β, H-3, H-4, H-6a),
3.16–3.11 (m, 2.6H, α/β, H-6b), 3.07 (dd, 3J (H2,H3) = 9.3Hz, 3J (H2,H1) = 7.7Hz, 1H,
β, H-2).
13C-NMR (CD3OD, 100MHz): δ 145.65 (q, α, Trt C-1), 145.53 (q, β, Trt C-1), 130.03
(α/β, 2 Trt C), 128.69 (β, 2 Trt C), 128.66 (α, 2 Trt C), 127.99 (β, Trt C), 127.96 (α, Trt
C), 98.27 (β, C-1), 94.00 (α, C-1), 78.39 (β, C-3), 77.04 (β, C-5), 76.31 (β, C-2), 75.20 (α,
C-3), 73.92 (α, C-2), 72.34 (α, C-4), 72.11 (β, C-4), 72.08 (α, C-5), 64.96 (β, C-6), 64.88
(α, C-6).
NSI-MS m/z (%): 867 (22, [2M+Na]+), 862 (26, [2M+NH4
+]), 445 (24, [M+Na+]), 243
(100, [Trt+]).
HRMS-NSI m/z : Calc. for C25H26NaO6 [M+Na
+]: 445.1622, found: 445.1620.









6-Trityl glucose 79 (1.5 g, 3.55mmol) and tetrabutylammonium iodide (133mg, 0.36mmol,
10%mol) were dissolved in dry DMF (25ml) under nitrogen atmosphere, benzyl bromide
(2.1ml, 17.66mmol, 5 eq. was added then. The solution was cooled on an ice-bath, before
addition of sodium hydride (60% suspension, 720mg, 18mmol, 5.1 eq.) in portions. The
reaction mixture was allowed to slowly warm to room temperature (17 ◦C) and was stirred
for 40 hours before quenching by addition of saturated NH4Cl solution. The reaction
mixture was extracted with ethyl acetate (2× 40ml) and the organic phase was wased
with saturated NH4Cl solution, water and brine (40ml each), then dried over Na2SO4.
Evaporation gave the crude product as thick, yellow oil (3.22 g), which was puriﬁed by
column chromatography (hexane/ethyl acetate: 2/1) to aﬀord benzyl 2,3,4-tri-O-benzyl-
6-O-trityl-d-glucopyranoside (80) as a pale yellow wax (2.12 g, 2.71mmol, 76%, α:β 1:1.9).
All analytical data is in good agreement with published data.231
IR (neat) cm-1: 3062 (w), 3030 (w), 2876 (w), 1494, 1449, 1068.
1H-NMR (CDCl3, 400MHz): δ 7.56–7.52 (m, 11H, Ar), 7.50–7.43 (m, 13H, Ar), 7.39–
7.16 (m, 72H, Ar), 6.88–6.85 (m, 5H, Ar), 5.08 (d, 2J = 11.8Hz, 1.9H, β, O−CH2−Ph),
5.02 (d, 2J = 11.0Hz, 1.9H, β, O−CH2−Ph), 4.97 (d, 2J = 10.7Hz, 1H, α, O−CH2−Ph),
4.95 (d, 3J (H1,H2) = 3.7Hz, 1H, α, H-1), 4.90 (d, 2J = 10.8Hz, 1H, β, O−CH2−Ph),
4.81 (d, 2J = 11.4Hz, 1H, α, O−CH2−Ph), 4.79 (‘d’, 2J = 11.3Hz, 4.8H, 2β/α, 3
O−CH2−Ph), 4.77 (d, 2J = 11.7Hz, 1.9H, β, O−CH2−Ph), 4.72 (d, 2J = 11.9Hz, 1H,
α, O−CH2−Ph), 4.70 (d, 2J = 10.3Hz, 2.9H, β/2α, 3× O−CH2−Ph), 4.64 (d, 2J =
12.2Hz, 1H, α, O−CH2−Ph), 4.63 (d, 2J = 12.0Hz, 1H, α, O−CH2−Ph), 4.56 (d, 3J (H1,
H2) = 7.4Hz, 1.9H, β, H-1), 4.37 (d, 2J = 10.4Hz, 1.8H, β, O−CH2−Ph), 4.30 (d, 2J =
10.4Hz, 1H, α, O−CH2−Ph), 4.02 (‘t’, 3J (H3,H2) = 9.6Hz, 3J (H3,H4) = 8.9Hz, 1H, α,
H-3), 3.87 (ddd, 3J (H5,H4) = 10.4Hz, 3J (H5,H6b) = 4.4Hz, 3J (H5,H6a) = 1.8Hz, 1H, α,
H-5), 3.83 (‘t’, 3J (H4,H5) = 9.9Hz, 3J (H4,H3) = 8.5Hz, 1.8H, β, H-4), 3.67 (‘t’, 3J (H4,
H5) = 10.2Hz, 3J (H4,H3) = 9.1Hz, 1H, α, H-4), 3.66–3.58 (m, 6.6H, β/α, H-2; β H-3; β,
H-6a), 3.46 (dd, 2J (H6a,H6b) = 10.1Hz, 3J (H6a,H5) = 1.9Hz, 1H, α, H-6a), 3.42 (ddd,
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3J (H5,H4) = 9.9Hz, 3J (H5,H6b) = 3.9Hz, 3J (H5,H6a) = 1.8Hz, 2.0H, β, H-5), 3.27 (dd,
2J (H6b,H6a) = 10.1Hz, 3J (H6b,H5) = 4.0Hz, 1.9H, β, H-6b), 3.19 (dd, 2J (H6b,H6a) =
10.1Hz, 3J (H6b,H5) = 4.4Hz, 1H, α, H-6b).
13C-NMR (CDCl3, 100MHz): δ 144.12 (q, α, Trt C-1), 144.09 (q, β, Trt C-1), 138.71
(q, Ar), 138.68 (q, Ar), 138.00 (q, Ar), 137.53 (q, Ar), 129.00 (4 Ar), 128.97 (2 Ar), 128.86
(Ar), 128.59 (2 Ar), 128.57 (2 Ar), 128.55 (2 Ar), 128.52 (2 Ar), 128.36 (2 Ar), 128.32 (3
Ar), 128.27 (Ar), 128.22 (2 Ar), 128.19 (2 Ar), 128.02 (Ar), 127.99 (Ar), 127.96 (4 Ar),
127.94 (2 Ar), 127.88 (Ar), 127.84 (Ar), 127.81 (Ar), 127.13 (2 Ar), 127.10 (Ar), 102.41
(β, C-1), 94.79 (α, C-1), 86.55 (q, β, −OCPh3), 86.47 (q, α, −OCPh3), 84.90 (β, C-3),
82.74 (β, C-2), 82.51 (α, C-3), 80.37 (α, C-2), 78.31 (α, C-4), 78.07 (β, C-4), 76.14 (α,
O−CH2−Ph), 76.11 (β, O−CH2−Ph), 75.23 (α, O−CH2−Ph), 75.18 (β, O−CH2−Ph),
75.12 (β, O−CH2−Ph), 74.80 (β, C-5), 73.12 (α, O−CH2−Ph), 70.86 (β, O−CH2−Ph),
70.71 (α, C-5), 68.76 (α, O−CH2−Ph), 62.61 (β/α, C-6).
NSI-MS m/z (%): 800 (100, [M+NH4
+]), 243 ([Trt+]).
HRMS-NSI m/z : Calc. for C53H54O6N [M+NH4









To a solution of 6-trityl glucoside 80 (434mg, 0.56mmol) in dry DCM (6ml) was added a
solution of AlCl3 (110mg, 0.833mmol, 1.5 eq.) in dry Et2O(2.5ml). The resulting bright
yellow solution was stirred at room temperature for 3 h. The reaction was quenched with
saturated NaHCO3 solution and diluted with Et2O. The aqueous phase was extracted with
Et2O and the combined organic phases washed twice each with saturated NaHCO3, water
and then brine. After drying over Na2SO4, evaporation gave a yellowish oil which slowly
crystallised as a pale yellow solid (418mg). The crude sugar was puriﬁed by column
chromatography (hexane/ethyl acetate: 10/0 → 9/1 → 3/1) to give benzyl 2,3,4-tri-O-
benzyl-d-glucopyranoside (81) as a colourless solid (218mg, 0.40mmol, 72%, α:β 1:1.3).
All spectroscopic data is in good agreement with published data.231 Melting point data
does not match the melting point of either anomer.288
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Melting point: m.p. 78−91 ◦C (lit. m.p. 101−103 ◦C (β anomer), m.p. 86−87 ◦C (α
anomer)).288
IR (neat) cm-1: 3358 (br), 3064 (w), 3030 (w), 2920 (w), 2870 (w), 1497, 1453, 1358, 1066,
1026.
1H-NMR (CDCl3, 400MHz): δ 7.41–7.28 (m, 44H, Ar), 5.01 (d,
2J = 10.9Hz, 1H, α,
O−CH2−Ph), 4.95 (d, 2J = 11.0Hz, 1.3H, β, O−CH2−Ph), 4.93 (d, 2J = 10.8Hz, 1.3H, β,
O−CH2−Ph), 4.92 (d, 2J = 11.9Hz, 1.3H, β, O−CH2−Ph), 4.89 (d, 2J = 10.9Hz, 1H, α,
O−CH2−Ph), 4.86 (d, 2J = 10.6Hz, 1.3H, β, O−CH2−Ph), 4.84 (d, 2J = 10.9Hz, 1H, α,
O−CH2−Ph), 4.81 (d, 2J = 10.7Hz, 1.3H, β, O−CH2−Ph), 4.80 (d, 3J (H1,H2) = 3.7Hz,
1H, α, H-1), 4.73 (d, 2J = 10.8Hz, 1.3H, β, O−CH2−Ph), 4.70 (d, 2J = 11.9Hz, 1.3H,
β, O−CH2−Ph), 4.69 (d, 2J = 11.8Hz, 1H, α, O−CH2−Ph), 4.68 (d, 2J = 12.1Hz, 1H,
α, O−CH2−Ph), 4.64 (d, 2J = 10.9Hz, 1H, α, O−CH2−Ph), 4.64 (d, 2J = 10.8Hz, 1.3H,
β, O−CH2−Ph), 4.57 (d, 3J (H1,H2) = 7.8Hz, 1H, β, H-1), 4.56 (d, 2J = 11.9Hz, 1H, α,
O−CH2−Ph), 4.55 (d, 2J = 12.1Hz, 1H, α, O−CH2−Ph), 4.07 (‘t’, 3J (H3,H2) = 9.6Hz,
3J (H3,H4) = 9.4Hz, 1H, α, H-3), 3.87 (broad d, J = 11.9Hz, 1.4H, β, H-6a), 3.73–3.65
(m, 5.6H, β, H-3; α, H-5; α, H-6a; β/α, H-6b), 3.57 (‘t’, 3J (H4,H5) = 9.7Hz, 3J (H4,H3)
= 9.1Hz, 1.3H, β, H-4), 3.54 (‘t’, 3J (H4,H3) = 9.4Hz, 3J (H4,H5) = 8.9Hz, 1H, α, H-4),
3.50 (dd, 3J (H2,H3) = 9.6Hz, 3J (H2,H1) = 3.7Hz, 1H, α, H-2), 3.49 (dd, 3J (H2,H3) =
9.0Hz, 3J (H2,H1) = 7.8Hz, 1.3H, β, H-2), 3.36 (ddd, 3J (H5,H4) = 9.7Hz, 3J (H5,H6a) =
4.6Hz, 3J (H5,H6b) = 2.8Hz, 1.3H, β, H-5), 1.82 (br, 1H, OH) 1.55 (br s, OH).
13C-NMR (CDCl3, 100MHz): δ 138.77 (q, Ar), 138.47 (q, Ar), 138.27 (q, Ar), 138.09 (q,
Ar), 137.93 (q, Ar), 137.43 (q, Ar), 137.25 (q, Ar), 137.05 (q, Ar), 128.49 (2 Ar), 128.40 (3
Ar), 128.37 (Ar), 128.14 (Ar), 128.10 (Ar), 128.07 (Ar), 127.94 (3 Ar), 127.88 (Ar), 127.80
(Ar), 127.71 (Ar), 127.65 (Ar), 127.60 (Ar), 102.83 (β, C-1), 95.56 (α, C-1), 84.53 (β, C-3),
82.33 (β, C-2), 81.94 (α, C-3), 80.00 (α, C-2), 77.55 (β, C-4), 77.21 (α, C-4), 75.73 (β/α,
2 O−CH2−Ph), 75.10 (α, O−CH2−Ph), 75.07 (β, O−CH2−Ph), 75.02 (β, C-5), 74.99 (β,
O−CH2−Ph), 73.08 (α, O−CH2−Ph), 71.68 (β, O−CH2−Ph), 70.95 (α, C-5), 69.26 (α,
O−CH2−Ph), 62.08 (β, C-6), 61.81 (α, C-6).
NSI-MS m/z (%): 1103 (15, [2M+Na+]), 1098 (15, [2M+NH4
+]), 563 (37, [M+Na+]),
558 (100, [M+NH4
+]).
HRMS-NSI m/z : Calc. for C34H40O6N [M+NH4
+]: 558.2850, found: 558.2846.












Benzyl 2,3,4-tri-O-benzyl-d-glucopyranoside (81) (162mg, 0.3mmol, α:β 1:2.25) was dis-
solved in dry DCM (1.5ml) under nitrogen atmosphere and cooled to 0 ◦C in an ice-bath.
Triethylamine (64 µl, 0.45mmol, 1.5 eq.) was added before addition of methanesulfonyl
chloride (28 µl, 0.36mmol, 1.2 eq.). The reaction was stirred at 0 ◦C for 35min before
dilution with DCM. The solution was washed twice with water and once with saturated
NaHCO3 solution. Drying over Na2SO4 and evaporation gave benzyl 2,3,4-tri-O-benzyl-d-
glucopyranoside 6-methanesulfonate (82) as a whitish oil which solidiﬁed as a pale yellow
solid over night (165mg, 0.27mmol, 89%, α:β 1:2.25).
All spectroscopic data is in good agreement with published data.289 Melting point data
does not match the reported melting point for the pure β anomer.289
Melting point: m.p. 81−96 ◦C (lit. m.p. 101−103 ◦C (β anomer)).289
IR (neat) cm-1: 3031 (w), 2935 (w), 1732 (w), 1497 (w), 1455, 1361, 1177, 1059, 990.
1H-NMR (CDCl3, 400MHz): δ 7.38–7.27 (m, 60H, Ar), 5.03 (d,
2J = 10.9Hz, 1H, α,
O−CH2−Ph), 4.96–4.88 (m, 10.2H, α, 4× β, O−CH2−Ph), 4.83 (d, 2J = 10.9Hz, 1H,
α, O−CH2−Ph), 4.82 (d, 3J (H1,H2) = 3.3Hz, 1H, α, H-1), 4.80 (d, 2J = 10.9Hz, 2.3H,
β, O−CH2−Ph), 4.72 (d, 2J = 10.9Hz, 2.4H, β, O−CH2−Ph), 4.68 (d, 2J = 12.1Hz,
3.3H, α/β, O−CH2−Ph), 4.67 (d, 2J = 12.0Hz, 1H, α, O−CH2−Ph), 4.62 (br d, 3.3H,
α/β, O−CH2−Ph), 4.58 (d, 2J = 12.2Hz, 1H, α, O−CH2−Ph), 4.55 (d, 2J = 11.3Hz,
1H, α, O−CH2−Ph), 4.54 (d, 3J (H1,H2) = 7.7Hz, 2.5H, β, H-1), 4.47 (dd, 3J (H6a,H6b)
= 11.3Hz, 3J (H6a,H5) = 1.2Hz, 2.4H, β, H-6a), 4.35 (‘ddd’, 2J = 11.4Hz, 3J = 4.0Hz,
3J = 1.8Hz, 3.3H, β, H-6b; α, H-6a), 4.21 (dd, 2J (H6b,H6a) = 11.1Hz, 3J (H6b,H5) =
1.9Hz, 1H, α, H-6b), 4.07 (t, 3J = 9.2Hz, 1H, β, H-3), 3.86 (ddd, 3J (H5,H4) = 10.1Hz,
3J (H5,H6a) = 4.0Hz, 3J (H5,H6b) = 1.8Hz, 1H, α, H-5), 3.67 (t, 3J = 8.7Hz, β, H-3),
3.57–3.47 (m, 8.8H, β, H-2, H-4, H-5; α, H-2, H-4), 3.02 (s, 6.8H, β ,−SO2CH3), 2.97 (s,
3H, α ,−SO2CH3).
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13C-NMR (CDCl3, 100MHz): δ 138.37 (q, Ar), 138.25 (q, 2 Ar), 138.06 (q, Ar), 137.83
(q, Ar), 137.65 (q, Ar), 137.13 (q, Ar), 137.00 (q, Ar), 128.81 (2 Ar), 128.78 (Ar), 128.74
(2 Ar), 128.68 (4 Ar), 128.63 (2 Ar), 128.40 (3 Ar), 128.38 (2 Ar), 128.34 (Ar), 128.22
(Ar), 128.20 (2 Ar), 128.15 (Ar), 128.11 (Ar), 128.08 (2 Ar), 128.01 (Ar), 128.00 (Ar),
102.65 (β, C-1), 95.86 (α, C-1), 84.49 (β, C-3), 82.24 (β, C-2), 81.97 (α, C-3), 79.92 (α,
C-2), 76.94 (α/β, C-4), 75.94 (β, O−CH2−Ph), 75.91 (α, O−CH2−Ph), 75.32 (α/β, 2
O−CH2−Ph), 75.15 (β, O−CH2−Ph), 73.29 (α, O−CH2−Ph), 72.94 (β, C-5), 71.66 (β,
O−CH2−Ph), 69.83 (α, O−CH2−Ph), 69.02 (α, C-5), 68.58 (β, C-6), 68.36 (α, C-6), 37.84
(β, −SO2CH3), 37.68 (α, −SO2CH3).
NSI-MS m/z (%): 1254 (13, [2M+NH4
+]), 636 (100, [M+NH4
+]).
HRMS-NSI m/z : Calc. for C35H42O8SN [M+NH4









Method A – From 6-methanesulfonate: Benzyl 2,3,4-tri-O-benzyl-d-glucopyranoside
6-methanesulfonate (82) (92mg, 150 µmol) and sodium azide (31mg, 480 µmol, 3.2 eq.)
were dissolved in non-dry DMF (1.5ml). The reaction mixture was heated to 110 ◦C
for 15 hours and then diluted with water and extracted with ethyl acetate (3×). The
combined organic phases were washed with brine and dried over Na2SO4. Evaporation
gave benzyl 6-azido-2,3,4-tri-O-benzyl-6-deoxy-d-glucopyranoside (75) as pale orange solid
(77mg, 136 µmol, 91%, 81% over both steps from 81).
Method B – One-pot reaction from 6-hydroxy sugar: Benzyl 2,3,4-tri-O-benzyl-d-
glucopyranoside (81) (216mg, 0.4mmol) was dissolved in dry DCM (3ml) and cooled to
−10 ◦C under nitrogen atmosphere. Triethylamine (84 µl, 0.6mmol, 1.5 eq.) was added and
then methanesulfonyl chloride (37 µl, 0.48 µmol, 1.2 eq.) was added slowly to the reaction
mixture. The reaction mixture was stirred at −10 ◦C for 30min, when TLC (hexane/ethyl
acetate: 3/1) showed full conversion of the starting material. The reaction mixture was
then evaporated to dryness and re-dissolved in non-dry DMF (3ml). Sodium azide (130mg,
2mmol, 5 eq.) was added and the reaction mixture heated to 120 ◦C for 17 hours. The
reaction mixture was diluted with saturated NaHCO3 and extracted with ethyl acetate.
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The organic phase was washed with brine and dried over Na2SO4. Evaporation gave a
waxy orange solid (215mg) which was puriﬁed by column chromatography (hexane/ethyl
acetate: 10/1) to give benzyl 6-azido-2,3,4-tri-O-benzyl-6-deoxy-d-glucopyranoside (75)
as an oﬀ-white solid (149mg, 265 µmol, 66% over two steps).
Melting point: m.p. 60−84 ◦C.
IR (neat) cm-1: 3066 (w), 3029 (w), 2922, 2856, 2097 (−N3), 1497, 1454, 1358, 1283, 1099,
1067, 1027.
1H-NMR (CDCl3, 400MHz): δ 7.43–7.22 (m, 65H, Ar), 5.01 (d,
2J = 10.8Hz, 1H, α,
3-O−CH2−Ph), 4.97 (d, 2J = 11.0Hz, 4.4H, β, 1-O−CH2−Ph, 2-O−CH2−Ph), 4.94 (d,
2J = 10.6Hz, 2.4H, β, 3-O−CH2−Ph), 4.90 (d, 2J = 10.8Hz, 1H, α, 4-O−CH2−Ph), 4.87
(d, 2J = 11.5Hz, 2.4H, β, 4-O−CH2−Ph), 4.84 (d, 3J (H1,H2) = 3.7Hz, 1H, α, H-1), 4.81
(d, 2J = 11.0Hz, 1H, α, 3-O−CH2−Ph), 4.77 (d, 2J = 10.8Hz, 2.4H, β, 3-O−CH2−Ph),
4.72 (‘d’, 2J = 12.4Hz, 2J = 10.9Hz, 3.3H, α, 1-O−CH2−Ph; β, 2-O−CH2−Ph), 4.67 (d,
2J = 11.7Hz, 2.4H, β, 1-O−CH2−Ph), 4.65 (d, 2J = 11.9Hz, 1H, α, 2-O−CH2−Ph), 4.57
(‘d’, 2J = 11.9Hz, 2J = 10.8Hz, 2H, α, 1-O−CH2−Ph, 4-O−CH2−Ph), 4.56 (d, 2J =
11.3Hz, 2.3H, β, 4-O−CH2−Ph), 4.55 (d, 3J (H1,H2) = 8.0Hz, 2.3H, β, H-1), 4.54 (d,
2J = 11.9Hz, 1H, α, 2-O−CH2−Ph), 4.04 (t, 3J (H3,H2,4) = 9.3Hz, 1H, α, H-3), 3.85
(ddd, 3J (H5,H4) = 9.7Hz, 3J (H5,H6b) = 5.4Hz, 3J (H5,H6a) = 2.8Hz, 1H, α, H-5), 3.65
(‘t’, 3J (H3,H2) = 9.2Hz, 3J (H3,H4) = 8.5Hz, 2.4H, β, H-3), 3.54 (dd, 3J (H2,H3) = 9.2Hz,
3J (H2,H1) = 3.8Hz, 1H, α, H-2), 3.53 (dd, 3J (H2,H3) = 9.3Hz, 3J (H2,H1) = 7.9Hz, 2.3H,
β, H-2), 3.50 (ddd, 3J (H5,H4) = 9.2Hz, 3J (H5,H6b) = 6.3Hz, 3J (H5,H6a) = 2.3Hz, 2.3H,
β, H-5), 3.44 (‘t’, 3.3H, β, 3J (H4,H2,4) = 9.2Hz, H-4; α, 3J (H4,H5) = 9.7Hz, 3J (H4,H3)
= 9.2Hz, H-4), 3.39 (dd, 2J (H6a,H6b) = 13.2Hz, 3J (H6a,H5) = 2.4Hz, 2.3H, β, H-6a),
3.36 (dd, 2J (H6a,H6b) = 12.9Hz, 3J (H6a,H5) = 2.8Hz, 1H, α, H-6a), 3.33 (dd, 2J (H6b,
H6a) = 13.1Hz, 3J (H6b,H5) = 6.3Hz, 2.3H, β, H-6b), 3.30 (dd, 2J (H6b,H6a) = 12.8Hz,
3J (H6b,H5) = 5.3Hz, 1H, α, H-6b).
13C-NMR (CDCl3, 100MHz): δ 138.76 (q, α, Ar), 138.47 (q, β, Ar), 138.36 (q, β, Ar),
138.11 (q, α, Ar), 138.02 (q, α, Ar), 137.80 (q, β, Ar), 137.21 (q, β, Ar), 137.02 (q, α, Ar),
128.64 (2 Ar), 128.61 (Ar), 128.58 (2 Ar), 128.56 (Ar), 128.53 (3 Ar), 128.49 (2 Ar), 128.28
(2 Ar), 128.24 (2 Ar), 128.19 (2 Ar), 128.15 (Ar), 128.11 (Ar), 128.05 (Ar), 128.00 (3 Ar),
127.94 (Ar), 127.84 (Ar), 127.82 (Ar), 127.76 (Ar), 102.33 (β, C-1), 95.31 (α, C-1), 84.57
(β, C-3), 82.38 (β, C-2), 81.95 (α, C-3), 80.08 (α, C-2), 78.51 (α, C-4), 78.48 (β, C-4),
75.85 (α/β, 3-O−CH2−Ph), 75.31 (α, 4-O−CH2−Ph), 75.20 (β, 4-O−CH2−Ph), 75.05
(β, 2-O−CH2−Ph), 74.92 (β, C-5), 73.11 (α, 2-O−CH2−Ph), 71.25 (β, 1-O−CH2−Ph),
70.40 (α, C-5), 69.39 (α, 1-O−CH2−Ph), 51.56 (β, C-6), 51.47 (α, C-6).
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NSI-MS m/z (%): 624 (42, [M+ACN+NH4
+]), 604 (17, [M+K+]), 588 (25, [M+Na+]),
583 (100, [M+NH4
+]).
HRMS-NSI m/z : Calc. for C34H39N4O5 [M+NH4













Benzyl maltol 33 (216mg, 1mmol) and propargylamine (130 µl, 2.0mmol) were dissolved
in a water/methanol mixture (5ml). Reaction mixture was adjusted to pH 12 with
1M NaOH and then heated to reﬂux over night. The solution was adjusted to pH 1
with HCl and extracted with Et2O. The organic phase was discarded and the aqueous
phase was adjusted to pH 12, then extracted with DCM. The organic phase was washed
with water, then dried over Na2SO4. Evaporation gave a brown gum (63mg), which was














Ethanolamine (3ml, 50mmol) was added to a solution of benzyl maltol 33 (4.0 g, 18.5mmol)
in methanol (20ml) and 1M NaOH (10ml). The reaction mixture was heated to reﬂux
over night (18 hours), then concentrated in vacuo. Upon acidifying the solution with HCl,
3-(benzyloxy)-1-(2-hydroxyethyl)-2-methylpyridin-4(1H )-one (83) precipitated as a cream
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coloured powder, which was collected by vacuum ﬁltration. Further product was isolated
by concentrating the mother liquor (3.1 g, 10.3mmol, 56%, as HCl salt).
All analytical data is in agreement with published data.199,290,291
Melting point: m.p. 200−202 ◦C (lit. m.p. 205−206 ◦C).199
IR (neat) cm-1: 3295, 1636, 1519, 1491, 1344, 1266,1241, 1076, 1033, 968.
1H-NMR (CD3OD, 400MHz): δ 8.30 (d,
3J (H6,H5) = 7.1Hz, 1H, H-6), 7.45–7.41 (m,
2H, Ph H-3,5), 7.40–7.37 (m, 3H, Ph H-2,4,6), 7.20 (d, 3J (H5,H6) = 7.1Hz, 1H, H-5),
5.18 (s, 2H, O−CH2−Ph), 4.45 (t, 3J (H1’,H2’) = 5.0Hz, 2H, H-1’), 3.87 (t, 3J (H2’,H1’)

















Under nitrogen atmosphere, pyridinone 83 (1.18 g, 4mmol) was dissolved in dry DMF
(20ml). Tetrabutylammonium iodide (148mg, 0.4mmol, 10%mol) was added and the
cloudy solution cooled to −10 ◦C, then sodium hydride (60% suspension, 400mg, 10mmol,
2.5 eq.) was added in portions and the solution left to stir for 30min. Propargyl bromide
(80% solution in toluene, 560 µl, 5mmol, 1.25 eq.) was added via a syringe and the reaction
mixture was stirred at−10 ◦C for 1 hour before it was allowed to warm to room temperature
and stir over night. The reaction was quenched by addition of saturated NH4Cl solution
and extracted with chloroform (2×). The combined organic phases were washed with
water and brine before drying over Na2SO4. Evaporation gave a brown oil (900mg) which
was puriﬁed by column chromatography (chloroform/methanol: 20/1→ 10/1→ 6/1) to
give 3-(benzyloxy)-2-methyl-1-[2-(prop-2-ynyloxy)ethyl]pyridin-4(1H )-one (84) as a pale
brown oil (774mg, 2.6mmol, 65%).
IR (neat) cm-1: 3285 (br), 2869 (br), 2109 (w), 1624, 1559, 1520, 1496, 1353, 1248, 1216,
1160, 1098.
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1H-NMR (CDCl3, 400MHz): δ 7.41 (‘dd’, 2H, Ph H-3,5), 7.35–7.29 (m, 3H, Ph H-2,4,6),
7.24 (d, 3J (H6,H5) = 7.6Hz, 1H, H-6), 6.41 (d, 3J (H5,H6) = 7.6Hz, 1H, H-5), 5.22 (s, 2H,
O−CH2−Ph), 4.09 (d, 4J (H3’,H5’) = 2.4Hz, 2H, H-3’), 3.96 (t, 3J (H1’,H2’) = 5.2Hz, 2H,
H-1’), 3.69 (t, 3J (H2’,H1’) = 5.2Hz, 2H, H-2’), 2.43 (t, 4J (H5’,H3’) = 2.4Hz, 1H, H-5’),
2.11 (s, 3H, CH3).
13C-NMR (CDCl3, 100MHz): δ 173.60 (C-4), 146.10 (C-3), 141.08 (C-2), 138.85 (C-6),
137.85 (Ph C-1), 129.16 (Ph C-3,5), 128.24 (Ph C-2,6), 127.94 (Ph C-4), 117.18 (C-5),
78.59 (C-4’), 75.38 (C-5’), 73.01 (O−CH2−Ph), 68.27 (C-2’), 58.65 (C-3’), 52.90 (C-1’),
12.73 (CH3).
NSI-MS m/z (%): 617 (17, [2M+Na+]), 595 (26, [2M+H+]), 298 (100, [M+H+]).
HRMS-NSI m/z : Calc. for C18H20NO3 [M+H










Phenyl propargyl ether (128 µl, 1mmol) and benzyl azide (125 µl, 1mmol) were dissolved
in tBuOH/water (3ml). Ascorbic acid (20.2mg, 11.5 µmol, 12%mol), 1M NaOH (100 µl,
100 µmol, 10%mol) and 1M copper sulfate (50 µl, 50 µmol, 5%mol) were added to the
reaction mixture, which was heated in a sealed tube at 60 ◦C for 1 hour. The reaction
mixture was diluted with water (10ml) and 10% aqueous ammonia (2ml) and stirred for
10min. The formed precipitate was collected by vacuum ﬁltration and dried over P4O10
to give the desired triazole 88 as olive green powder (224mg, 0.84mmol, 84%).
Analytical data is in good agreement with published data.292
IR (neat) cm-1: 3134 (w), 2924 (w), 1598, 1585, 1487, 1467, 1457, 1429, 1383, 1332, 1292,
1240, 1219, 1178, 1120, 1054, 1030, 1007, 988.
1H-NMR (CDCl3, 400MHz): δ 7.53 (s, 1H), 7.40–7.35 (m, 3H), 7.30–7.25 (m, 4H),
6.99–6.94 (m, 3H), 5.53 (s, 2H), 5.19 (s, 2H).
















Phenyl propargyl ether (31 µl, 250 µmol) and azido glucoside 73 (93mg, 250 µmol) were dis-
solved in a tBuOH/water mixture (1.5ml). Then, ascorbic acid (5mg, 28 µmol, 11%mol),
1M NaOH (25 µl, 25 µmol, 10%mol) and 1M copper sulfate (12.5µl, 12.5 µmol, 5%mol) were
added to the reaction mixture, which was subsequently heated in a sealed tube at 60 ◦C
for 22 hours. TLC (hexane/ethyl acetate: 5/1) showed full conversion of phenyl propargyl
ether. Water (5ml) was added to the reaction mixture, which led to the formation of
a gel. This gel was dissolved with ethyl acetate and partitioned with dilute ammonia.
The aqueous phase was extracted twice with ethyl acetate and the combined organic
phases were washed with saturated NaHCO3 and brine, then dried over Na2SO4. Evapor-
ation gave 1-(2,3,4,6-tetra-O-acetyl-β-d-glucopyranosyl)-4-(phenoxymethyl)-1H -1,2,3-tri-
azole (89) as oﬀ-white solid (118mg, 233 µmol, 93%).
Spectral data is in good agreement with published data.292
Melting point: m.p. 106−108 ◦C (lit. m.p. 142−143 ◦C).292
1H-NMR (CDCl3, 400MHz): δ 7.86 (s, 1H, H-3), 7.33–7.28 (m, 2H, H-3’,5’), 7.01–6.96
(m, 3H, H-2’,4’,6’), 5.89 (d, 3J (H1”,H2”) = 8.8Hz, 1H, H-1”), 5.48–5.39 (m, 2H, H-2”,3”),
5.27–5.20 (m, 3H, H-1, H-4”), 4.30 (dd, 3J (H6a”,H6b”) = 12.6Hz, 3J (H6a”,H5”) = 5.0Hz,
1H, H-6a”), 4.15 (dd, 3J (H6b”,H6a”) = 12.6Hz, 3J (H6b”,H5”) = 2.0Hz, 1H, H-6b”), 4.00
(ddd, 3J (H5”,H4”) = 10.1Hz, 3J (H5”,H6a”) = 5.0Hz, 3J (H5”,H6b”) = 2.0Hz, 1H, H-5”),
2.09 (s, 3H, CH3), 2.07 (s, 3H, CH3), 2.03 (s, 3H, CH3), 1.85 (s, 3H, CH3).
13C-NMR (CDCl3, 100MHz): δ 170.49 (C=O), 169.91 (C=O), 169.32 (C=O), 168.89
(C=O), 158.04 (C-1’), 145.11 (C-2), 129.54 (C-3’,5’), 121.34 (C-4’), 121.03 (C-3), 114.77
(C-2’,6’), 85.73 (C-1”), 75.14 (C-5”), 72.62 (C-3”), 70.19 (C-2”), 67.63 (C-4”), 61.75 (C-1),
61.49 (C-6”), 20.68 (CH3), 20.52 (CH3), 20.50 (CH3), 20.11 (CH3).
NSI-MS m/z (%): 1033 (14, [2M+Na+]), 1011 (55, [2M+H+]), 528 (15, [M+Na+]), 506
(100, [M+H+]), 331 (28, [PhOCH2triazolyl]).
HRMS-NSI m/z : Calc. for C23H28N3O10 [M+H
+]: 506.1769; found: 506.1770.





Triazole 88 (50mg, 190 µmol) was dissolved in DCM (5ml) and boiled with activated
charcoal for 10min, then ﬁltered and evaporated; residual solvent was co-evaporated with
methanol. The residue was then dissolved in methanol (5ml) and Pd/C (10% wt., 5mg)
was added. The suspension was shaken in a Parr shaker under hydrogen atmosphere (2 bar)
over night. The reaction mixture was ﬁltered through a pad of celite and evaporated to





















Alkyne 84 (149mg, 0.5mmol) and benzyl azide (62 µl, 0.5mmol) were dissolved in a
tBuOH/water mixture (1.5ml). Then, ascorbic acid (9.7mg, 55 µmol, 11%mol), 1M NaOH
(50 µl, 50 µmol, 10%mol) and 1M copper sulfate (25 µl, 25 µmol, 5%mol) were added to the
reaction mixture which was subsequently heated in a sealed tube at 60 ◦C for 20 hours.
The reaction mixture was diluted with 5% ammonia and the solution stirred for 5min,
then further diluted with water and extracted with ethyl acetate (2×). The combined
organic phases were washed with water and brine, then dried over Na2SO4. Evaporation
gave the desired triazole 90 as pale tan plates (187mg, 0.44mmol, 87%).
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Melting point: m.p. 118−121 ◦C.
IR (neat) cm-1: 3033 (w), 2965 (w), 2926 (w), 1733 (w), 1626, 1570, 1528, 1494, 1455,
1246, 1216, 1123, 1085, 1058.
1H-NMR (CDCl3, 400MHz): δ 7.42–7.34 (m, 5H, OBn), 7.33–7.26 (m, 5H, ArBn), 7.22
(s, 1H, H-5’), 7.13 (d, 3J (H6,H5) = 7.5Hz, 1H, H-6), 6.33 (d, 3J (H5,H6) = 7.5Hz, 1H,
H-5), 5.51 (s, 2H, H-6’), 5.21 (s, 2H, O−CH2−Ph), 4.52 (s, 2H, H-3’), 3.89 (t, 3J (H1’,H2’)
= 5.1Hz, 2H, H-1’), 3.68 (t, 3J (H2’,H1’) = 5.1Hz, 2H, H-2’), 2.06 (s, 3H, 2-CH3).
13C-NMR (CDCl3, 100MHz): δ 173.50 (C-4), 146.15 (C-3), 144.55 (C-4’), 140.73 (C-2),
138.97 (C-6), 137.65 (OBn C-1), 134.48 (ArBn C-1), 129.16 (OBn C-3,5), 129.08 (OBn
C-2,6), 128.82 (OBn C-4), 128.25 (ArBn C-2,3,5,6), 127.97 (ArBn C-4), 122.48 (C-5’),






















Method A: Hydrogenation Triazole 90 (99mg, 230 µmol) and Pd/C (10% wt., 3mg)
were taken up in methanol (5ml) and the suspension shaken over night (16 hours) in a
Parr shaker under hydrogen atmosphere (2bar, pressure dropped to 0.5bar over night).
TLC (chloroform/methanol: 6/1) showed no conversion, the reaction mixture was acidiﬁed
with HCl, then hydrogenated for 20 hours, but no reaction occurred. The reaction mixture
was then ﬁltered through a pad of celite (previously washed with HCl) and evaporated to
give a pale brown wax, which was redissolved in DCM and boiled with activated charcoal
(10mg) for 15min. After ﬁltration and evaporation, the residue was dissolved in methanol
(5ml) and Pd/C (10% wt., 5mg) was added before shaking in a Parr shaker under hydrogen
atmosphere (2bar) for 18 hours. Filtration through a pad of celite and evaporation aﬀorded
the unreacted starting material 90.
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Method B: Boron tribromide Triazole 90 (99mg, 230 µmol) was dissolved in dry
DCM (6ml) under nitrogen atmosphere and cooled in an ice-bath. Boron tribromide (1M
solution in DCM, 1.8ml) was added slowly via a syringe and the reaction mixture stirred
for 10min at 0 ◦C, then allowed to warm to room temperature and stirred for 2 days. The
reaction mixture was quenched by the slow addition of methanol (10ml) and stirred for
1 hour before evaporation and drying under high vacuum. The residue was puriﬁed by
reverse phase chromatography (Lichroprep RP-18 resin, gradient 0.05 M TEAB/methanol:
100/0 → 70/30) The product-containing fractions were combined, evaporated in vacuo






























Alkyne 84 (358mg, 1.2mmol) and 1-azido glucoside 73 (447mg, 1.2mmol, 1 eq.) were
dissolved in tBuOH (2ml) and water (1ml). Ascorbic acid (21.1mg, 120 µmol), 1M NaOH
(120 µl, 120 µmol) and 1M copper sulfate (60 µl, 60 µmol) were added and the reaction
mixture was then heated in a sealed tube at 60 ◦C for 18 hours. Thin layer chromatography
(chloroform/methanol: 6/1) showed only one spot with a similar Rf value as the alkyne.
This spot did not stain when treated with KMnO4 solution, indicating the consumption of
the starting material and formation of a new product. The reaction mixture was diluted
with water and then extracted with chloroform (2×). The combined organic phases were
washed twice with water and once with brine, before drying over Na2SO4. Evaporation
gave a brown waxy solid (1.1 g), which was puriﬁed by column chromatography (chloro-
form/methanol: 20/1), yielding 1-(2-{[1-(2,3,4,6-tetra-O-acetyl-β-d-glucopyranosyl)-1H -
1,2,3-triazol-4-yl]methoxy}ethyl)-3-(benzyloxy)-2-methylpyridin-4(1H )-one (91) as oﬀ-
white foam (685mg, 1.04mmol, 85%).
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Melting point: m.p. 72−78 ◦C.
IR (neat) cm-1: 1745, 1626, 1563, 1366, 1211, 1095, 1034.
1H-NMR (CDCl3, 400MHz): δ 7.58 (s, 1H, H-5’), 7.43–7.39 (m, 2H, Ph H-3,5), 7.33–
7.26 (m, 3H, Ph H-2,4,6), 7.23 (d, 3J (H6,H5) = 7.5Hz, 1H, H-6), 6.40 (d, 3J (H5,H6) =
7.5Hz, 1H, H-5), 5.81 (d, 3J (H1”,H2”) = 9.0Hz, 1H, H-1”), 5.42 (t, 3J (H3”,H2”) = 9.5Hz,
3J (H3”,H4”) = 9.2Hz, 1H, H-3”), 5.35 (t, 3J (H2”,H3”) = 9.5Hz, 3J (H2”,H1”) = 9.0Hz,
1H, H-2”), 5.30 (‘t’, 3J (H4”,H5”) = 10.1Hz, 3J (H4”,H3”) = 9.2Hz, 1H, H-4”), 5.23 (s,
2H, O−CH2−Ph), 4.58 (s, 2H, H-3’), 4.35 (dd, 2J (H6a”,H6b”) = 12.7Hz, 3J (H6a”,H5”)
= 5.1Hz, 1H, H-6a”), 4.20 (dd, 2J (H6b”,H6a”) = 12.7Hz, 3J (H6b”,H5”) = 2.0Hz, 1H,
H-6b”), 4.01 (ddd, 3J (H5”,H4”) = 10.1Hz, 3J (H5”,H6a”) = 5.1Hz, 3J (H5”,H6b”) = 2.0Hz,
1H, H-5”), 3.93 (t, 3J (H1’,H2’) = 5.2Hz, 2H, H-1’), 3.69–3.60 (m, 2H, H-2’), 2.10 (s, 3H,
2-CH3), 2.08 (s, 3H, CH3), 2.07 (s, 3H, CH3), 2.03 (s, 3H, CH3), 1.86 (s, 3H, CH3).
13C-NMR (CDCl3, 100MHz): δ 173.48 (C-4), 170.49 (C=O), 169.91 (C=O), 169.33
(C=O), 168.91 (C=O), 145.92 (C-3), 144.93 (C-4’), 140.73 (C-2), 139.04 (Ph C-1), 129.15
(Ph C-3,5), 128.22 (Ph C-2,6), 127.92 (Ph C-4), 121.00 (C-5’), 117.01 (C-5), 85.81 (C-1”),
75.32 (C-5”), 72.97 (O−CH2−Ph), 72.43 (C-3”), 70.45 (C-2”), 68.51 (C-2’), 67.70 (C-4”),
64.41 (C-3’), 61.55 (C-6”), 52.91 (C-1’), 20.72 (CH3), 20.55 (CH3), 20.52 (CH3), 20.18
(CH3), 12.66 (2-CH3).
NSI-MS m/z (%): 1341 (12, [2M+H+]), 693 (13, [M+Na+]), 671 (100, [M+H+]).
HRMS-NSI m/z : Calc. for C32H39N4O12 [M+H
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Triazole 91 (201mg, 0.3mmol) was dissolved in dry methanol (3ml) and 1M sodium meth-
oxide (800 µl, 0.8mmol) was added. The reaction progress was complete after 5min as de-
termined by TLC (chloroform/methanol: 3/1). The reaction mixture was neutralised with
2M HCl (450ml) and evaporated to dryness. The residue was puriﬁed by column chroma-
tography (chloroform/methanol: 20/1→10/1→ 3/1) to give 3-(benzyloxy)-1-(2-{[1-(β-d-
glucopyranosyl)-1H -1,2,3-triazol-4-yl]methoxy}ethyl)-2-methylpyridin-4(1H )-one (97) as
oﬀ-white foam (153mg, 0.3mmol, quantitative).
IR (neat) cm-1: 3252 (br), 2921 (w), 1623, 1546, 1507, 1454, 1404, 1253, 1222, 1093, 1042.
1H-NMR (CD3OD, 400MHz): δ 8.05 (s, 1H, H-5’), 7.63 (d,
3J (H6,H5) = 7.5Hz, 1H,
H-6), 7.41–7.37 (m, 2H, Ph H-3,5), 7.35–7.30 (m, 3H, Ph H-2,4,6), 6.42 (d, 3J (H5,H6) =
7.5Hz, 1H, H-5), 5.58 (d, 3J (H1”,H2”) = 9.2Hz, 1H, H-1”), 5.05 (s, 2H, O−CH2−Ph), 4.56
(s, 2H, H-3’), 4.16 (t, 3J (H1’,H2’) = 5.0Hz, 2H, H-1’), 3.88 (dd, 2J (H6a”,H6b”) = 12.3Hz,
3J (H6a”,H5”) = 2.0Hz, 1H, H-6a”), 3.85 (‘t’, 3J (H2”,H1”) = 9.2Hz, 3J (H2”,H3”) = 8.9Hz,
1H, H-2”), 3.74 (t, 3J (H2’,H1’) = 5.0Hz, 2H, H-2’), 3.71 (dd, 2J (H6b”,H6a”) = 12.4Hz,
3J (H6b”,H5”) = 5.5Hz, 1H, H-6b”), 3.57 (ddd, 3J (H5”,H4”) = 9.5Hz, 3J (H5”,H6b”) =
5.4Hz, 3J (H5”,H6a”) = 2.0Hz, 1H, H-5”), 3.55 (‘t’, 3J (H3”,H2”) = 8.9Hz, 3J (H3”,H4”) =
8.7Hz, 1H, H-3”), 3.49 (‘t’, 3J (H4”,H5”) = 9.5Hz, 3J (H4”,H3”) = 8.7Hz, 1H, H-4”), 2.18
(s, 3H, 2-CH3).
13C-NMR (CD3OD, 100MHz): δ 174.00 (C-4), 146.52 (C-3), 146.23 (C-2), 145.39 (C-
4’), 142.18 (C-6), 138.23 (Ph C-1), 130.19 (Ph C-3,5), 129.46 (Ph C-2,6), 129.40 (Ph C-4),
124.48 (C-5’), 116.73 (C-5), 89.40 (C-1”), 81.06 (C-5”), 78.34 (C-3”), 74.69 (O−CH2−Ph),
73.99 (C-2”), 70.87 (C-4”), 69.85 (C-2’), 64.82 (C-3’), 62.28 (C-6”), 54.88 (C-1’), 13.31
(2-CH3).
NSI-MS m/z (%): 525 (11, [M+Na+]), 503 (100, [M+H+]), 371 (42).
HRMS-NSI m/z : Calc. for C24H31N4O8 [M+H
+]: 503.2136; found: 503.2132.





























To a solution of triazole 91 (101mg, 150 µmol) in methanol (10ml) was added Pd/C
(10% wt., 3mg). The suspension was shaken in a Parr shaker under hydrogen atmosphere
(2 bar) over night, then ﬁltered through a pad of celite (previously washed with HCl) and
evaporated to give a colourless glass. The residue was re-dissolved in dilute methanolic HCl,
evaporated and dried under high vacuum to give 1-(2-{[1-(2,3,4,6-tetra-O-acetyl-β-d-gluco-
pyranosyl)-1H -1,2,3-triazol-4-yl]methoxy}ethyl)-3-hydroxy-2-methylpyridin-4(1H )-one (96)
as colourless glass (62mg, 108 µmol, 71%).
IR (neat) cm-1: 3265 (br), 2922 (w), 1634, 1506, 1335, 1250, 1092, 1025.
1H-NMR (CD3OD, 400MHz): δ 8.10–7.80 (br, 2H, H-6, H-5’), 7.28–7.17 (br, 1H, H-5),
6.06–5.89 (br, 1H, H-1”), 5.50–5.35 (m, 2H, H-2”,3”), 5.28 (‘t’, 1H, H-4”), 4.70–4.60 (br,
2H, H-3’), 4.61–4.45 (br, 2H, H-1’), 4.37–4.29 (m, 1H, H-6a”), 4.28–4.20 (m, 1H, H-6b”),
4.18–4.11 (m, 1H, H-5”) 4.10–3.90 (br, 2H, H-2’), 2.62 (br s, 3H, 2-CH3), 2.09 (s, 3H, CH3),
2.07 (s, 3H, CH3), 2.04 (s, 3H, CH3), 1.88 (s, 3H, CH3).
13C-NMR (CD3OD, 100MHz): δ 170.56 (C=O), 169.87 (C=O), 169.40 (C=O), 169.02
(C=O), 158.49 (C-4), 143.27 (C-3), 142.24 (C-2), 142.21 (C-4’), 138.12 (C-6), 122.16 (C-
5’), 112.12 (C-5), 85.77 (C-1”), 75.08 (C-5”), 72.35 (C-3”), 70.50 (C-2”), 67.82 (C-2’), 67.58
(C-4”), 63.77 (C-3’), 61.47 (C-6”), 56.32 (C-1’), 20.75 (CH3), 20.53 (2x CH3), 20.24 (CH3),
13.44 (2-CH3).
NSI-MS m/z (%): 1169 (16), 1127 (27), 1085 (12), 603 (30, [M+Na+]), 581 (100,
[M+H+]), 539 (55, [M-Ac+H+]).
HRMS-NSI m/z : Calc. for C25H33N4O12 [M+H
+]: 581.2089; found: 581.2082.





























In a solution of triazole 97 (130mg, 260 µmol) in methanol (5ml) and concentrated
hydrochloric acid (7 drops) was suspended Pd/C (10% wt., 3mg). The reaction mixture
was shaken in a Parr shaker under hydrogen atmosphere (2 bar) over night (18 hours), then
ﬁltered through a pad of celite (previously washed with HCl) and evaporated and dried
under high vacuum to give 1-(2-{[1-(β-d-glucopyranosyl)-1H -1,2,3-triazol-4-yl]methoxy}-
ethyl)-3-hydroxy-2-methylpyridin-4(1H )-one (98) as a pale yellow foam (120mg, 260 µmol,
quantitative, as HCl salt).
Melting point: m.p. 61−70 ◦C.
IR (neat) cm-1: 3264 (w), 2922 (w), 1634, 1537 (w), 1505, 1335, 1250, 1093, 1025.
1H-NMR (CD3OD, 400MHz): δ 8.10 (s, 1H, H-5’), 8.01 (d,
3J (H6,H5) = 7.0Hz, 1H,
H-6), 7.01 (d, 3J (H5,H6) = 7.0Hz, 1H, H-5), 5.57 (d, 3J (H1”,H2”) = 9.2Hz, 1H, H-1”),
4.59 (s, 2H, H-3’), 4.57–4.53 (m, 2H, H-1’), 3.95 (t, 3J (H2’,H1’) = 4.9Hz, 2H, H-2’), 3.94
(dd, 2J (H6a”,H6b”) = 12.1Hz, 3J (H6a”,H5”) = 2.1Hz, 1H, H-6a”), 3.84 (t, 3J (H2”,H1”) =
9.2Hz, 3J (H2”,H3”) = 9.0Hz, 1H, H-2”), 3.74 (dd, 2J (H6b”,H6a”) = 12.1Hz, 3J (H6b”,H5”)
= 5.8Hz, 1H, H-6b”), 3.60 (ddd, 3J (H5”,H4”) = 9.7Hz, 3J (H5”,H6b”) = 5.8Hz, 3J (H5”,
H6a”) = 2.1Hz, 1H, H-5”), 3.56 (t, 3J (H3”,H2”) = 9.0Hz, 3J (H3”,H4”) = 8.8Hz, 1H, H-3”),
3.47 (‘t’, 3J (H4”,H3”) = 9.7Hz, 3J (H4”,H5”) = 8.9Hz, 1H, H-4”), 2.61 (s, 3H, 2-CH3).
13C-NMR (CD3OD, 100MHz): δ 159.66 (C-4), 145.16 (C-3), 144.74 (C-2), 143.69 (C-4’),
139.75 (C-6), 124.42 (C-5’), 111.34 (C-5), 89.55 (C-1”), 81.16 (C-5”), 78.47 (C-3”), 74.02
(C-2”), 70.97 (C-4”), 69.17 (C-2’), 64.59 (C-3’), 62.45 (C-6”), 57.17 (C-1’), 13.05 (2-CH3).
NSI-MS m/z (%): 435 (17, [M+Na+]), 413 (92, [M+H+]), 251 (100, [M-Glc+H+]).
HRMS-NSI m/z : Calc. for C17H25N4O8 [M+H
+]: 413.1667; found: 413.1662.






















The azido sugar 74 (250mg, 0.67mmol) and alkyne 84 (230mg, 0.77mmol, 1.15 eq.) were
each dissolved in tBuOH (1.5ml), the two solutions were combined and diluted with water
(3ml) to form a pale yellow, cloudy solution. Ascorbic acid (14mg, 80 µmol, 12%mol),
1M NaOH (80 µl, 80 µmol, 12%mol) and 1M copper sulfate (40 µl, 40 µmol, 6%mol) were
added and the reaction mixture was then heated to 60 ◦C in a sealed tube for 23 hours. The
reaction mixture was diluted with water (50ml) and extracted with chloroform (2× 25ml).
The combined organic phases were washed twice with water and once with brine, then dried
over Na2SO4. Evaporation gave a brown waxy residue (523mg), which was puriﬁed by
column chromatography (ﬁrst column: chloroform/methanol: 100/0→20/1→10/1→ 5/1;
second column: 100/0→ 50/1→ 20/1) to give 1-(2-{[1-(1,3,4,6-tetra-O-acetyl-2-deoxy-d-
glucopyranos-2-yl)-1H -1,2,3-triazol-4-yl ]methoxy}ethyl)-3-(benzyloxy)-2-methylpyridin-
4(1H )-one (92) as white foam (378mg, 0.56mmol, 84%, α:β 1:1.8).
Melting point: m.p. 70−77 ◦C.
IR (neat) cm-1: 1746, 1626, 1564, 1366, 1210, 1034.
1H-NMR (CDCl3, 400MHz): δ 7.56 (s, 1H, α, H-5’), 7.44 (s, 2H, β, H-5’), 7.36–7.22
(m, 19H, H-6, Ph H-2–6), 6.55 (d, 3J (H5,H6) = 7.4Hz, 2H, β, H-5), 6.52 (d, 3J (H5,H6)
= 7.8Hz, 1H, α, H-5), 6.30 (d, 3J (H1”,H2”) = 3.6Hz, 1H, α, H-1”), 6.10 (d, 3J (H1”,H2”)
= 8.7Hz, 2H, β, H-1”), 5.86 (dd, 3J (H3”,H2”) = 11.3Hz, 3J (H3”,H4”) = 9.3Hz, 1H, α,
H-3”), 5.60 (dd, 3J (H3”,H2”) = 10.7Hz, 3J (H3”,H4”) = 9.3Hz, 2H, β, H-3”), 5.21 (dd, 3J =
10.1Hz, 3J = 9.5Hz, 1H, α), 5.17–5.03 (m, 6H, O−CH2−Ph), 4.63 (dd, 3J (H2”,H3”) =
10.7Hz, 3J (H2”,H1”) = 8.7Hz, 2H, β, H-2”), 4.50 (s, 3H, β/α, H-3’), 4.48 (d, J = 2.6Hz,
2H), 4.36–4.26 (m, 4H), 4.16 (ddd, J = 10.1Hz, J = 4.1Hz, J = 2.0Hz, 2H), 4.07 (ddd,
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J = 12.5Hz, J = 8.1Hz, J = 5.2Hz, J = 2.1Hz, 3H), 3.98–3.91 (m, 5H, β/α, H-2’), 3.60
(t, 3J = 5.1Hz, 5H, β/α, H-1’), 2.10 (s, 6H, β, 2-CH3), 2.09 (s, 3H, α, 2-CH3), 2.05 (s, 3H,
α, CH3), 2.04 (s, 5H, β, CH3), 2.03 (s, 3H, α, CH3), 2.00 (s, 3H, α, CH3), 1.96 (s, 5H, β,
CH3), 1.89 (s, 5H, β, CH3), 1.78 (s, 5H, β, CH3), 1.77 (s, 3H, α, CH3).
13C-NMR (CDCl3, 100MHz): δ 172.88 (β/α, C-4), 170.74 (C=O), 170.70 (C=O), 169.93
(C=O), 169.72 (C=O), 169.69 (C=O), 169.46 (C=O), 169.30 (C=O), 168.20 (C=O), 145.89
(β/α, C-3), 144.93 (β/α, C-4’), 144.71 (β/α, C-2), 139.75 (β or α, C-6), 139.52 (β or α,
C-6), 137.57 (β or α, Ph C-1), 137.55 (β or α, Ph C-1), 129.20 (β or α, Ph C-3,5), 129.16
(β or α, Ph C-3,5), 128.47 (β or α, Ph C-2,6), 128.45 (β or α, Ph C-2,6), 128.24 (β/α,
Ph C-4), 122.15 (β, C-5’), 122.09 (α, C-5’), 116.74 (β/α, C-5), 91.61 (β, C-1”), 90.10 (α,
C-1”), 73.32 (β/α, O−CH2−Ph), 72.98 (β, C-5”), 72.14 (β, C-3”), 70.06 (α, C-3”), 69.05
(α, C-5”), 68.76 (α, C-2’) 68.70 (β, C-2’), 68.19 (α, C-4”), 67.88 (β, C-4”), 64.77 (β, C-3’),
64.70 (α, C-3’), 63.32 (β/α, C-2”), 61.48 (β, C-6”), 61.40 (α, C-6”) 53.53 (β, C-1’), 53.36
(α, C-1’), 20.89 (β or α, CH3), 20.87 (β or α, CH3), 20.83 (β or α, CH3), 20.69 (β or α,
CH3), 20.68 (β/α, CH3), 20.47 (β or α, CH3), 20.39 (β or α, CH3), 12.97 (β/α, 2-CH3).
NSI-MS m/z (%): 671 (100, [M+H+]), 693 (13, [M-Ac+Na+]).
HRMS-NSI m/z : Calc. for C32H39N4O12 [M+H






















The triazole 92 (149mg, 222 µmol) was dissolved in dry methanol (3ml), then 1M so-
dium methoxide (400 µl, 400 µmol) was added and the reaction mixture stirred at room
temperature for 30min. The reaction was quenched by the addition of 2M HCl (200 µl)
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and then evaporated to give crude product (137mg), which was puriﬁed by column chro-
matography (chloroform/methanol: 6/1) to give 3-(benzyloxy)-1-(2-{[1-(2-deoxy-d-gluco-
pyranos-2-yl)-1H -1,2,3-triazol-4-yl]methoxy}ethyl)-2-methylpyridin-4(1H )-one (100) as a
colourless glass (30mg, 60 µmol, 27%).
Melting point: m.p. 95−109 ◦C.
IR (neat) cm-1: 3252 (br), 1623, 1547, 1506, 1455 (w), 1252, 1220, 1079, 1033.
1H-NMR (CD3OD, 400MHz): δ 8.08 (s, 1H, β or α, H-5’), 7.92 (s, 1H, β or α, H-5’),
7.64 (d, 3J (H6,H5) = 7.4Hz, 2H, β/α, H-6), 7.41–7.28 (m, 10H, β/α, Ph H-2–6), 6.42
(d, 3J (H5,H6) = 7.4Hz, 2H, β/α, H-5), 5.26 (d, 3J (H1”,H2”) = 3.3Hz, 1H, α, H-1”), 5.11
(d, 3J (H1”,H2”) = 8.2Hz, 1H, β, H-1”), 5.05 (s, 4H, O−CH2−Ph), 4.64 (dd, 3J (H2”,H3”)
= 10.9Hz, 3J (H2”,H1”) = 3.4Hz, 1H, α, H-2”), 4.58–4.52 (m, 4H, β/α, H-3”), 4.19–4.11
(m, 5H, β/α, H-1’; β, H-2”), 3.99–3.78 (m, 6H, α, H-3”,4”,5”,6”; β, H-5”,6”), 3.77–3.70 (m,
5H, β/α, H-2’,6”), 3.63 (dd, 3J = 9.8Hz, 3J = 8.8Hz, 1H, α, H-4”), 3.57–3.46 (m, 2H, β,
H-3”,4”), 2.19 (s, 6H, 2-CH3).
13C-NMR (CD3OD, 100MHz): δ 174.92 (C-4), 146.84 (C-3), 145.52 (β or α, C-4’),
154.50 (β or α, C-4’), 145.01 (C-2), 141.88 (C-6), 138.47 (Ph C-1), 130.21 (Ph C-2,6),
129.41 (Ph C-3,5), 129.31 (Ph C-4), 126.48 (β or α, C-5’), 124.55 (β or α, C-5’), 116.98
(C-5), 96.09 (β, C-1”), 92.55 (α, C-1”), 85.27 (β, C-5”), 81.81 (α, C-5”), 78.12 (β, C-3”),
74.53 (O−CH2−Ph), 73.32 (α, C-3”), 72.08 (α, C-4”), 71.92 (β, C-4”), 69.96 (β or α, C-2’),
69.88 (β or α, C-2’), 68.65 (β, C-2”), 65.80 (α, C-2”), 65.07 (β or α, C-3’), 64.99 (β or α,
C-3’), 62.45 (β or α, C-6”), 62.21 (β or α, C-6”), 54.64 (C-1’), 13.13 (2-CH3).
NSI-MS m/z (%): 517 (100, [M+14m/z]), 503 (8, [M+H+]).
HRMS-NSI m/z : Calc. for C24H31N4O8 [M+H
+]: 503.2136; found: 503.2132.






















The triazole 92 (80mg, 119 µmol) was dissolved in methanol (5ml) and acidiﬁed with HCl,
then Pd/C (10% wt., 7mg) was added and the suspension was shaken in a Parr shaker
under hydrogen atmosphere (2 bar) for 74 hours, then left at room room temperature for
1 day. Filtration through a pad of celite and evaporation gave an oﬀ-white residue which
was puriﬁed by column chromatography over a very short column (chloroform/methanol:
6/1) to give 1-(2-{[1-(2-deoxy-d-glucopyranos-2-yl)-1H -1,2,3-triazol-4-yl]methoxy}ethyl)-
3-hydroxy-2-methylpyridin-4(1H )-one (101) as a colourless gummy syrup (49mg, 109 µmol,
92%).
Melting point: m.p. 54−73 ◦C.
IR (neat) cm-1: 3219 (br), 2922 (w), 1634, 1535 (w), 1505, 1333, 1251, 1024.
1H-NMR (CD3OD, 400MHz): δ 8.22 (s, 1H, β or α, H-5), 8.16 (s, 1H, β or α, H-5), 8.12
(d, 3J (H6,H5) = 6.9Hz, 2H, β/α, H-6), 7.12 (d, 3J (H5,H6) = 6.9Hz, 2H, β/α, H-5), 5.32
(d, 3J (H1”,H2”) = 3.3Hz, 1H, β/α, H-1”), 5.12 (d, 3J (H1”,H2”) = 8.1Hz, 1H, β/α, H-1”),
4.70–4.64 (m, 5H, β/α, H-3’; α, H-2”), 4.61 (‘t’, 4H, β/α, H-1’), 4.27 (dd, 3J (H3”,H2”)
= 10.5Hz, 3J (H3”,H4”) = 8.6Hz, 1H, α, H-3”), 4.21 (dd, 3J (H2”,H3”) = 10.4Hz, 3J (H2”,
H1”) = 8.0Hz, 1H, β, H-2”), 4.11 (dd, 3J (H3”,H2”) = 10.4Hz, 3J (H3”,H4”) = 7.9Hz, 1H,
β, H-3”), 3.99–3.91 (m, 6H, β, H-2’,6a”; α, H-2’,5”), 3.85 (dd, 3J (H6a”,H6b”) = 12.0Hz,
3J (H6a”,H5”) = 2.4Hz, 1H, α, H-6a”), 3.79 (dd, 3J (H6b”,H6a”) = 12.0Hz, 3J (H6b”,H5”)
= 4.9Hz, 1H, α, H-6b”), 3.75 (dd, 3J (H6b”,H6a”) = 12.0Hz, 3J (H6b”,H5”) = 5.2Hz, 1H, β,
H-6b”), 3.55 (dd, 3J (H4”,H5”) = 9.8Hz, 3J (H4”,H3”) = 8.6Hz, 1H, α, H-4”, overlapping),
3.53 (ddd, 3J (H5”,H4”) = 9.6Hz, 3J (H5”,H6b”) = 5.3Hz, 3J (H5”,H6a”) = 2.1Hz, 1H, β,
H-5”, overlapping), 3.48 (dd, 3J (H4”,H5”) = 9.6Hz, 3J (H4”,H3”) = 7.9Hz, 1H, β, H-4”,
overlapping), 2.63 (s, 6H, 2-CH3).
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13C-NMR (CD3OD, 100MHz): δ 159.76 (β/α, C-4), 144.75 (β/α, C-2,3), 143.79 (β/α,
C-4’), 143.75 (β or α, C-4’), 140.01 (β/α, C-6), 127.08 (β or α, C-5’), 125.54 (β or α,
C-5’), 111.44 (β or α, C-5), 111.42 (β or α, C-5), 96.03 (β, C-1”), 92.42 (α, C-1”), 78.23
(β, C-5”), 75.40 (β, C-3”), 73.32 (α, C-5”), 72.31 (α, C-4”), 72.11 (β, C-4”), 71.63 (α, C-3”),
70.16 (β, C-2”), 69.38 (β/α, C-2’), 67.46 (α, C-2”), 64.38 (β or α, C-3’), 64.28 (β or α,
C-3’), 62.55 (β or α, C-6”), 62.39 (β or α, C-6”), 57.12 (β/α, C-1’), 13.15 (β/α, 2-CH3).
NSI-MS m/z (%): 497 (26, [M+2Ac+H+]), 455 (100, [M+Ac+H+]), 413 (67, [M+H+]).
HRMS-NSI m/z : Calc. for C17H25N4O8 [M+H

























Alkyne 84 (89mg, 0.3mmol) and 6-azido sugar 75 (170mg, 0.3mmol) were dissolved in
tBuOH (2ml) and water (2ml), then ascorbic acid (5.3mg, 30 µmol, 10%mol), 1M NaOH
(30 µl) and 1M copper sulfate (15 µl, 15 µmol, 5%mol) were added. The reaction mixture
was heated to 60 ◦C in a sealed tube for 20 hours, then diluted with water and extracted
with chloroform. The combined organic phases were washed with water, 1M NaOH
and brine before drying over Na2SO4. Evaporation gave the crude product as brown
solid (238mg) which was puriﬁed by column chromatography (chloroform/methanol: 50/1
→ 20/1), yielding pure 1-(2-{[1-(1,2,3,4-tetra-O-benzyl-6-deoxy-d-glucopyranos-6-yl)-1H -
1,2,3-triazol-4-yl]methoxy}ethyl)-3-(benzyloxy)-2-methylpyridin-4(1H )-one (93) as a pale
yellow, waxy solid (154mg, 199 µmol, 66%, α:β 1:1.4).
Melting point: <40 ◦C.
IR (neat) cm-1: 3030 (w), 2869 (w), 1626, 1571, 1496, 1454, 1322, 1250, 1213, 1068.
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1H-NMR (CDCl3, 400MHz): δ 7.43 (s, 2.7H, H-5’), 7.41–7.24 (m, 67H, Ar), 7.17 (d,
3J (H6,H5) = 7.5Hz, 2.5H, H-6), 6.42 (d, 3J (H5,H6) = 6.4Hz, 2.4H, H-5), 5.20 (s, 5.1H,
3-O−CH2−Ph), 4.99 (d, 2J = 10.6Hz, 1H, α, O−CH2−Ph), 4.92 (d, 2J = 10.8Hz, 1H,
α, O−CH2−Ph), 4.91 (d, 2J = 11.0Hz, 2.4H, β, O−CH2−Ph), 4.86 (d, 2J = 10.5Hz,
2.2H, β, O−CH2−Ph), 4.81–4.75 (m, 3J (H1”,H2”) = 3.5Hz, 5.2H, β, 2 O−CH2−Ph; α,
O−CH2−Ph, H-1”), 4.73–4.67 (m, 4.1H, α, O−CH2−Ph; β, 2 O−CH2−Ph), 4.65–4.60
(m, 3.5H, α, 2 O−CH2−Ph; β, H-6a”) 4.57–4.48 (m, 10.1H, α, O−CH2−Ph, H-3’, H-6a”;
β, 2 O−CH2−Ph, H-3’, H-6b”), 4.46 (d, 3J (H1”,H2”) = 7.8Hz, 1.4H, β, H-1”), 4.43 (dd,
2J (H6b”,H6a”) = 14.5Hz, 3J (H6b,H5) = 2.9Hz, 1H, α, H-6b”), 4.31 (d, 2J = 11.8Hz,
1H, α, O−CH2−Ph), 4.05 (‘t’, 3J (H3”,H2”) = 9.6Hz, 3J (H3”,H4”) = 8.8Hz, 1H, α, H-3”),
4.00 (ddd, 3J (H5”,H4”) = 9.9Hz, 3J (H5”,H6a”) = 6.0Hz, 3J (H5”,H6b”) = 2.8Hz, 1H, α,
H-5”), 3.91–3.86 (m, 4.7H, H-1’), 3.70 (t, 3J (H2’,H1’) = 5.1Hz, 4.7H, H-2’), 3.68–3.61
(m, 3J (H5”,H4”) = 9.7Hz, 3J (H3”,H2”) = 9.2Hz, 3J (H3”,H4”) = 9.0Hz, 3J (H5”,H6a”) =
5.8Hz, 3J (H5”,H6b”) = 2.8Hz, 3.6H, β, H-3”, H-5”), 3.42–3.37 (m, 2.4H, α, 3J (H2”,H3”) =
9.6Hz, 3J (H2”,H1”) = 3.4Hz, H-2”; β, 3J (H2”,H3”) = 9.2Hz, 3J (H2”,H1”) = 7.8Hz, H-2”),
3.18 (dd, 3J (H4”,H5”) = 9.6Hz, 3J (H4”,H3”) = 9.0Hz, 1.5H, β, H-4”), 3.11 (dd, 3J (H4”,
H5”) = 9.9Hz, 3J (H4”,H3”) = 8.8Hz, 1.5H, α, H-4”), 2.07 (s, 7.7H, 3-CH3).
13C-NMR (CDCl3, 100MHz): δ 171.58 (q, C-4), 145.85 (q, C-3), 143.88 (q, C-4’), 141.06
(q, C-1), 139.06 (C-6), 138.42 (q, Ar), 138.14 (q, Ar), 137.96 (q, Ar), 137.79 (q, Ar), 137.58
(q, Ar), 137.02 (q, Ar), 136.67 (q, Ar), 129.07 (2 Ar), 128.55 (2 Ar), 128.50 (Ar), 128.47
(2 Ar), 128.44 (Ar), 128.40 (Ar), 128.30 (Ar), 128.28 (2 Ar), 128.12 (Ar), 128.08 (2 Ar),
128.04 (Ar), 127.98 (2 Ar), 127.91 (2 Ar), 127.85 (Ar), 127.82 (Ar), 127.80 (Ar), 124.62
(β, C-5’), 124.34 (α, C-5’), 116.74 (C-5), 102.46 (β, C-1”), 95.30 (α, C-1”), 84.44 (β,
C-3”), 82.08 (β, C-2”), 81.86 (α, C-3”), 79.93 (α, C-2”), 77.92 (α, C-4”), 77.70 (β, C-
4”), 75.81 (O−CH2−Ph), 75.80 (O−CH2−Ph), 75.06 (O−CH2−Ph), 74.98 (O−CH2−Ph),
74.92 (O−CH2−Ph), 73.08 (3-O−CH2−Ph), 73.04 (β, C-5”), 72.99 (O−CH2−Ph), 71.40
(O−CH2−Ph), 69.35 (α, O−CH2−Ph), 69.27 (α, C-5”), 68.37 (α, C-2’), 68.30 (β, C-2’),
64.41 (α, C-3’), 64.31 (β, C-3’), 53.14 (C-1’), 50.65 (β, C-6”), 50.59 (α, C-6”), 12.69
(2-CH3).
NSI-MS m/z (%): 885 (14, [M+Na+]), 863 (100, [M+H+]), 355 (13).
HRMS-NSI m/z : Calc. for C52H55N4O8 [M+H
+]: 863.4014, found: 863.4006.

























Method A: Hydrogenation The triazole 93 (111mg, 128 µmol) was dissolved in meth-
anol (5ml) and chloroform (0.5ml), Pd/C (10%wt., 10mg) was added and the reaction
was shaken under hydrogen atmosphere (2 bar) in a Parr shaker for 17 hours. Filtration of
the reaction mixture through a pad of celite and evaporation gave a crude material which
was unreacted starting material 112, as conﬁrmed by NMR.
Method B: Boron tribromide The triazole 93 (111mg, 128 µmol) was dissolved in
dry DCM (3ml) under nitrogen atmosphere. The solution was cooled on an ice-bath and
boron tribromide (1M solution in DCM, 2ml) was added slowly. The reaction mixture
was stirred at 0 ◦C for 10min, then at room temperature for 2.5 hours before quenching by
addition of methanol (5ml). The solution was evaporated and dried under high vacuum
before puriﬁcation by reverse phase chromatography (Lichroprep RP-18 resin, gradient
0.05M TEAB/methanol: 100/0→50/50). Multiple fractions were isolated, but none were
found to contain the desired product.
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7.2 Biological Evaluation
7.2.1 General
Cells. Primary brain endothelial cells (PBEC), previously isolated from fresh pig brains,
were stored in liquid nitrogen,255 and kindly provided by Prof Joan Abbott and Dr
Jane Preston (Drug Delivery Group, Institute of Pharmaceutical Science, King’s College
London).
Reagents. Low glucose Dulbecco’s modiﬁed Eagle’s medium (DMEM, 1mg/ml glucose,
D5546), Hank’s balanced salt solution (HBSS, H8264), HBSS with phenol red and without
calcium and magnesium (‘HBSS red’, H9394), ﬁbronectin from bovine plasma (F1141),
puromycin (P8833), heparin (H3149), penicillin/streptomycin (P/S, P0781), l-glutamine
(G7513), hydrocortisone (H0135), trypsin-EDTA, 8-(4-chlorophenylthio)-cAMP sodium
salt (pCPT-cAMP, C3912) and DMSO were obtained from Sigma-Aldrich. Bovine plasma
derived serum (BPDS, 10% solution, 60-00-850) was obtained from First Link Ltd (Birm-
ingham, UK), RO-20-1724 (Calbiochem 557502) from Merck KGaA. All other reagents
were obtained from major suppliers.
Growth Medium. DMEM containing 1% BDPS, 2mm glutamine, 125 µg/ml heparin,
100U/ml penicillin, 100 µg/ml streptomycin.
Induction Medium. DMEM containing 2mm glutamine, 125 µg/ml heparin, 100U/ml
penicillin, 100 µg/ml streptomycin, 550 nm hydrocortisone, 250 µm pCPT-cAMP, 17.5 µm
RO-20-1724.
Assay Buffer. Deionised water containing 135mm sodium chloride, 25mmHEPES, 5.4mm
potassium chloride, 1.5mm calcium chloride, 1.2mm magnesium chloride and 1mm pyr-
uvate (added shortly before the experiment) adjusted to pH 7.4 with sodium hydroxide.
Stopping Buffer. Phloretin (100 µm) and mercuric chloride (1 µm) in phosphate buﬀered
saline composed of 137mm sodium chloride, 10mm phosphate, 2.7mm potassium chloride
in deionised water.
Transwells and TEER. ’Transwell’ inserts (12mm polycarbonate membrane, 0.4 µm
pore size, tissue-culture treated, 3401) were obtained from Corning Lifesciences. Transen-
dothelial electrical resistance (TEER) was measured with a STX100 probe and an EVOM
Volt-Ohm meter (World Precision Instruments, Sarasota, FL, USA). All TEER values are
given as Ω cm2 and were corrected by the baseline resistance of a collagen-coated ﬁlter
insert without cells.
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Radioisotopes. [3H]3-O-Methylglucose (3OMG, 1.0mCi/ml, speciﬁc activity 37mCi/mmol)
was obtained from PerkinElmer and [14C]sucrose (0.1mCi/ml, speciﬁc activity 643mCi/mmol)
from GE Healthcare. A scintillation cocktail liquid (PerkinElmer, Waltham, MA, USA)
was added to each of the scintillation vials and samples were counted on a LKB Wallac
1219 Rackbeta liquid scintillation counter (LKB Wallac, Wallac, MD, USA).
Plate Readers. Fluorescence (excitation/emission wavelengths: 485/528nm) was meas-
ured on a BioTek Synergy HT microplate reader (BioTek Instruments, Winooski, VT,
USA) and absorption on a MTX Multiskan Ascent microplate reader (MTX Lab Systems,
Vienna, VA, USA).
HPLC. Samples were analysed on a Waters HPLC system (600 controller, 626 pump,
996 PDA detector, 717 autosampler; Waters Corp, Milford, MA, USA). A reverse-phase
polymer column (PLRP-S 150 x 4.6mm, pore size 300Å, particle size 8 µm) with a ﬂow
rate of 1ml/min was used for separation with gradient elution. Acetonitrile, water and 1-
heptanesulfonic acid (all HPLC grade) were obtained from Thermo Fisher Scientiﬁc. The
mobile phase was composed of a buﬀer (5mmol 1-heptanesulfonic acid in water, adjusted
to pH 2 with HCl) and acetonitrile.
A gradient of 2-35% acetonitrile was run for 20 min, followed by 5 min at 35% acetonitrile
and a 5 min post-run period at 2% acetonitrile. The total time per sample was 31 min,
samples were injected twice or thrice (100µl per injection). Sample components were
detected by UV absorption at 280 nm. Chromatograms were processed and exported with
Millennium32 (Waters Corp).
7.2.2 Thawing and Growth of PBEC
T75 cell-culture ﬂasks were coated at room temperature with lab-made rat-tail collagen
(300 µg/ml in sterile water) for at least 2 h , then washed twice with HBSS and coated
with ﬁbronectin (7.5 µg/ml in sterile water) for at least 2 h. One vial (microvessels from
approx. half of a pig brain) PBECs was thawed and quickly added to 20ml warmed
growth medium including puromycin (4 µg/ml). Puromycin inhibits protein synthesis and
serves to remove contaminant cells, but does not aﬀect healthy endothelium with active
eﬄux transporters to exclude the drug. The cell suspension was split evenly between two
ﬂasks. Cells were grown in an incubator at 37 ◦C in 5% CO2 in air and reached about 70%
conﬂuence within 3 days. If the cells had not reached the desired cell density on day 3,
they were fed with fresh growth medium and their conﬂuence checked daily.
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7.2.3 Harvesting
Flasks that had reached the desired cell density (about 70% conﬂuence) were harvested as
follows. The medium was removed by aspiration, and the cells washed twice with ‘HBSS
red’ (without calcium and magnesium, 4ml each). Trypsin (2ml) was added and the ﬂasks
incubated for 7 min, then – under observation under the microscope – shaken and tapped
lightly for 2 min to detach the cells, incubated for a further minute and shaken/tapped for
another 2 min. Trypsin was quenched by the addition of growth medium to the ﬂasks (8ml
each), and the contents were transferred to a centrifuge tube. The cells were centrifuged
for 5 min at 380g and the cell pellet re-suspended in 1ml growth medium. The cell number
was determined using a haemocytometer.
7.2.4 Microplate-based Assays
Cells were seeded in collagen-coated transparent multiwell plates and grown to conﬂuence
and fed after 3 days, if necessary. The seeding density for 96-well, 24-well and 12-well
plates was 2.5× 104, 1× 105 and 2× 105 cells per well, respectively (1× 105 cells/ml),
whilst only the central 10×6 wells were used in 96-well plates. Cells were supplemented
with hydrocortisone, cell permeable cAMP (pCPT-cAMP) and type IV phosphodiesterase
inhibitor RO-20-1724 to increase intracellular cAMP levels and facilitate tight junction
formation.
Diﬀerent experiments were performed in this microplate setup:
• The uptake of CP20, Phe, and Phe in the presence of glucose (100 or 500 µm) in
96-well plates (200 µl per well) was evaluated at 1, 4 and 24 hours. At the end of
the experiment, cells were washed 3× with PBS and lysed with water (100 µl). The
content of triplicate wells was pooled, protein removed by the precipitation with
triﬂuoroactic acid (9% ﬁnal concentration) and centrifugation (15 min at 5400g)
The samples were then analysed by HPLC.
• Four compounds (CP20, CP40, Phe, Val; 0–500 µm) were evaluated for their
eﬀect on the uptake of 3OMG (1.5µCi/ml, 0.3 µCi per well) at 10 and 20 min in
96-well plates (200 µl per well). [14C]Sucrose (0.15 µCi/ml, 0.03 µCi per well) was
herein used as extracellular marker. At the end of the experiment, cells were washed
3× with PBS and lysed with 1% Triton X-100 solution (200 µl, 45 min). 100 µl of the
lysate were added to scintillation vials and diluted with 3.5ml scintillation cocktail
before analysis in the scintillation counter.
• Cells were pre-incubated with assay buﬀer 500 µl per well for 30 min. The uptake
of 3OMG (1.5 µCi/ml, 0.75 µCi per well) was evaluated at 15 and 60 min in 24-well
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plates (500 µl per well) in the presence of CP20 and Phe (500 µm). [14C]Sucrose
(0.15 µCi/ml, 0.075 µCi per well) was used as extracellular marker. To stop the
experiment, the cells were washed 3× with ice-cold stopping buﬀer and lysed with 1%
Triton X-100 solution (200 µl, 45 min). The lysate was added to a scintillation vial
and diluted with 3.5ml scintillation cocktail before before analysis in the scintillation
counter.
• The uptake of 3OMG (1.5 µCi/ml) was evaluated in the presence and absence of
5mm glucose at 15 seconds in 24- and 12-well plates (500 and 1000 µl per well,
respectively). [14C]Sucrose (0.15µCi/ml) was used as extracellular marker. To stop
the experiment, cells were washed 3× with equal volume of ice-cold stopping buﬀer
and lysed for 15 min with 200 µl 0.1 m sodium hydroxide solution (500 µl for 12-
well plates). The lysate was added to scintillation vials and diluted with 3.5ml
scintillation cocktail before counting.
7.2.5 Transwell-based Assays
Transwell inserts (12 mm diameter, 1.12 cm2) were coated with collagen and ﬁbronectin
as described for T75 ﬂasks (500µl per insert). Cells were then seeded onto the inserts at a
density of 1× 105 cells per insert and grown for 3 days (500 µl in the apical compartment,
1.5ml in the basolateral compartment). On day 3 and every day thereafter, the medium
was replaced with induction medium. When treated with induction medium, pCPT-cAMP
and RO-20-1724 were added directly to the apical and basolateral compartments, whilst
BPDS (50 µl, 1% ﬁnal concentration) was added only to the apical compartment. TEER
values were measured 1 and 2 days after the switch to induction medium and the cells
were not manipulated further for at least 2 h after the TEER measurement. Cells were
used for experiments after two days of treatment with induction medium.
Inhibition Assay. The inhibition of 3OMG transport by glucose (5mm), phloretin (250 µm)
and HPOs (CP20, 26a, Val, Phe, M6, M10; 500 µm) was determined in a Transwell
setup. Sample buﬀers were prepared from the assay buﬀer and contained 3OMG (1.5 µCi/ml,
0.75 µCi/ml per well) and [14C]sucrose (0.5 µCi/ml, 0.075 µCi/ml per well), as well as a
ﬁnal concentration of 1% DMSO (HPO stocks were 50mm solutions in 100% DMSO). The
sample buﬀers (500 µl) were added to the apical side of the Transwell, the basolateral side
contained assay buﬀer (1.5ml) and incubation was performed up to 2 hours in an orbital
shaker (300 rpm) at 37 ◦C. Samples from both compartments (sample size is 10% of the
compartment volume) were taken at speciﬁc time points and the volume was replaced with
fresh assay buﬀer.
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Diﬀerent experiments were performed based on the described method in this microplate
setup:
• The transport of 3OMG across the monolayer was measured at 30 sec, 2 min, 5 min,
1 h and 2 h. The eﬀects glucose, CP20 and Phe, as well as pre-incubation with assay
buﬀer on 3OMG transport were determined. Samples (10% of compartment volume)
were taken at each time point from both compartments, diluted with scintillation
liquid (3.5ml) and measured in a scintillation counter.
• The transport of 3OMG at 2, 5, 30, 60 min was investigated after glucose, CP20 and
Phe had been added to the apical side, or both sides. Samples from each time point
(10% of compartment volume) were analysed by scintillation counting. Samples from
the 60 min time point were also analysed by HPLC in order to determine the amount
of test compound that had crossed the monolayer.
• The inhibition of 3OMG uptake in the presence of glucose, phloretin and HPOs
(CP20, 26a, Val, Phe) was measured at 2, 5, 10 and 30 min by scintillation
counting. HPLC samples were only taken at the 30 min time point.
• The inhibition of 3OMG uptake in the presence of glucose and HPOs (CP20, 26a,
Phe, M6, M10) was measured at 2, 5, 10 and 30 min by scintillation counting.
HPLC samples were taken at the 30 min time point only. Instead of [14C]sucrose as
paracellular marker in every well, sodium ﬂuorescein (7.5µg/ml ﬁnal concentration)
was used in separate wells. For the ﬂuorescence read-out, 150 µl were sampled from
the basolateral side and 50 µl from the apical side, which were diluted to 150 µl with
assay buﬀer.
Permeability Assay. The permeability of HPOs (500 µm) across the BBB was determ-
ined by measuring the permeability of the compound across a PBEC monolayer. Sodium
ﬂuorescein (7.5 µg/ml ﬁnal concentration) was used as marker for the paracellular per-
meability. After 30 min preincubation with assay buﬀer, fresh buﬀer was added to the
basolateral side (1.5ml, receiver compartment) and the sample solutions (compound plus
sodium ﬂuorescein, 1% DMSO) were added to the apical side (0.5ml, donor compartment).
The inserts were incubated for 60 min in an orbital shaker (300 rpm) in the dark at
37 ◦C. The incubation was stopped by removing the insert from the receiver compartment.
Samples for ﬂuorescence measurement were taken in triplicate from each compartment
(10% of compartment volume each). The apical samples (50µl) were diluted to 150 µl with
assay buﬀer. Samples for HPLC were taken from both sides and measured in duplicate
without further work-up.
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7.2.6 Calculations and Statistical Analysis.
All calculations were done with Microsoft Excel 2003 or 2010 and statistical test and
graphs were done using GraphPad Prism 6 (GraphPad Software, Inc.). milogP values
were calculated online on the Molinspiration webpage.264
The apparent permeability Papp (cm s−1) of compounds, which allows the comparison of
results with other cell based assays, was calculated using the equation:
Papp = VD/(A ∗MD) ∗ (∆MR/∆t) (7.1)
where VD = apical (donor) volume, A = membrane surface area (1.12 cm2), MD =
apical (donor) amount (nmol) and ∆MR/∆t = amount (nmol) of compound transferred
to receiver compartment over time in seconds.263
For each plate, the Papp was also normalised as Papp % of CP20 on that plate, in order to
account for day-to-day variation between experiments.
Assays were performed on at least two independent days and in duplicate or triplicate on
each plate. All data is presented as mean ± SEM. The TEER of batches was compared
with 2-way ANOVA, with Sidak’s correction for multiple comparisons. Papp values from
Transwell experiments were compared by one-way ANOVA, with Holm-Sidak’s correction
for multiple comparisons.
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